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Summary 
Differences in efficacy and safety of drugs among patients are a recognized problem in 
pharmacotherapy. The reasons are multifactorial and, therefore, the choice of a drug and its dosage 
for a particular patient based on different clinical and genetic factors is suggested to improve the 
clinical   outcome.   Four   drugs   are   currently   used   for   the   treatment   of   Alzheimer’s   disease:   three  
acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and the N-methyl-D-aspartate-
antagonist memantine. For these drugs, a high interindividual variability in plasma levels was 
observed, which might influence the response to treatment. The main objective of this thesis was to 
provide a better understanding of clinical and genetic factors affecting the plasma levels of 
antidementia drugs. Furthermore, the relationship between plasma levels, genetic variations and side 
effects was assessed. For this purpose, a pharmacogenetic study was conducted including 300 
patients from a naturalistic clinical setting. 
Analytical methods for the simultaneous measurement of antidementia drugs in plasma have been 
developed and validated using liquid chromatography methods coupled with mass spectrometry 
detection. Presently, these methods are used in the therapeutic drug monitoring service of our 
laboratory. The routine use of therapeutic drug monitoring for antidementia drugs cannot yet be 
recommended with the available data, but it may be beneficial for some patients in special clinical 
cases such as insufficient treatment response, side effects or drug interactions. 
Donepezil and galantamine are extensively metabolized by the liver enzymes cytochromes P450 
(CYP) 2D6 and 3A and are substrates of the drug transporter P-glycoprotein. The relationship of 
variations in genes affecting the activity of these metabolic enzymes and drug transporter (CYP2D6, 
CYP3A, POR, NR1I2, ABCB1) with donepezil and galantamine plasma levels was investigated. The 
CYP2D6 genotype appeared to be the major genetic factor involved in the pharmacokinetics of these 
two drugs. Thus, CYP2D6 poor metabolizers demonstrated significantly higher drug plasma levels 
than extensive metabolizers. Additionally, in the donepezil study population, the frequency of side 
effects was significantly increased in poor metabolizers. Lower donepezil plasma levels were 
observed in ultra rapid metabolizers, which might expose those patients to the risk of non-response. 
Memantine is mainly eliminated unchanged by the kidney, with implication of tubular secretion by renal 
transporters. A population pharmacokinetic model was developed to quantify the effects of clinical 
factors and genetic variations in renal cation transporters (SLC22A1/2/5, SLC47A1, ABCB1), and 
nuclear receptors (NR1I2, NR1I3, PPARG) involved in transporter expression, on memantine plasma 
levels. In addition to the renal function and gender, a genetic variation in the nuclear receptor 
Pregnane-X-Receptor (NR1I2) significantly affected memantine elimination. 
These findings suggest that an individualized therapy approach for antidementia drugs, taking into 
account clinical characteristics and genetic background of a patient, might increase efficacy and safety 
of the treatment. 
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Résumé 
Les différences interindividuelles  dans   l’efficacité  et   la   tolérance  des  médicaments  sont  un  problème  
connu en pharmacothérapie. Les raisons sont multiples, et le choix du médicament et de la dose, 
basé sur des facteurs cliniques et génétiques spécifiques au patient, peut contribuer à améliorer la 
réponse clinique. Quatre médicaments sont couramment utilisés dans le traitement de la maladie 
d’Alzheimer :   trois   inhibiteurs   de   l’acétylcholinestérase   (donépézil,   galantamine,   rivastigmine)   et   un  
antagoniste du récepteur N-méthyl-D-aspartate, la mémantine. Une forte variabilité interindividuelle 
dans les taux plasmatiques de ces quatre composés a été observée, ce qui pourrait influencer la 
réponse  au  traitement.  L’objectif  principal  de  ce  travail  de  thèse est de mieux comprendre les facteurs 
cliniques et génétiques influençant les taux des médicaments pro-cognitifs. En outre, des associations 
entre les taux, la variabilité génétique et les effets secondaires ont été recherchées. Dans ce but, 
300 patients sous traitement avec un médicament pro-cognitif ont été recrutés pour une étude 
pharmacogénétique. 
Des méthodes de dosage simultané de médicaments pro-cognitifs par chromatographie liquide 
couplée à la spectrométrie de masse ont été développées et validées. Ces méthodes sont 
actuellement utilisées dans le service de suivi thérapeutique de notre unité. Malgré le fait qu’un  suivi  
des taux sanguins des pro-cognitifs ne puisse pas encore être recommandé en routine, un dosage 
peut être utile dans des cas cliniques spécifiques, comme une réponse insuffisante, une intolérance 
ou une interaction médicamenteuse. 
Le donépézil et la galantamine sont fortement métabolisés par les cytochromes P450 (CYP) 2D6 et 
3A, et sont également substrats du transporteur P-glycoprotéine. Les associations entre les 
polymorphismes génétiques de ces enzymes, cofacteur, récepteur nucléaire et transporteur (CYP2D6, 
CYP3A, POR, NR1I2, ABCB1) et les taux de donépézil et de galantamine ont été étudiées. Le 
génotype du CYP2D6 a été montré comme le facteur génétique majeur impliqué dans la 
pharmacocinétique de ces deux médicaments. Ainsi, les métaboliseurs déficients du CYP2D6 ont 
démontré des taux plasmatiques significativement plus élevés comparé aux bons métaboliseurs. 
De plus, dans la population traitée avec le donépézil, la fréquence des effets secondaires était plus 
élevée chez les métaboliseurs déficients. Des taux plasmatiques bas ont été mesurés chez les 
métaboliseurs ultra-rapides traités avec le donépézil, ce qui pourrait être un facteur de risque à une 
non-réponse au traitement.  
La mémantine est principalement éliminée sous forme inchangée par les reins, et partiellement par 
sécrétion tubulaire grâce à des transporteurs rénaux. Un modèle de cinétique de population a été 
développé pour quantifier les effets des différents facteurs cliniques et de la variabilité génétique des 
transporteurs rénaux (SLC22A1/2/5, SLC47A1, ABCB1) et des récepteurs nucléaires (NR1I2, NR1I3, 
PPARG,   impliqués   dans   l’expression   des   transporteurs)   sur   les   taux plasmatiques de mémantine. 
En plus de la fonction rénale et du genre, une variation génétique dans le récepteur nucléaire 
Pregnane-X-Receptor (NR1I2) a  montré  une  influence  significative  sur  l’élimination  de  la  mémantine.   
Ces   résultats   suggèrent   qu’une   approche   thérapeutique   individualisée, prenant en compte des 
facteurs  cliniques  et  génétiques  du  patient,  pourrait  améliorer   l’efficacité  et   la  sécurité  du   traitement  
pro-cognitif. 
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Abbreviations 
Aβ    Amyloid-β 
AChE    Acetylcholinesterase 
AChEI    Acetylcholinesterase inhibitor 
ABC    ATP-binding cassette 
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CV    Coefficient of variation 
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EM    Extensive metabolizer 
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HPLC-MS   High performance liquid chromatography-mass spectrometry 
IS    Internal standard 
LLOQ    Lower limit of quantification 
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NMDA    N-methyl-D-aspartate 
OCT    Organic cation transporter 
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POR    Cytochrome P450 oxidoreductase 
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PPAR    Peroxisome proliferator-activated receptor 
PXR    Pregnane-X-receptor 
QC    Quality control sample 
RXR    Retinoid-X-receptor 
SIM    Single ion monitoring 
SLC    Solute carrier 
SNP    Single nucleotide polymorphism 
SPE    Solid phase extraction 
t1/2    Elimination half-life 
tmax    Time to maximum peak plasma concentration 
TDM    Therapeutic drug monitoring 
ULOQ    Upper limit of quantification 
UPLC-MS/MS   Ultra performance liquid chromatography-tandem mass spectrometry 
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1.1  Alzheimer’s  disease  and  pharmacological  treatment 
 
Over 100 years ago, Alois Alzheimer presented a case of a 51-year-old woman with mental 
degeneration at a congress in Germany.1 This was the first demonstration of the disease, which was 
later  named  Alzheimer’s  disease  (AD).  He  described  the  typical  characteristics  of  an  Alzheimer  patient  
with memory disturbances, disorientation, aphasia, delusions and unpredictable behavior as main 
clinical symptoms, and the neuropathological picture with plaques and neurofibrillary tangles, which 
we today know as hallmarks of the disease.1,2 
AD is the most common type of dementia, accounting for 50-60% of all cases, followed by vascular 
dementia, Lewy body dementia and mixed dementia (coexistence of AD and vascular dementia).1,3 
With the rapid increase of the aging population, dementia has become an important public health 
challenge. By 2005, the global prevalence of dementia was estimated to be as high as 24 million. The 
number of people affected is predicted to double every 20 years to 80 million by 2040.4 In Switzerland, 
it is estimated that currently around 110 000 people suffer from dementia.5 
As described by Alois Alzheimer, the typical features of AD are amyloid plaques caused by a gradual 
deposition of beta-amyloid   (Aβ)   peptides,   and   intraneuronal   neurofibrillary   tangles   formed   by  
aggregation of abnormally hyperphosphorylated tau proteins.1,6 However, it is suggested that several 
other pathogenic mechanisms also contribute to the AD pathophysiology, such as neurovascular 
dysfunction, cell-cycle dysregulation, inflammatory processes, oxidative stress, and mitochondrial 
dysfunction.6 The neuropathological lesions are leading to a degeneration of neurons and synapses. 
Thus, brain regions involved in learning and memory processes, including the temporal and frontal 
lobes of the cerebral cortex, are reduced in size in AD patients (Figure 1).7  
 
 
Figure 1: Alzheimer’s  disease  results  in  shrinkage  of  brain  regions  involved  in  learning  and  memory  (a)  which  is  
correlated with major reductions in cellular energy metabolism in living patients (red and yellow indicate high 
levels of glucose uptake) (b). Picture from Mattson MP, Nature, 2004;430(7000):631-9. 
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The current pharmacotherapy of AD is based on observed neurotransmitter disturbances, on one 
hand the cholinergic hypofunction and on the other hand the glutamatergic overstimulation of the 
postsynaptic N-methyl-D-aspartate (NMDA) receptors.8,9 To date, the three acetylcholinesterase 
inhibitors donepezil, galantamine and rivastigmine are licensed in Switzerland, which inhibit the 
enzyme acetylcholinesterase and thereby increase the level of acetylcholine in the synaptic clefts 
(Figure 2a).10,11 They are indicated for the treatment of mild to moderate AD. Moreover, the NMDA 
receptor antagonist memantine, acting against excessive receptor activation by glutamate, is licensed 
for moderate to severe AD (Figure 2b).10,12,13 The detailed mechanism of action of each antidementia 
drug is described in the review article at the end of the introduction chapter (Article I, Chapter 1.3). 
 
 
Figure 2: Mode of action of AD drugs. a. Acetylcholinesterase inhibitors are blocking the enzyme 
actylcholinesterase, responsible for the degradation of the neurotransmitter acetylcholine, thereby increasing the 
concentrations of acetylcholine in the synaptic cleft. N=nicotinic and M=muscarinic acetylcholine receptors. b. In 
AD, NMDA receptors channels are excessively stimulated by glutamate, which lead to constantly high intracellular 
calcium (Ca2+) levels. In turn, synaptic noise rises, impairing relevant signal detection such as learning. 
Memantine is a low affinity receptor antagonist blocking open NMDA receptor channels. The intracellular Ca2+ 
level and, therefore, the synaptic noise are decreased, which allows incoming signals to be detected. Pictures 
adapted from Wilkinson DG, Drugs Aging, 2004;21(7):453-78 and Parsons CG, Neuropharmacology, 
2004;430(7000):631-9. 
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Acetylcholinesterase inhibitors and memantine offer primarily symptomatic benefits regarding 
cognition and global change, and they might slow down, but do not prevent, the progression of the 
disease.6,14,15 Numerous disease-modifying approaches are under investigations. The majority of them 
are  targeting  the  production  and  clearance  of  Aβ  and  the  abnormal  aggregation  of  tau  filaments,  but  
also neuro-inflammatory pathways and oxidative stress are considered (Figure 3).6 Large multicentre 
trials conducted to study the efficacy of disease-modifying therapies did not provide the beneficial 
effects hoped for.14,16 It is expected that an early diagnosis of the disease, when no irreversible 
cognitive deficits are present, would lead to more positive results.14,16 However, since AD is a complex 
multifactorial disorder, the discovery of a sole cure is unlikely. A treatment strategy based on multiple 
targets, eventually combined with a symptomatic therapy, is more probable.6,14 Therefore, continued 
search for causative factors and new therapies, as well as for biomarkers for an early diagnosis, is 
required. 
 
 
Figure 3: Current   pharmacotherapeutic   targets   in   Alzheimer’s   disease.   Picture   from   Chopra   K,   Expert   Opin  
Pharmacother. 2011;12(3):335-50. 
 
1.2 General aspects of clinical pharmacology 
1.2.1 Pharmacokinetics and pharmacodynamics 
 
The objective of a pharmacological treatment is to administer effective drugs to patients while 
minimizing the occurrence of side effects. After drug application, there is an interplay between two 
overlaying processes: the pharmacokinetics, which refers to the time-course of the drug in the body, 
including absorption, distribution, metabolism and elimination, and the pharmacodynamics, which 
refers to the relationship between concentration and intensity of the therapeutic and adverse effects 
Chapter 1: Introduction   
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(Figure 4).17 The basis of clinical pharmacology is the fact that the intensity of many pharmacological 
effects  depends  on  the  amount  of  drug  in  the  body  and  more  specifically  on  the  drug’s  concentration  
at the site of action.18 For numerous directly and reversibly acting drugs, it has been shown that the 
intensity and time course of the effect is correlated with the time course of the plasma 
concentrations.18 This direct relationship allows the prediction of the pharmacologic effects based on a 
patient’s  drug  plasma  concentration measurement. However, more complex correlations between the 
plasma concentration, concentration at the site of action and drug effects are possible.18 Examples are 
a time delay between the attainment of effective plasma concentrations and drug action due to a 
retarded distribution of the compound to the site of action or time consuming synthesis or degradation 
of an endogenous substance necessary for the drug effect.18 Moreover, for some drugs time-
dependent change in effect intensities without changes in drug concentrations occurs through 
phenomena known as tolerance or sensitization.18 
 
 
Figure 4: Relationship of pharmacokinetics and pharmacodynamics and factors affecting the two processes. PK= 
pharmacokinetics, PD= pharmacodynamics. Picture adapted from Derendorf H, Pharm Res, 1999;16(2):176-85.  
 
For most drugs, substantial differences in treatment response exist among patients due to inter-
individual variabilites in pharmacokinetics and pharmacodynamics. Therefore, a standard dose of a 
drug might not be suitable for every patient. Several factors influence the pharmacokinetics of a drug, 
including gender, body composition, diseases, medication, environmental factors (e.g. food or 
smoking) or genetic variants in metabolizing enzymes or drug transporters. Possible explanations for 
the pharmacodynamic variability are differences in drug receptor density or affinity, genetic factors and 
drug interactions (Figure 4).19  
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The development of a personalized pharmacotherapy is an approach to get closer to the aim of an 
optimal drug response with minimal side effects. It takes inter-individual variations in pharmacokinetics 
and   pharmacodynamics   into   account   in   order   to   administer   the   “right   drug”   at   the   “right   dose”   to   a  
particular patient. 
 
1.2.2 Pharmacogenetics 
 
The recognition that a part of the variability in drug response is inherited, and therefore predictable, 
created the field of pharmacogenetics fifty years ago.20 With the advances in sequencing and 
genotyping technologies and the completion of the Human Genome Project in 2003,21 the interest on 
pharmacogenetics increased sharply. The Human Genome Project was an international research 
effort to determine the sequence of the human genome, consisting of 3.2 billion base paires (bp), and 
to   identify   the   approximately   20’000   genes   that   it   contains.20,21 If two unrelated individuals are 
compared, they differ from one another by approximately 0.1% or 3 million bp.22 Of the DNA variants, 
90-95% are single nucleotide polymorphisms (SNP), which are single nucleotide substitutions 
occurring at a frequency of at least 1% in the population.20 Other DNA variants include nucleotide 
insertions, deletions, inversions and translocation, as well as copy number variations and variable 
number of tandem repeats.23 A specific set of genetic variations, occurring together on a single 
chromosome or on a part of a chromosome, is called a haplotype.22  
Currently, there are two main approaches to investigate the influence of genetic variations on drug 
response.24 The candidate gene approach consists in analyzing one or more genes in which variants 
could plausibly explain a given phenotype.24 Candidate genes may be in pharmacokinetic or 
pharmacodynamic pathways, for instance genes involved in drug metabolism, drug transport, drug 
targets or disease type. The second approach is based on genome-wide association studies (GWAS), 
in which the entire genome is screened for variations associated with a given phenotype.24 The 
increasing use of the term pharmacogenomics instead of pharmacogenetics reflects the trend towards 
GWAS.20 In this work, we investigated polymorphisms in candidate genes implicated in the 
pharmacokinetics of antidementia drugs. Moreover, we performed haplotype analyses to examine the 
combined effect of SNPs.  
Today, the use of genotyping to support clinical decisions about drug use is not widely practiced.25 In 
2010, only about 10% of the Food and Drug Administration (FDA) approved drugs contained 
pharmacogenomic information in their drug labels,26,27 thus, the potential has hardly been exhausted 
by now. In fact, pharmacogenetics is an emerging field with many challenges that have to be 
overcome, most importantly the proof of clinical utility with appropriate clinical trials, but also the cost-
effectiveness, ethical issues regarding genetic analyses and the acceptance of genotyping in clinical 
practice.24,25  
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1.2.2.1 Drug Metabolism 
 
The elimination of most drugs involves the participation of several families of drug metabolizing 
enzymes that convert hydrophobic drugs to more polar forms that are more readily excreted. The 
biotransformation can be divided in phase I and phase II metabolism. In phase I metabolic reactions a 
functional group is introduced into the parent molecule and in phase II metabolic reactions the parent 
molecule and phase I metabolites are further converted by conjugation with hydrophilic endogenous 
moieties.28 Phase I metabolism is primarily mediated by cytochrome P450 (CYP) enzymes, whereas 
phase II metabolism involves a larger number of enzyme families, including the UDP-
glucuronosyltransferases (UGTs), sulfotransferases (SULTs), N-acetyltransferases (NATs) and 
glutathione S-transferases (GSTs).28  
Around 90% of drugs are metabolized by enzymes of the CYP families 1 to 3.28 The genes of these 
enzymes are highly polymorphic and alleles leading to decreased or increased enzyme activity as well 
as   to   loss   of   function   have   been   described.  On   the   “Home  Page   of   the   Human  Cytochrome  P450  
Allele  Nomenclature  Committee”  known CYP alleles are listed and their impact on enzyme activity is 
indicated.29 In addition, genetic polymorphisms have been reported, that affect the activity of the 
cytochrome P450 oxidoreductase (POR).30 POR is a protein that transfers electrons from NADPH to 
the CYP enzymes and might, therefore, be a general limiting factor for drug metabolizing capacity.31 
Genetic variations influencing the activity of phase II enzymes have been described. It appears that 
they have less impact on drug clearance because phase I enzymes usually mediate the rate-limiting 
steps in overall drug biotransformation.28 However, it should be mentioned that they have been less 
studied than CYP enzymes.28 The importance of genetic variations in drug-metabolizing enzymes is 
reflected in the above-mentioned FDA list of pharmacogenomic biomarkers included in drug labels.27 
The majority of them concern enzymes of phase I or phase II metabolism.27 
While for some enzymes genotyping is a valuable tool to predict the phenotype (e.g. CYP2D6), for 
others the large inter-individual variability in enzyme activity could only be partially explained by 
genetic variations (e.g. CYP3A4) and phenotyping by probe drugs may be more appropriate.32-34 
Phenotyping describes the metabolic situation of the patient at the moment of the test and may be 
influenced by environmental factors such as comedications or smoking. Depending on the clinical 
question, this can be an advantage. In contrast, the results of genotyping have a lifetime value as they 
are not affected by environmental factors, and it can be carried out in any situation.32 
The acetylcholinesterase inhibitors donepezil and galantamine are mainly metabolized by the CYP2D6 
and CYP3A, whereas rivastigmine is metabolized by its target enzymes acetylcholinesterase and 
butyrylcholinesterase.11 Variations in the genes encoding CYP2D6, CYP3A and the cholinesterases 
have been investigated in some pharmacogenetic studies on these drugs. The current findings of 
these investigations are summarized in Article I. Memantine, in contrast, is only metabolized to a 
minor extent; it is mainly excreted unchanged by the kidneys.35 
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1.2.2.2 Drug transporter 
 
Many drugs are transported across biological membranes via passive diffusion at a rate related to 
their lipophilicity.36 However, a growing number of membrane transporters involved in the cellular 
uptake or efflux of a large variety of drugs has been characterized in almost all tissues, and their 
important role in drug delivery and disposition has been recognized (Figure 5).37 Likewise drug-
metabolizing enzymes, drug transporters are implicated in the detoxification systems of the body and 
may work in synergy. Uptake transporters help delivering the drugs to the metabolizing system, 
whereas efflux transporters help with excreting the drugs from the body and thereby decrease the load 
on detoxification enzymes.37 Moreover, the chemical modification of the drugs by the enzymes 
increases their hydrophilicity and provides the transporters with better substrates.37 There are two 
major transporter superfamilies, the solute carrier (SLC) and the ATP-binding cassette (ABC) families. 
SLC transporters allow the passage of drugs across the membrane by passive transport down their 
electrochemical gradients or by ion coupled symporters or antiporters, and the ABC transporters 
actively pump drugs out of the cells by using the energy of ATP hydrolysis.38 
 
 
Figure 5: Schematic representation of drug uptake and efflux transporters as determinants of drug disposition. 
Picture from Kerb R, Cancer Lett. 2006;234(1):4-33. 
Chapter 1: Introduction   
18 
 
The field of pharmacogenetics began with a focus on drug metabolizing enzymes, but it has been 
extended to membrane transporters that influence drug absorption, distribution and excretion.37 Up to 
now, convincing evidence of functional relevance for most of the transporter variants is still emerging 
or equivocal.39 Several reasons are conceivable for the current lack of conclusive findings. First of all, 
the most common genetic variants in transporters do not result in severe consequences such as a 
complete loss of function. Therefore, the resulting phenotypes are more subtle than those observed 
for inactivating mutations in metabolizing enzymes.39 Furthermore, transporters show extensive 
overlap in their substrate specificity. It is therefore likely that other transporters can compensate for 
single failure.37 Finally, transporter expression shows strong inter-individual differences, probably due 
to the regulation by several upstream signal transduction pathways and to the influence of non-genetic 
factors, such as sex hormones.39 Taking this into account, a more integrative approach might be 
required, considering the interaction of uptake and efflux transporters, metabolizing enzymes and 
pathways involved in gene expression.37,39 
Donepezil and galantamine are substrates of the P-glycoprotein (P-gp) transporter,40,41 belonging to 
the ABC family. P-gp is located in tissues with excretory function, including intestine, liver and kidney, 
and the blood-brain-barrier.42 Memantine is a substrate of the organic cation transporter 2 (OCT2), 
which belongs to the SLC family.43 OCT2 is predominantly expressed in the kidney36 and might, 
therefore, play an important role in the renal elimination of memantine. For both transporters, genetic 
variants have been described that alter protein expression and/or function. More details on the current 
pharmacogenetic research on drug transporters with respect to antidementia drugs are reported in 
Article I. 
 
1.2.2.3 Nuclear Receptors 
 
It is recognized that nuclear receptors, such as the Pregnane-X-Receptor (PXR) or the constitutive 
androstane receptor (CAR), are involved in the gene expression regulation of metabolizing enzymes 
and transporters (Figure 6).44 Moreover, there is emerging evidence that polymorphisms in nuclear 
receptors influence the expression of CYPs, as it has been shown for CYP3A4 and CYP1A2.45-47 For 
example, in vitro studies revealed genetic variants in the regulatory region of NR1I2, encoding the 
nuclear receptor PXR, which are associated with inducible and constitutive CYP3A4 expression.45,47 
Furthermore, in vivo studies demonstrated the influence of genetic variants in NR1I2 on the 
pharmacokinetics of drugs that are CYP3A substrates.48-50 A similar effect of genetic variations in 
nuclear receptors on drug transporter expression might be hypothesized, potentially influencing drug 
disposition. 
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Figure 6: Schematic representation of the gene expression regulation by nuclear receptors, PXR serves as 
example. Following ligand binding, PXR forms a heterodimer with the Retinoid-X-Receptor (RXR) and 
subsequently binds to the PXR response elements in the target genes (Phase I and Phase II enzymes, 
transporters), inducing their expression. Picture adapted from Ma X, Expert Opin Drug Metab Toxicol. 2008 
Jul;4(7):895-908. 
 
To date, no pharmacogenetic studies have been published that investigated the influence of 
polymorphisms in genes of nuclear receptors on the pharmacokinetics of antidementia drugs. 
 
1.2.3 Dose optimization trough Therapeutic Drug Monitoring 
 
The determination of the optimal dosage for a given treatment is generally performed by relating the 
therapeutic response to the administered dose. However, the blood concentration of a drug can be a 
better predictor of the pharmacologic effect(s) than the dose, as it takes inter-individual differences in 
pharmacokinetic processes into account. Therefore, Therapeutic Drug Monitoring (TDM), the 
measurement and interpretation of drug concentrations, has found wide acceptance.51 It has been 
shown that by maintaining patients drug plasma concentrations in the target range through individual 
dose adaption, efficacy and safety of many treatments, including psychotropic drugs, can be 
improved.32,51 
Presently, no TDM analyses are performed for antidementia drugs in clinical routine. Even though little 
evidence exists, several factors indicate that TDM might be beneficial and in recent consensus 
guidelines, therapeutic ranges for these drugs have been proposed.32 A high inter-individual variability 
in response to treatment has been observed,52-54 which might partly be due to high inter-individual 
variabilites in plasma concentrations.55-57 In elderly people, the presence of comorbidities and multiple 
comedication leading to drug-drug interactions, as well as genetic variations in metabolizing enzymes 
and transporters, might be causes of the observed inter-individual variabilities in plasma 
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concentrations. Moreover, non-adherence to the treatment could be revealed by TDM, which is a 
particular problem in patients with cognitive deficits.58 
The clinical efficacy of TDM is strongly associated with appropriate pharmacokinetic interpretation of 
the drug measurement and is reflected by individualized dose recommendations.51 For this purpose, 
the understanding of the dose-concentration relationship is essential. Population pharmacokinetic 
analyses are an important tool in TDM. Using Bayesian modeling, the extent of variability in 
pharmacokinetic parameters in a population sample is investigated and factors influencing this 
variability are identified.59 In contrast to traditional pharmacokinetic studies, including healthy 
volunteers or highly selected patients, population pharmacokinetic analyses collect relevant 
pharmacokinetic information in patients who are representative of the target population and it 
recognize variability as important feature that should be quantified.59 Moreover, data from sparse 
blood sampling can be used. This enables pharmacokinetic investigations in special populations, such 
as elderly patients, where the number of samples to be obtained per subject is limited because of 
ethical and/or medical concerns.59 The population pharmacokinetic parameters provide a framework 
for optimum dosing strategies in a population, and the identified influencing factors allow the 
elaboration of dose recommendations in subgroup of patients.59 Moreover, the extent of unexplained 
variability is determined, which is important because the efficacy and safety of a drug may decrease 
as unexplainable variability increases.59 Finally, with an established population model, individual 
pharmacokinetic parameters of a patient can be estimated based on a random plasma concentration 
measurement. This information can further be used for dosage individualization in TDM.59 
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1.3 Article I: Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used 
in the treatment of Alzheimer’s  disease 
 
Summary 
The aim of this review is to summarize the pharmacodynamics and pharmacokinetics of the four 
commonly used antidementia drugs and to give an overview on the current knowledge of 
pharmacogenetics in this field.  
Donepezil, galantamine and rivastigmine are acetylcholinesterase inhibitors with different 
pharmacodynamic and pharmacokinetic profiles. Donepezil inhibits selectively the 
acetylcholinesterase and has a long half-life of 70 hours. Galantamine is also a selective 
acetylcholinesterase inhibitor, but modulates as well presynaptic nicotinic receptors. It has a half-life of 
6 to 8 h. Donepezil and galantamine are mainly metabolized by CYP2D6 and CYP3A4 in the liver. 
Rivastigmine   is   a   so   called   “pseudo-irreversible”   inhibitor of the actylcholinesterase and the 
butyrylcholinesterase. The plasma half-life of the drug is very short (1 to 2 h), but the duration of action 
is longer as the enzymes are blocked for around 8.5 h and 3.5 h, respectively. Rivastigmine is 
metabolized by esterases in liver and intestine. Memantine is a non–competitive low affinity antagonist 
of the NMDA receptor with a half-life of 70 h. Its major route of elimination is unchanged via the 
kidneys. 
Addressing the issue of inter-patient variability in treatment response might be of special importance 
for the vulnerable population taking antidementia drugs. Pharmacogenetic considerations might help 
to avoid multiple medication changes due to non-response and/or adverse events. Some 
pharmacogenetic studies conducted on donepezil and galantamine reported an influence of the 
CYP2D6 genotype on the pharmacokinetics of the drugs and/or on the response to treatment. 
Moreover, polymorphisms in genes of the cholinergic markers acetylcholinesterase, 
butyrylcholinesterase, choline acetyltransferase and paraxonase were found to be associated with 
better clinical response to acetylcholinesterase inhibitors. However, confirmation studies in larger 
collectives are necessary to establish evidence of which subgroups of patients will most likely benefit 
from antidementia drugs. 
 
 
Review article in preparation 
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Abstract 
 
With the aging population,   Alzheimer’s   disease   has   become   a   major   public   concern   in   developed  
countries. To date, the pharmacological treatment is symptomatic and based on the observed 
neurotransmitter disturbances. The four mainly used drugs are the acetylcholinesterase inhibitors 
donepezil, galantamine and rivastigmine, and the NMDA receptor antagonist memantine. 
Pharmacogenetic studies have been conducted to evaluate the influence of genetic predisposition on 
the inter-patient variability in response to antidementia drugs. Since comorbidities, drug interactions 
and non-compliance are substantial therapeutic problems in the aging population, pharmacogenetic 
considerations could be of special importance to avoid multiple medication changes due to non-
response and/or adverse events. In this review we give an overview on the pharmacodynamic and 
pharmacokinetic profiles of antidementia drugs and we summarize the current knowledge of 
pharmacogenetics in this field. 
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Introduction 
 
Dementia is a syndrome of acquired cognitive deficits, characterized by various central 
neurodegenerative and ischemic processes, sufficient to interfere with social and occupational 
functioning.1 With the rapid global increase of the aging population, dementia has become an 
important public health challenge. It is estimated that currently around 24 million people suffer from 
dementia worldwide.2,3 The prevalence of dementia is age-specific and almost doubles every 5 years, 
from approximately 1.5% in individuals aged 60-69 years to 40% in people aged over 90 years.2 
Alzheimer’s  disease  (AD)  is  the  most  common  type  of  dementia,  accounting  for  50-60% of all cases, 
followed by vascular dementia, Lewy body dementia and mixed dementia (coexistence of AD and 
vascular dementia).1,4 
AD is a complex multifactorial and polygenetic disease. The key features of AD are formations of 
amyloid plaques by oligomerisation of beta-amyloid (A) proteins and neurofibrillary tangles by 
aggregation of tau protein in the medial temporal lobe structures and cortical areas of the brain.4 
These neuropathological lesions are leading to a degeneration of neurons and synapses. It is 
estimated that this process already starts 20-30 years before onset of clinical symptoms.4 Increasing 
evidence exists that A proteins interfere with certain neurotransmitter systems, including the 
cholinergic and glutamatergic neurotransmission, known to have important roles in learning and 
memory. These findings provide a pathophysiological basis of the observed neurochemical deficits in 
AD.5 Over   20   years   ago,   the   “cholinergic   hypothesis”   was   formulated,   that   states   that   a   loss   of  
cholinergic function in the central nervous system (CNS) contributes significantly to the cognitive 
decline associated with advanced age and AD.6 The cholinergic hypofunction is linked to a reduction 
in a number of cholinergic markers such as the choline acetyltransferase (ChAT), muscarinic and 
nicotinic acetylcholine receptor binding as well as levels of acetylcholine (ACh) in the synaptic clefts.7 
In addition to the cholinergic hypofunction, the glutamate metabolism has an important impact on the 
cognitive functions of the brain.4,8 There is good evidence that glutamatergic overstimulation of the 
postsynaptic N-methyl-D-aspartate (NMDA) receptors is implicated in the pathogenesis of AD and may 
results in neuronal damage.8-10 
Up to date, mutations in the APP gene coding for the amyloid precursor protein (APP) and in the 
presenilin genes (PSEN1 and PSEN2), coding for proteins involved amongst others in APP 
cleavage,11 are known to be associated with the early-onset familial form of AD.12 In contrast, for the 
late-onset  sporadic  form  of  AD,  only  the  APOε4  allele  of  the  apolipoprotein  E  gene  (APOE), that codes 
for a protein   with   different   functions   including   lipid   homeostasis   and   Aβ   scavenging,   has   been  
recognized as major risk factor for the disease.4,12 However, with the advances in high-throughput 
genomic association studies, novel risk factors have been identified (e.g. gene variants in the clusterin 
gene (CLU), complement receptor type 1 gene (CR1), phosphatidylinositol-binding clathrin assembly 
protein gene (PICALM)), for review see 3,13,14). 
To date, the treatment of AD is based on the above mentioned disturbances of the neurotransmitters 
ACh and glutamate. Three acetylcholinesterase inhibitors (AChEIs) are currently used, namely 
donepezil, galantamine and rivastigmine, which are licensed for the treatment of mild to moderate AD. 
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Donepezil has as well the indication for treatment of severe stages of the disease in the US.15 
Additionally, rivastigmine is approved for the use in mild to moderate dementia associated with 
Parkinson’s   disease   by   regulatory   agencies   such   as   the   Food   and   Drug   Administration   (FDA),   the  
European Medicines Agency (EMEA) and SwissMedic.15-17 Tacrine, the first AChEI on market, is 
associated with serious side effects, including hepatotoxicity, and has largely been replaced with the 
other available AChEIs.18 The NMDA receptor antagonist memantine is licensed for moderate to 
severe AD and acts on the glutamate transmission. 
Meta-analyses report consistent benefits of antidementia drugs regarding cognition and global 
assessment in AD, but with small treatment effects.19-21 Depending on measurement scales and 
duration of study period, it has been shown that the proportions of responders to AChEIs and 
memantine were only 15-35% and around 30%, respectively.10,22-25 Furthermore, AChEIs have non 
negligible adverse effects that occur at a rate of 8% in excess to placebo, the most frequent are 
nausea, vomiting and diarrhea.21,24 Memantine is generally well tolerated with dizziness, headache, 
constipation, somnolence and hypertension as side effects with slightly higher incidence than 
placebo.26  
The person-to-person variability of a drug response is a major problem in clinical practice leading to 
therapeutic failure or adverse effects of drugs in individuals or subpopulation of patients.27 The source 
of this variability is likely to be manifold, but genetic variations in drug-metabolizing enzymes, drug 
transporters and drug receptors can have a significant impact. Comorbidities, drug-drug interactions, 
adverse reactions, and non compliance are important problems in the pharmacological management 
of elderly patients. 28 It would therefore be particularly useful for this population to avoid multiple 
medication changes due to non-response or side effects.28 Pharmacogenetic considerations for 
antidementia drugs could therefore be of special interest as its understanding might be beneficial for 
prediction of drug efficacy and toxicity in the individual patient. Even though some pharmacogenetic 
studies have been conducted on antidementia drugs, by now there is no strong evidence of which 
subgroups of patients have favorable response to treatment or are at higher risks to develop side 
effects. 
The aim of this review is to summarize the pharmacodynamics and pharmacokinetics of antidementia 
drugs and to give an overview on the current knowledge of pharmacogenetics in this field. 
 
 
1. Pharmacodynamics 
 
In Table 1 are summarized the pharmacodynamic properties of antidementia drugs. 
 
1.1 Acetylcholinesterase Inhibitors 
 
The main pharmacological action of donepezil, galantamine and rivastigmine is to decrease the 
breakdown of acetylcholine in the synapse through inhibition of cholinesterases. In humans, two major 
forms of cholinesterases (ChE) are found, AChE and butyrylcholinesterase (BuChE).29 In the CNS, the 
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AChE activity is higher than the BuChE activity, whereas in the periphery the BuChE is the 
predominant form.29,30 The principal function of the AChE is to terminate the action of acetylcholine by 
hydrolyzing it to acetate and choline.31 The brain AChE is present in two globular forms, the tetrameric 
G4 form and the monomeric G1 form.31 Whereas AChE is highly selective for ACh, BuChE is also able 
to metabolize various other molecules.32 The physiological function of the BuChE is not clear, but it is 
conceivable that it acts as a scavenger, detoxifying certain chemicals and thereby limiting their entry to 
the CNS.31 In the course of AD, a selective reduction of the AChE G4 form from the mild to the severe 
stage is seen, while the activity of the G1 form is relatively preserved.31,32 In contrast, the activity of 
BuChE remains unchanged or is even increased.30 
The three currently used cholinesterase inhibitors (ChEI) differ in their pharmacological properties. 
Donepezil is a non-competitive and rapidly reversible inhibitor with a 300-fold higher selectivity for 
AChE than for BuChE.33,34 Galantamine is as well a reversible inhibitor of AChE, but binds to the 
enzyme in a competitive manner.35 Its selectivity for AChE is 50-fold higher than for BuChE.36 In 
addition to the effect on the AChE, galantamine modulates presynaptic nicotinic receptors, thereby 
further enhancing cholinergic activity at the synapse.37,38 Rivastigmine is described as a 
“pseudoirreversible”   inhibitor   due   to   its   particular   interaction   with   the   ChEs.   Like   ACh,   rivastigmine  
undergoes hydrolysis by the enzyme, but leaves the esteratic site of the enzyme carbamylated and 
therefore inactivates the central AChE and BuChE up to 8.5 and 3.5 hours, respectively.39,40 For that 
reason, the short plasma half-life (t1/2) of approximately 1-2 hours does not influence the duration of 
the inhibitory effect.41 
In contrast to donepezil and galantamine, rivastigmine shows no selectivity for AChE over BuChE.40,42 
Because of a significant decrease in AChE activity in AD patients, an additional inhibition of BuChE 
might be beneficial.29,31 Another particularity of rivastigmine is its preferential inhibition of the AChE G1 
form.31,40 Differences between the three AChEIs are also seen in the central versus peripheral 
selectivity. In contrast to galantamine, donepezil and rivastigmine demonstrated a preferential 
inhibition of the central AChE.37,39,43 The different selectivities of the drugs, AChE over BuChE, G1 
over G4 form and central over peripheral, are thought to affect their efficacy and side effect profile.32 
However, meta-analyses do not reveal significant differences with respect to efficacy of the three 
AChEIs, but donepezil is associated with fewer side effects compared to rivastigmine and 
galantamine.20,21,24 Finally, recent in vitro and in vivo data show, that ChEIs not only increase ACh 
levels   in   the   synapses   but   could   as   well   modulate   APP   processing.   The   resultant   reduction   of   Aβ  
deposition might be important for delaying the progressive cognitive decline.44-47 
 
1.2 Memantine 
 
As NMDA receptor antagonist, memantine acts on the glutamatergic system. Glutamate is the major 
excitatory neurotransmitter binding to a family of ionotropic receptors, among others the NMDA 
receptor.48 It is recognized that blockade of NMDA receptors leads to impairment of learning 
processes while their over-activation leads as well to disturbances in learning and, in a further step, to 
neurotoxicity.48 Therefore, the homeostasis in the glutamatergic system is very important.48 Excessive 
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activation of NMDA receptors is thought to be involved in AD.5,48,49 It is supposed that the continuous 
activity of the receptors results in a raise of synaptic noise, impairing detection of relevant signals such 
as learning.48 In AD, magnesium, an endogenous inhibitor which normally works as filter to detect 
relevant signals, is too weak to serve this role.50 
Before introduction of memantine, clinical trials with NMDA receptors antagonists have failed due to 
high binding affinity towards NMDA receptors or unspecificity of the drugs leading to unacceptable 
side effects.49 Memantine has a more favorable side-effect profile because of its special features as 
non-competitive low affinity antagonist. Since it binds only to open channels, a pathological increased 
NMDA receptor activity, with resultant excessive channel openings, is inhibited to a greater extent 
than physiological receptor activity.51 Moreover, the low binding affinity ensures that the drug does not 
accumulate in the ion channels, and therefore, does not block subsequent synaptic 
neurotransmission.51 With these characteristics, memantine is thought to act as a slightly more 
effective surrogate for the intrinsic NMDA inhibitor magnesium.48 Clinical trials on memantine are 
focused on improvements in cognitive function and behavioral aspects, but memantine is potentially 
as well a neuroprotective agent.50,51  
Given the complementary mode of action, different studies were conducted to investigate the effect of 
concomitant administration of memantine with AChEIs. The majority of these studies revealed a 
beneficial effect of coadministration of the two drug classes on different measurement scales, also on 
a long-term basis.52-56 
 
 
2. Pharmacokinetics 
 
In Table 2 are shown the steady-state pharmacokinetic parameters of antidementia drugs. 
 
2.1 Donepezil 
2.1.1 Pharmacokinetic parameters and metabolism 
 
Donepezil is well absorbed with a bioavailability approaching 100% and peak plasma concentrations 
(Cmax) are achieved after 3-5 h.57,58 Food intake has no significant effect on the drug absorption.58 The 
drug demonstrates linear kinetic properties with a t½ of approximately 70 h indicating that once daily 
administration is appropriate and that steady-state conditions are reached within two to three weeks.59 
The mean serum protein binding of the compound is around 93% and the volume of distribution (V) is 
approximately 12 L/kg. 58,60,61 
Donepezil is metabolized hepatically by the enzymes cytochrome P450 (CYP) 3A4 and 2D6 and the 
primary route of elimination of the parent drug and the metabolites is renal.62 There are three 
suggested metabolic pathways: O-demethylation to the metabolites M1 and M2 followed by 
glucuronide conjugation to the metabolites M11 and M12, N-dealkylation to the metabolite M4 and as 
minor route N-oxidation to the metabolite M6.62,63 Unchanged donepezil was found to be the principal 
component in plasma and urine.62 The metabolite M1 (6-O-desmethyl-donepezil) is the only active 
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metabolite with a comparable potency in AChE inhibition as donepezil. In human plasma, M1 is only 
present at about 20% of the concentration of the parent drug.57 Moreover, in rats the transfer of M1 
into the brain as target organ is very low.64 Therefore, it is suggested that M1 does not significantly 
contribute to the pharmacological activity of the drug. 
Due to its CYP dependent metabolism, it is suggested that drug interactions via CYP3A4 and CYP2D6 
could be important. Two studies in healthy volunteers showed an influence of CYP inhibitors on 
donepezil plasma levels. The concurrent administration of ketoconazole, a strong CYP3A4 inhibitor, 
resulted in a significant increase in donepezil plasma concentrations, estimated to be 23-30% at 
steady state.65 Moreover, the coadministration of cimetidine, a CYP3A4 and CYP2D6 inhibitor, leaded 
to slightly higher Cmax and area under the curve (AUC) values (11-13% and 10%, respectively).66 In 
both studies the t1/2 and time to maximum peak plasma concentration (tmax) of donepezil were not 
significantly altered.65,66 The clinical significance of these interactions remains to be determined, but 
careful monitoring is recommended when donepezil is coadministrated with CYP3A4 and CYP2D6 
inhibitors. 
 
2.1.2 Effects of age, renal and hepatic impairment on the pharmacokinetics 
 
Results of a single dose study in healthy young volunteers (age 20-27 years) and elderly patients (age 
65-82 years) suggest that some of the pharmacokinetic parameters are affected by aging due to a 
slower absorption and a wider distribution of the drug.61 The t1/2, tmax and V in steady state conditions 
are significantly higher in the elderly than in the young. However, as the AUC, Cmax and the clearance 
(CL) did not differ between the two groups, modification of the dose in elderly does not appear to be 
necessary.61 
As donepezil and its metabolites are predominantly renally cleared, a rise in plasma concentrations 
could be expected in subject with impaired kidney function.67 Nevertheless, in a single and a multiple 
dose study with 5 mg donepezil daily, no significant differences in pharmacokinetic parameters were 
found between healthy controls and subjects with moderately to severely (CLcreat 7-30 mL/min/1.73m2) 
and moderately (CLcreat 17-33 mL/min/1.73m2) impaired renal function, respectively.67,68 Therefore, no 
dose adjustment is required for patients with moderate renal insufficiency. In contrast, at steady state 
mean values for AUC, t1/2, Cmax and the mean concentration at steady-state (Css) were significantly 
increased in subjects with impaired liver function (Child-Pugh grade A or B) compared with healthy 
controls.69 It is suggested that the administration of 5 mg donepezil daily is safe and well tolerated in 
patients with mild to moderate hepatic impairment.69 However, a doubling of the dose to 10 mg daily 
should be monitored. 
 
2.2 Galantamine 
2.2.1 Pharmacokinetic parameters and metabolism 
 
Galantamine is well and quickly absorbed with a bioavailability approaching 100%.70 Coadministration 
with food does not alter the total amount of absorbed drug substance, but tmax is delayed by 
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approximately 1.5 h and Cmax is decreased by 25%.71 Galantamine has a linear kinetic over a large 
dose range and a t½ of around 7 h.70,72,73 The V is 2.6 L/kg and the drug exhibits a low plasma protein 
binding of 17%.70,74 An extended-release (ER) formulation of galantamine was developed allowing 
once-daily drug administration. The immediate-release (IR) and the extended-release (ER) 
formulations are bioequivalent with respect to AUC and minimum plasma concentration (Cmin) for a 
daily dose of 24 mg. As expected, the ER formulation resulted in higher tmax values (4.4 h versus 1.2 
h) and Cmax values were reduced by 25%.72 
Approximately 30% of galantamine is excreted unchanged in the urine; the other part is metabolized 
through multiple pathways, primarily by O-demethylation by CYP2D6, O-oxidation by CYP3A4 and 
glucuronidation.75 After a single dose of 4 mg radiolabeled galantamine, the parent compound 
accounted for the bulk radioactivity in plasma.75 Beside, two major metabolites were found, namely the 
glucuronide of O-desmethyl-galantamine and the glucuronide of galantamine itself.75 In vitro it has 
been shown that O-desmethyl-galantamine is a more potent inhibitor of AChE than galantamine. 
However, the unconjugated metabolite was not detected in plasma and may not contribute to the 
pharmacological activity of the drug since it is immediately inactivated by glucuronidation.75,76 
The effect of the strong CYP2D6 inhibitor quinidine on the metabolism of galantamine was 
investigated.76 Four subjects received a single dose of 15 mg galantamine alone and 7 days later in 
combination with 250 mg quinidine. The inhibition of the O-demethylation pathway resulted in an 
almost complete suppression of the renal elimination of O-desmethyl-galantamine glucuronide. The 
urinary excretion of unchanged galantamine and other metabolites was consequently increased. 
Additionally, multiple dose pharmacokinetic studies showed an increase of the AUC by 40%, 30% and 
10% when galantamine was coadministrated with paroxetine (inhibitor of CYP2D6), ketoconazole 
(inhibitor of CYP3A34 and CYP2D6), and erythromycin (inhibitor of CYP3A4), respectively.77 Dose 
reduction may be required when galantamine is given with inhibitors of CYP2D6 and CYP3A4. 
 
2.2.2 Effects of age, renal and hepatic impairment on the pharmacokinetics 
 
A galantamine population pharmacokinetic study, including data from 15 clinical trials, showed a 
decreased galantamine CL with increasing age.78 In AD patients the CL was, on average, reduced by 
30% compared to healthy young subjects.78 In the same study, model simulations were conducted in 
AD patients with renal and hepatic impairment. No significant difference in galantamine plasma 
concentrations were found between patients with and without renal insufficiency (CLcreat 9-51 
mL/min).78 In contrast, their model investigating hepatic impairment showed a 60% reduction in 
metabolic CL among patients with moderate hepatic dysfunction (Child-Pugh grade B) and therefore 
higher apparent galantamine levels.78 These results are in line with the findings of a single dose study 
of 4 mg galantamine comparing healthy volunteers and subjects with mildly (Child-Pugh grade A) and 
moderately (Child-Pugh grade B) reduced hepatic function.74 No significant difference in CL was found 
in subjects with mild hepatic dysfunction, but the CL was reduced by 23% in subjects with moderate 
hepatic impairment.74 Consequently, dose titration should proceed cautiously in patients with 
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moderately impaired hepatic function and the use in patients with severely impaired liver function is 
not recommended. 
 
2.3 Rivastigmine 
2.3.1 Pharmacokinetic parameters and metabolism 
 
After oral administration, rivastigmine is rapidly and almost completely absorbed reaching maximum 
plasma concentrations within 1 h.79,80 Concomitant food slows the absorption, lowers Cmax by 30% and 
increases AUC by 30% compared to fasting conditions.39 Since it is supposed that the high peak 
plasma concentrations are related to gastrointestinal side effects, administration of rivastigmine with 
food is recommended for a better tolerability.39 Rivastigmine exhibits non-linear pharmacokinetics due 
to a capacity-limited elimination.39,79 Thus, the plasma level and AUC of the drug increase more than 
proportionally with increasing dose. Nonlinearity is also shown in the non proportional enhancement in 
absolute bioavailability of the drug. Following a single dose of 3 mg and 6 mg rivastigmine, the 
bioavailability is 35% and 70%, respectively.41,81 Rivastigmine has a very short t½ life of 1.5 to 2 h, 
therefore, steady state conditions are essentially reached by the second dose.39,41,79,80 The drug is 
widely distributed throughout the body with a V between 1.8 and 2.7 L/kg and about 40% is bound to 
plasma proteins.39,82 To improve the tolerability of rivastigmine and the patient compliance, a 
transdermal patch has been developed.83,84 This formulation shows beneficial pharmacokinetic 
characteristics as the patch gradually releases the drug substance over the 24 h application period. 
Findings of a comparison study of patch for 24 h and capsules b.i.d demonstrated a lowered Cmax by 
around 30% and a considerably later tmax (8 h versus 1 h), with a similar level of exposure.79 
Additionally, the continuous release of rivastigmine lowered the fluctuation between peak and trough 
plasma concentrations significantly.79,83 
Rivastigmine is extensively metabolized by cholinesterases in the liver and to a lesser extent in the 
intestine to NAP 226-90, an inactive and non-toxic metabolite.40,79,82 Renal excretion of the sulfate 
conjugate of NAP 226-90 is the primary route of elimination.40 After 24 h, the drug and the metabolite 
are almost completely excreted.39 Less of the metabolite NAP226-90 is formed following patch 
administration due to the lack of first-pass metabolism, and less inter-patient variability was observed 
for the treatment with the patch versus capsules.79,83,85 Hepatic microsomal enzymes are not involved 
to any significant extent in the metabolism of rivastigmine, making drug-drug interactions unlikely.80 
 
2.3.2 Effects of age, renal and hepatic impairment on the pharmacokinetics 
 
Findings of a study comparing pharmacokinetics in young and elderly healthy subjects demonstrated a 
slightly prolonged t1/2 in elderly persons (0.88-1.25h versus 0.80-0.99 h). However, another study in 
AD patients aged 50 to 92 years revealed no difference in drug absorption and exposure with age.39 A 
dose escalating study with 1-3 mg rivastigmine investigated the influence of renal and hepatic 
impairment on the pharmacokinetics of the drug. Compared to healthy controls, the AUCs of 
rivastigmine and its metabolite were 1.4 fold and 1.5 fold increased in patients with severe renal 
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impairment (CLcreat <10 mL/min).86 In patients with moderately severe liver cirrhosis, the AUCs of 
rivastigmine and NAP 226-90 were 2.3-fold higher and 0.8-fold lower compared to healthy 
controls.39,86 However, no specific dose recommendations are given for patients with renal and hepatic 
impairment, because of the clinical practice of dose titration according to tolerability of the drug.39,86 
 
2.4 Memantine 
2.4.1 Pharmacokinetic parameters and metabolism 
 
Memantine is well absorbed with a bioavailability close to 100%, reaching maximum plasma levels 
within 3-8 h.87 The drug exhibits linear pharmacokinetics in a wide dose range with a t1/2 between 60 
and 70 hours.88,89 Steady state conditions are attained within 11 days with plasma levels 3-4 times 
higher than Cmax following a single dose.
89,90 The V is reported between 4 and 9 L/kg and the rate of 
plasma protein binding is approximately 45%.87,91 Memantine and its metabolites are mainly excreted 
via the kidneys with contribution of tubular secretion.87 In man, about 80% of the circulating 
memantine dose is present as the parent compound.92 Main metabolites are N-3,5-dimethyl-
gludantan, the isomeric mixture of 4- and 6-hydroxy-memantine, and 1-nitroso-3,5-dimethyl-
adamantane, none of which is active.92 Despite the fact that memantine undergoes hydroxylation and 
oxidation, typical CYP-catalyzed reactions, no contribution of these enzymes have yet been 
detected.93 However, it has been found that memantine is a potent and selective inhibitor of the 
CYP2B6 enzyme at clinically relevant concentration.93 Tubular secretion of memantine occurs via the 
renal cation transport system.87 Memantine has been shown to be a substrate of the organic cation 
transporter 2 (OCT2),94 which is predominantly expressed in human kidneys.95 Therefore, OCT2 might 
play an important role in memantine elimination. Urine pH has been shown to be a major determinant 
for the renal excretion of alkaline drugs like memantine.96 A clinical trial with healthy volunteers 
demonstrated a 7-10 fold higher renal CL in alkaline urine (pH 8) compared with acidic urine (pH 5).96 
To alkalize the urine the subjects received sodium bicarbonate, and for acidification ammonium 
chloride was administered. Nevertheless, in a more naturalistic approach measuring the urine pH of a 
representative  patient’s  population,  no  significant  effect  of  urine  pH  (pH  range  4.9-9) on memantine CL 
was found.91 
Co-medication with drugs which are eliminated via tubular secretion resulted in a lower CL of 
memantine.91 A competitive drug-memantine interaction at the OCT2 in the kidney could be a possible 
explanation, even though the memantine concentrations necessary for the interaction with OCT2 are 
higher than the therapeutic serum concentrations. However, it is conceivable that other renal 
transporters are implicated in the observed drug interactions.91 Another study investigated the 
pharmacokinetic interaction of memantine and glyburide/metformin.97 Healthy subjects received a 
single dose of memantine with and without previous administration of glyburide/metformin for 6 days. 
Although metformin is cleared renally via organic cation transporters, no pharmacokinetic interaction 
between metformin and memantine was found.97 
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2.4.2 Effects of age, renal and hepatic impairment on the pharmacokinetics 
 
Considering studies conducted in young and elderly healthy subjects, the pharmacokinetic parameters 
changed only slightly with age, most probably due to variations in body weight and fat.87 
Significant differences were seen in patients with moderate (CLcreat 30-49 mL/min) to severe (CLcreat 5-
29 mL/min) renal impairment compared to healthy subjects regarding AUC (increased by 60% and 
115%) and CL (decreased by 36% and 52%). In addition, t1/2 was enhanced by 95% in subjects with 
severe renal impairment.88 According to the prescription information, memantine dose can be 
increased up to the normal dose of 20 mg per day if 10 mg is well tolerated during the titration 
phase.92 In patients with severe renal impairment, half of the normal daily memantine dose is 
recommended. As memantine is metabolized only to a minor extent and into inactive compounds, no 
clinically relevant changes in pharmacokinetics are expected in patients with hepatic impairment.87 
 
 
3. Pharmacogenetics 
 
3.1 Acetylcholinesterase Inhibitors 
 
It is widely accepted that genetic variations in drug metabolizing enzymes contribute to therapeutic 
failures and adverse drug reactions. With regard to the metabolism of donepezil and galantamine, the 
liver enzymes CYP2D6 and CYP3A4 are interesting candidates for pharmacogenetic investigations.18 
Genetic polymorphisms in CYP2D6 are extensively studied in many different populations and over 80 
allelic variants have been described.98 Phenotypically four types of metabolizers can be distinguished 
with different frequencies in the Caucasian population: poor metabolizers (PM), intermediate 
metabolizers (IM), extensive metabolizers (EM) and ultrarapid metabolizers (UM) accounting for 
approximately 5-10%, 10-17%, 70-80% and 3-5%, respectively.99,100 The PM phenotype is 
characterized by the presence of two null alleles, which do not encode a functional protein. 
Consequently, they are unable to use the CYP2D6-dependent metabolic pathway for drug elimination 
which can lead to very high plasma concentrations and even toxicity. The CYP-dependent metabolism 
is as well limited in the IM phenotype, as they usually carry a null allele in combination with a reduced-
function allele. The EM phenotype is due to one or two alleles with normal function. By contrast, 
multiple gene copies are causing the UM phenotype.99,100 UMs typically exhibit decreased drug plasma 
concentrations at conventional doses and are therefore prone to a lack of response regarding drugs 
metabolized by CYP2D6. 
To our knowledge, only one clinical trial has been conducted investigating the impact of genetic 
variations in CYP2D6 on donepezil plasma concentrations. This steady-state study in 42 patients of 
Caucasian ethnicity included 2 UMs, 10 heterozygous EMs (one functional CYP2D6 allele) and 30 
homozygous EMs (two functional CYP2D6 alleles) receiving donepezil for at least 3 months.101 An 
impact of the CYP2D6 genotype on drug plasma concentrations is suggested since UMs had lower 
drug plasma concentrations compared to EMs, and homozygous EMs had lower plasma levels than 
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heterozygous   EMs.   However,   the   differences   in   plasma   concentrations   didn’t   reach   statistical  
significance, possibly because only a small number of subjects and no PMs were included.101 
Interestingly, heterozygous EMs showed a significantly better clinical response to treatment than 
homozygous EMs, as measured by change in the MMSE score (1.4 versus -1.3).101 Moreover, 
different clinical trials were carried out to evaluate the influence of the CYP2D6 genotype on the 
response to donepezil treatment. In a prospective study including 94 Spanish AD patients, the 
subjects were treated with a combination therapy consisting of donepezil and three other drugs (CDP-
choline, piracetam, nicergoline).28 The best responders were the EMs and IMs with a clear 
improvement of cognition after one year (MMSE change 2.2 and 1.1), and the worst responders were 
the PMs and UMs showing a progressive cognitive decline (MMSE change -2.7 and -1.4).28 In a 
prospective study including 127 Caucasian AD patients treated with donepezil, a significant higher 
frequency of patients with the G allele of the rs1080985 single nucleotide polymorphism (SNP) in 
CYP2D6 was found in non-responders compared to responders (60% versus 35%) after 6 months.102 
Since it has been reported that the G allele is associated with a higher enzyme activity and therefore a 
faster metabolism, it is thought that the poorer response to donepezil is due to lower plasma levels of 
the drug.102 The same group investigated 16 functional polymorphisms in CYP2D6 on the clinical 
response after 6 months of treatment with donepezil in a new cohort of 57 patients with mild-to-
moderate AD.103 A significant higher frequency of gene variants conferring decreased or absent 
enzyme activity was observed in responders than in non-responder patients (74% versus 37%). 
Finally, the clinical outcome in 171 Italian AD patients treated with donepezil, galantamine or 
rivastigmine was investigated in a prospective study taking into account genetic variations in CYP2D6 
and BCHE, encoding the BuChE.104 In this study population, no significant association was found 
between CYP2D6 and BCHE genotypes and response to treatment after one year for all three 
ChEIs.104 The discrepancy of the results regarding the impact of genetic variations in CYP2D6 on 
response to donepezil treatment might be due to different follow-up periods and to different 
approaches to classify responders and non-responders as well as prediction of the CYP2D6 
phenotypes from genotypes. However, since it is suspected that higher plasma levels could be 
associated with a higher response rate but possibly also with a higher frequency of side-effects, more 
studies are needed to clarify the influence of polymorphisms in CYP2D6 on plasma concentrations of 
donepezil and the clinical response. 
In three studies the impact of the CYP2D6 genotype on galantamine pharmacokinetics was assessed. 
In the first study, genotyping was performed in a subset of 356 patients included in two phase III 
clinical trials, among 336 EMs and 20 PMs.78 The population pharmacokinetic model indicated that the 
galantamine CL is reduced by 25% in PMs compared to EMs.78 In the second study, the metabolite 
profile was investigated in two EMs and two PMs after administration of a single low dose of 4 mg 
galantamine.75 There was a considerable difference regarding the CYP2D6 catalyzed O-demethylation 
between EMs and PMs. In EMs, six metabolites resulting from O-demethylation represented over 33% 
of the dose, whereas in PMs these metabolites accounted for only 5% of the dose. However, the lower 
level excretion of metabolites formed by O-demethylation in PMs was compensated by excretion of 
higher levels of unchanged galantamine and the N-oxid of galantamine. No apparent difference in 
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galantamine plasma levels was seen between EMs and PMs in these four subjects.75 In another study 
comparing galantamine pharmacokinetic parameters in 13 Japanese with 12 Caucasian healthy 
volunteers, one PM was identified in the Caucasian group.73 No apparent pharmacokinetic difference 
was seen in this subject. In none of these studies UMs were taken into account. 
Likewise CYP2D6, the second CYP implicated in the metabolism of donepezil and galantamine, the 
CYP3A4, demonstrates a large inter-individual variability in expression and activity. CYP3A4 is the 
major form of human cytochromes in the liver and it is also abundant in the intestine.105 To date, 
various genetic variations in CYP3A4 have been described, but their predictive information on protein 
expression or activity is limited.105 There is a large overlap in substrate specificity between the 
isoenzyme CYP3A4 and CYP3A5, therefore, it might be that donepezil and galantamine are to some 
extent as well metabolized by the latter. Compared to CYP3A4, CYP3A5 is expressed at a much lower 
level in the liver, but it has a wider tissue distribution.105 CYP3A5*3 is the most common allele in 
Caucasians with a frequency of 95% leading to a low expression of the enzyme. However, in 
homozygous carriers of the CYP3A5*1 allele, the CYP3A5 can contribute up to 50% of the CYP3A 
content in the liver and might therefore be important in drug metabolism.105 Furthermore, it has been 
shown that polymorphisms in the cytochrome P450 oxidoreductase (POR) or in the pregnane X 
receptor (PXR), a regulator of CYP3A transcription, could influence drug metabolism by CYP3A.106-108 
A study in 54 Caucasian AD patients has been conducted to investigate the influence of different 
CYP3A4 and CYP3A5 alleles on the plasma levels and the clinical outcome of donepezil.109 The 
results suggest that the investigated genetic variants of CYP3A4 and CYP3A5 do not play a pivotal 
role in the variability in donepezil metabolism. In contrast, an influence of polymorphisms in the 
ABCB1 gene on donepezil concentrations and response to treatment was found. ABCB1 codes for the 
membrane transporter P-Glycoprotein (P-gp), which has a large substrate overlap with CYP3A4 and is 
implicated in absorption, distribution and excretion of many drugs.110 Patients homozygous for the 
ABCB1 1236T/2677T/3435T haplotype showed a tendency towards a better clinical response and 
lower  plasma  concentrations.  However,  the  differences  didn’t  reach  statistical  significance.109  
Associations of genetic variations in ACHE, encoding the AChE, and BCHE with response to AChEI 
treatment were studied in a few clinical trials. These investigations could be especially interesting for 
rivastigmine since AChE and BuChE are the target enzymes and at the same time the main 
metabolizing enzymes for this agent. In an Italian study population of 461 AD patients, gene frequency 
distributions of one SNP in ACHE and two SNPs in BCHE, as well as one SNP in the gene of ChAT, 
were investigated.111 Additionally, the association of these SNPs with response to either donepezil or 
rivastigmine treatment was assessed in a subset of 171 patients. It was found that carriers of the 
ACHE rs2571598 AA genotype receiving rivastigmine showed a slightly better response to treatment 
evaluated by the MMSE score changes (-1.62 for G/G, -2.71 for G/A and -1.03 for A/A). In contrast, no 
association was seen in patients treated with donepezil. Additionally, no influence of the K-variant of 
BCHE (rs1803274), which leads to a lower enzyme expression, was seen on the treatment effect.111 
This result is in agreement with the above mentioned study investigating genetic variations in CYP2D6 
and BCHE in a cohort of 171 Italian AD patients treated for one year with donepezil, rivastigmine or 
galantamine.104 However, in a retrospective analysis in 114 Caucasian AD patients younger than 75 
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years, a differential response to rivastigmine regarding BCHE genotype was found.112 On different 
measurement scales wild-type BCHE carriers had a better response to rivastigmine treatment 
compared to donepezil, whereas the treatment response was similar within carriers of the K-allele.112 
Furthermore, polymorphisms in other cholinergic markers were studied regarding responsiveness of 
patients to AChEI therapy. The influence of six polymorphisms in CHAT, encoding the enzyme 
responsible for ACh biosynthesis, was studied in 121 patients recruited in Northern Ireland and 
receiving an AChEI. The SNP rs733722, lying in a putative promoter region of the gene and appearing 
with a frequency of 33%, showed to be a marker of response to AChEI treatment.113 Carriers of two T 
alleles had a significant smaller change in MMSE/year than subjects carrying at least one copy of the 
C allele (-0.18 versus -1.84).113 Paraxonase-1 (PON-1) is an arylesterase with multiple biological 
functions, showing high inter-individual differences in activity.114 It is known that the PON1 192Q/R 
polymorphism (rs662) is influencing the activity of the enzyme.114 Interestingly, this enzyme is also a 
potent endogenous cholinesterase inhibitor.114 Therefore, it might be that PON-1 interacts 
synergistically with drugs inhibiting ChEs.114 A study investigated the PON1 192Q/R polymorphism 
(rs662) in 73 Caucasian patients treated with donepezil or rivastigmine.114 The R allele was present in 
44% of patients that responded to treatment, while its frequency was only 26% among non-
responders, thus, suggesting that carriers of the R allele have more treatment benefits than Q allele 
carriers.114 However, these results could not be confirmed by a recent study, investigation this 
polymorphism in 101 Polish patients.115 Furthermore, phenotypic screening of the constitutive m1 
muscarinic acetylcholine receptor activity (CHRM1) was done in a cohort of 74 individuals, including 
48 diagnosed with primarily AD and stratified by their treatment response to AChEIs.116 The authors 
concluded that the m1 receptor gene is not highly polymorphic in the human population suggesting 
that genetic variation within this gene is not a contributing factor to the clinical variability in treatment 
with AChEIs.116 Further studies are needed to clarify the impact of SNPs in cholinergic markers on 
response to treatment with AChEIs. 
In contrast, many pharmacogenetic studies were conducted to evaluate the impact of the lipoprotein 
APOE genotype on treatment response to AChEIs. There are three major polymorphic forms of APOE, 
ε2  (Cys112,  Cys158),  ε3  (Cys112,  Arg158)  and  ε4  (Arg112,  Arg158),  which  differ  from  one  another  by  
one amino acid substitution.117 The   APOε4   allele   is   known   to   be   a   major   risk   factor   for   the  
development of AD. APOE plays various roles in the CNS, it is proposed to influence the amyloid-β  
metabolism, lipid homoeostasis, synaptic activity, response to cellular injury, and 
neuroinflammation.117 Since it is suggested that the integrity of the cholinergic system vary between 
carriers of the different APOE alleles, it was suggested that the APOE genotypes might be a predictor 
for the quality and size of drug response.118 However, the results of the pharmacogenetic studies are 
conflicting and the majority of the studies report no association of the APOE genotype with donepezil, 
rivastigmine or galantamine treatment response.119-128  
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3.2 Memantine 
 
Given the large inter-individual differences in plasma levels and the concentration dependent 
probability of adverse events of memantine,87,88,91 it would be beneficial to understand the 
demographic and genetic factors influencing this variability. To our knowledge, no pharmacogenetic 
studies have been conducted on memantine. The high inter-individual variability could partly be due to 
differences in renal elimination as memantine is mainly excreted unchanged via the kidneys.87 Since it 
is suggested that OCT2 is an important transporter involved in the active secretion of memantine, 
genetic variation in this transporter might cause inter-individual differences in the renal CL of the drug. 
In vitro data have revealed genetic variations in SLC22A2, coding for OCT2, altering protein function 
and expression.129-133 The most common coding polymorphism 808G>T (rs316019), occurring at a 
frequency of 10 to 15% in different ethnics, has been investigated in several pharmacokinetic studies 
of metformin and in one clinical trial of cisplatin, both agents renally excreted by OCT2.134-138 The 
results of these studies are divergent, thus, up to now no conclusion can be drawn for the predictive 
effect of this SNP on metformin and cisplatin pharmacokinetic parameters. However, plasma 
concentrations of memantine could be influenced by genetic variations in OCT2 or other renal 
transporters. More studies are requested to elucidate the impact of polymorphisms in drug 
transporters on pharmacokinetics of renally eliminated drugs.  
 
 
4. Conclusion 
The current treatment of AD is based on the observed neurotransmitter disturbances: the cholinergic 
hypofunction and the glutamatergic overstimulation of NMDA receptors. Donepezil, galantamine and 
rivastigmine are AChEIs, increasing the level of ACh in the synaptic clefts. The three drugs have 
different pharmacodynamic and pharmacokinetic profiles, therefore, efficacy and tolerability may not 
be identical in the individual patient and a change from one AChEI to another might be beneficial. 
Donepezil is a selective AChEI and has a t1/2 of 70 h, therefore, once-daily dosing is applied. The drug 
is mainly metabolized by CYP2D6 and CYP3A4 in the liver. Galantamine is as well a selective AChEI 
but modulates as well presynaptic nicotinic receptors. It has a t1/2 of 6 to 8 h, but once daily dosing is 
possible by administration of the ER formulation. Galantamine is metabolized hepatically by the 
CYP2D6  and  CYP3A4.  Rivastigmine  is  a  so  called  “pseudo-irreversible”  inhibitor  of  AChE  and  BuChE.  
The plasma t1/2 of the drug is very short (1 to 2 h), but the duration of action is longer as the AChE and 
the BuChE are blocked for around 8.5 h and 3.5 h, respectively. Oral formulations of the drug have to 
be given twice a day, whereas the patch allows a once-daily administration. Rivastigmine is 
metabolized by esterases in liver and intestine. Memantine is a non–competitive low affinity antagonist 
of the NMDA receptor, inhibiting the pathological excessive channel openings. It has a t1/2 of around 
70 h, a once daily dosing is therefore sufficiently. Mematine is only metabolized to a minor extent, the 
major route of elimination is unchanged via the kidneys. 
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Pharmacogenetic studies addressing the issue of inter-patient variability in response to antidementia 
drugs  might  be  valuable  to  develop  a  “personalized  pharmacotherapy”  with  the potential to maximize 
the benefit of therapy and to minimize side effects. This approach could be of special importance for 
the population taking antidementia drugs, since it is vulnerable to comorbidities, polypharmacy and 
non-compliance. Some pharmacogenetic studies conducted on donepezil and galantamine reported 
an influence of the CYP2D6 genotype on the pharmacokinetics of the drugs as well as on the 
response to treatment. Moreover, polymorphisms in genes of the cholinergic markers AChE, BuChE, 
ChAT and PON-1 were found to be associated with better clinical response to AChEIs. However, 
confirmation studies in larger collectives are necessary to establish evidence of which subgroups of 
patients will most likely benefit from antidementia drugs. 
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Table 1: Pharmacodynamic properties of antidementia drugs. 
 
Cholinesterase inhibitors 
NMDA-
receptora 
antagonist 
References 
Drug  Donepezil Galantamine Rivastigmine Memantine  
Mode of 
action 
Mode of 
inhibition 
Non-
competitive, 
rapidly 
reversible  
Competitive, 
rapidly 
reversible  
Non-
competitive, 
very slowly 
reversible  
Uncompetitive, 
low-affinity 
NMDA-
receptor 
antagonist  
32,51 
AChE/BuChEb 
selectivity 
300  50  1   
33,34,36,42 
Brain versus 
peripheral 
selectivity 
Yes  No  Yes  
31,34,40 
ACh isoform 
selectivity 
None   None   G1>G4  
31,32,40,139 
nAChRc 
modulation  
No  Yes  No  
32 
Major 
side 
effects 
 Nausea, vomiting, diarrhea  Dizziness, 
headache, 
constipation, 
somnolence, 
hypertension  
21,24,26 
 
a) NMDA-receptor=N-methyl-D-aspartate-receptor  
b) AChE=acetylcholinesterase, BuChE=butyrylcholinesterase 
c) nAChR=nicotinic acetylcholine receptor  
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Table 2: Steady-state pharmacokinetic parameters of antidementia drugs. 
 
a) The new dosage of 23 mg has recently been approved by the FDA for the treatment of 
moderate to severe AD. 
b) The half-life of the drug is short, but the duration of action is longer as the acetylcholinesterase 
and butyrylcholinesterase are inhibited for 8.5 h and 3.5 h, respectively, through its pseudo-
irreversible mechanism.  
c) cap=capsule, IR= immediate release, ER=extended release formulation 
average±SD. 
Drug Donepezil Galantamine Rivastigmine Memantine References 
Daily dose 
5-10 mg, 23 
mga 
16-24 mg 6–12 mg 10-20 mg  
Bioavailability 100%  100%  
35% (3 mg),  
70 % (6 mg)  
100%  41,57,70,87 
Protein binding  93%  17%  40%  45%  61,74,81,87 
t1/2  70 h 6-8 h  
1.5-2 hb (capc),  
3.4 hb (patch)  
60-70 
 
41,59,60,70,72,73
,79,80,88,89 
tmaxss  4 h  
1 h (IRc),  
4-5 h (ERc)  
1 h (capc), 
8 h (patch)  
3-8 h  60,72,79,87,140 
Cmaxss
d [ng ml-1] 
 
61 ± 10 
(10 mg/d)  
53±10  
(ERc 16 mg/d)  
30±13  
(capc 12 mg/d),  
7.9±2.9 
(patch 9.5 mg/24h)  
70-180  
(20 mg)  
60,79,91,140 
AUCss
d [ng h ml-1] 
 
 
1128±196  
(10 mg/d)  
830±177 
(ERc 16 mg/d)  
191±140 
(capc 12 mg/d), 
127±41  
(patch 9.5 mg/24h)  
386 ± 59  
(5mg)  
60,79,89,140 
CLtot
 [L h-1] 10±2.5  20±5  120  5-10    81,91,96,140 
V [L kg-1] 12 ± 2 L/kg  2.64 L/kg  1.8–2.7 L/kg  4-9   
60,70,82,87,91 
Metabolism 
Hepatic 
(CYP2D6, 
CYP3A4, UGT)  
Hepatic 
(CYP2D6, 
CYP3A4, UGT)  
Esterases in liver 
and intestine  
Metabolized 
to a minor 
extent  
40,62,63,76,82,87 
Kinetics Linear  Linear  Non-linear  Linear  41,58,59,70,89 
Steady State 14-21 d  6 d 1 d 11 d 39,59,72,89 
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2.1 General objectives 
 
The objectives of this thesis are to determine pharmacogenetic factors influencing the treatment with 
antidementia drugs, focusing on drug-metabolizing enzymes and transporters. For this purpose, a 
clinical study was initiated in collaboration with different psychiatric and geriatric hospitals, outpatient 
centers and nursing homes in the cantons of Vaud, Geneva and Fribourg. Moreover, analytical 
methods have to be developed for the measurement of plasma concentrations of antidementia drugs 
in the study participants and for further use in our TDM service. 
 
2.2 Specific objectives 
2.2.1 Analytical methods 
 
The specific aims of the analytical chemistry part of the thesis are: 
 to develop a high performance liquid chromatography method with mass spectrometry detection 
(HPLC-MS) for the plasma level determination of antidementia drugs in the study participants 
(Article II, Chapter 3), 
 to transfer the HPLC-MS method to the newly acquired ultra performance liquid chromatography 
system coupled with tandem mass spectrometry (UPLC-MS/MS) for the use in the routine TDM 
service of our laboratory (Article III, Chapter 3) 
 
2.2.2 Pharmacogenetic study on antidementia drugs 
 
The specific aims of the pharmacogenetic study are: 
 to determine genetic factors influencing donepezil steady-state plasma concentrations by 
analysis of polymorphisms in CYP2D6, CYP3A, POR and NR1I2 genes, and to investigate the 
relationship of plasma concentrations and the occurrence of side effects (Article IV, Chapter 4), 
 to determine genetic factors influencing the clearance of memantine by a population 
pharmacokinetic analysis including polymorphisms in genes of organic cation transporters and 
nuclear receptors and to investigate the relationship of memantine plasma concentrations and the 
occurrence of side effects (Article V, Chapter 4), 
 to determine genetic factors influencing galantamine steady-state plasma concentrations by 
analysis of polymorphisms in CYP2D6, CYP3A and POR genes, and to investigate the 
relationship of plasma concentrations and the occurrence of side effects (Article VI, Chapter 4). 
  
Chapter 2: Objectives   
52 
 
2.2.3 Review article 
 
The specific aims of the review article are to perform an extensive literature research on the current 
knowledge on pharmacodynamics, pharmacokinetics and pharmacogenetics of antidementia drugs 
and to summarize it for publication in an international journal (Article I, Chapter 1). 
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3.1 Clinical Study 
 
A naturalistic cross-sectional study was conducted during the period from December 2008 to March 
2011. At different psychiatric and geriatric hospitals, outpatient centers and nursing homes in the 
cantons of Vaud, Geneva and Fribourg, 303 patients were enrolled receiving for at least one month a 
treatment with the following antidementia drugs at a stable dose: donepezil (n=129), galantamine 
(n=27), rivastigmine (n=44) and memantine (n=108). One blood sampling was carried out to measure 
the steady-state plasma concentration of the drug, to conduct genetic analyses and to determine 
potential renal and hepatic impairment. Additionally, concomitant diseases, comedication, 
consumption of grapefruit, alcohol and tobacco and the presence of adverse events related to the 
antidementia treatment were recorded. The study was approved by the local ethic committees and 
written informed consent was obtained from all study participants or their legal tutors.  
 
3.2 Analytical Methods 
 
For the quantification of drugs in plasma, reliable and reproducible analytical methods are required. 
Liquid chromatography coupled to mass spectrometry is the most specific and sensitive technique that 
is presently used for drug concentration measurements. In this work, a reverse phase HPLC-MS 
method was developed and subsequently transferred to the newly acquired UPLC-MS/MS system. 
 
HPLC-MS is a powerful technique for the separation and quantification of analytes dissolved in a 
liquid. The injected sample is transported by the mobile phase through a column containing the 
stationary phase. Through interaction with the stationary phase, the analytes are retained on the 
column and, depending on their chemical properties, are eluted from the column at characteristic 
retention times. The analytes are conducted to the MS detector, where they are ionized in the source 
and analyzed in an electromagnetic field according to their mass-to-charge ratio. The UPLC-MS/MS 
technology offers several benefits compared to HPLC-MS. A shortened run time and a higher 
resolution are achieved by the use of smaller columns packed with sub-2-µm particles in combination 
with a system that allows to work at high pressures and with low dispersion. Moreover, the MS/MS 
detector increases the specificity of the method. Since two mass spectrometer selections are involved 
in the detection, separated by a collision cell where a fragmentation of the molecule takes place, the 
MS/MS determines specifically the mass of the analyte and its characteristic fragment. 
 
To analyze drugs in plasma, a sample clean-up is needed prior to injection into the chromatography 
system. Through the sample preparation, interfering substances as well as particles or proteins that 
could precipitate in the system are removed from the matrix, thus, the quality of the results are 
improved, and the instrument performance and column life time are prolonged. In this work, a sample 
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preparation by solid phase extraction (SPE) was used for the HPLC-MS procedure, whereas the 
increased specificity allowed a simple protein precipitation for the UPLC-MS/MS procedure. 
 
It is important that the applied bioanalytical methods are well characterized and fully validated. The 
objective of a method validation is to give guarantees that measurements performed in routine will be 
close to the unknown true value of the sample and inside acceptance limits that were set according to 
the intended application of the method.60 In this work, the method validations were conducted in 
accordance  with   the   international  guidelines  of   the  FDA,   the  EMEA  and   the   “Société  Française  des  
Sciences  Techniques  Pharmaceutiques”.60-62 The decision to accept a bioanalytical method is based 
on different validation parameters, including accuracy, precision, selectivity, matrix effects and stability 
of the compounds in the biological matrix and in the working solutions.  
Once the analytical method has been validated, its accuracy and precision should be regularly 
monitored to ensure that the method continues to perform satisfactorily during routine use. Therefore, 
internal quality control samples are added to each  run  of  patients’  samples  and  external  quality  control  
samples are analyzed several times per year. 
 
Details of the development and validation of the HPLC-MS and UPLC-MS/MS procedures for the 
simultaneous determination of antidementia drugs are described in Article II and III (Chapter 3.4 and 
3.5). 
 
3.3 Genetic Methods 
 
In this work, the patients were genotyped for selected SNPs by real-time polymerase chain reaction 
(PCR)  with  5’-nuclease allelic discrimination assays, also known as TaqMan SNP genotyping assays. 
With the PCR technique, a selective enrichment of a specific DNA sequence by a factor of one million 
is feasible.63 PCR amplification involves two oligonucleotide primers that flank the DNA segment to be 
amplified and repeated cycles of heat denaturation of the DNA, annealing of the primers to their 
complementary sequences and extension of the primers with a thermostable DNA polymerase.63 
Since the two resulting extension products are also complementary to and capable of binding primers, 
each successive cycle essentially doubles the amount of DNA synthesized in the previous cycles, 
leading to an exponential accumulation of the specific target fragment over the approximately 40 
cycles used in a PCR reaction.63 
For genotyping with the TaqMan technique, two differentially labeled fluorescent TaqMan probes are 
added to the PCR reaction, that are designed as perfect matches to either of the two allelic variants 
(Figure 7).64 During each amplification cycle, the TaqMan probes hybridize to its complementary target 
region   and,   during   the   primer   extension   step,   is   cleaved   by   the   5’-nuclease activity of the DNA 
polymerase. Thereby, the quencher and fluorescent reporter are separated. As a result, the reporter 
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fluorescent signal can be measured quantitatively for each of the two allele-specific TaqMan probes. 
The fluorescent intensity increases with each subsequent amplification cycle.64 
 
 
Figure 7: a.The  5’-nuclease activity of the polymerases used in the PCR reaction cleaves the TaqMan probes 
during the amplicon extension step, which separates the detecable reporter fluorophore (R) from the quencher 
(Q). b. The emitted fluorescence is measured at each PCR cycle for the two TaqMan probes. Homozygous 
subjects for the allele 1, heterozygous subjects and homozygous subjects for the allele 2 can be differentiated. 
Picture adapted from Koch WH, Nat Rev Drug Discov, 2004;3(9):749-61. 
 
CYP2D6 gene deletion or multiplication (CYP2D6*5 and CYP2D6*xN) was determined by the 
CYP2D6 TaqMan copy number assay. For this analysis, two labeled TaqMan probes are used, one 
probe detects a sequence in the target gene, whereas the other probe detects a sequence on a gene 
that is known to exist in only two copies in the genome. By relative quantification of the emitted 
fluorescence, the number of CYP2D6 gene copies is assigned. Moreover, the presence of gene 
multiplication was confirmed by long PCR analyses followed by amplicon separation through gel 
electrophoresis, according to the method of Løvlie et al.65 In patients with multiple gene copies, an 
additional amplicon with a specific length is detected, corresponding to a sequence of the CYP2D6-
CYP2D6 intergenetic region. 
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3.4 Article II: Simultaneous determination of antidementia drugs in human plasma for 
therapeutic drug monitoring 
 
Summary 
In this article, an HPLC-MS method for the quantification of antidementia drugs in human plasma is 
described. The analytical method allows the simultaneous determination of donepezil, galantamine, 
rivastigmine and its major metabolite NAP 226-90, and memantine at therapeutic concentrations, with 
lower limits of quantifications at 1 ng/mL or 2 ng/mL. The analytical procedure met the validation 
criteria of international guidelines and showed to be reliable and reproducible in the following 
analyses. It was successfully applied to the plasma samples of the 300 participants of the 
pharmacogenetic study as well as to external quality control samples and samples of other 
laboratories with known concentrations. 
 
 
 
 
 
Article published in Therapeutic Drug Monitoring 2011, 33: 227-238 
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Abstract 
Backgrounds: A simple liquid chromatography mass spectrometry method was developed and 
validated for the simultaneous determination of antidementia drugs including donepezil, galantamine, 
rivastigmine and its major metabolite NAP 226-90, and memantine.  
Methods: A solid phase extraction procedure with a mixed-mode sorbent was used to isolate the 
drugs from 0.5 mL human plasma. Reverse-phase chromatographic separation of the compounds was 
obtained with a gradient elution of an ammonium acetate buffer at pH 9.3 and acetonitrile and the 
analytes were detected by mass spectrometry in the single ion monitoring mode.  
Results: The method was validated according to the recommendations of the FDA, including 
assessment of trueness (-8.0 to +10.7 %), precision (repeatability: 1.1 to 4.9%, intermediate precision: 
2.1 to 8.5 %), selectivity and matrix effects variability (<6%), as well as short- and long-term stability in 
plasma. The calibrated ranges were comprised between 1 ng/mL to 300 ng/mL (rivastigmine and 
memantine) and 2 ng/mL to 300 ng/mL (donepezil, galantamine and NAP 226-90).  
Conclusions: The   method   was   successfully   applied   to   patients’   samples   and   might   contribute   to  
evaluate whether a Therapeutic Drug Monitoring (TDM) guided dose adjustment of antidementia drugs 
could contribute to minimize the risk of adverse reactions and to increase the probability of efficient 
therapeutic response. 
 
1. Introduction 
Alzheimer’s   disease   (AD)   is   the   most   frequent   type   of   dementia   among   elderly   people.   It   is  
characterized by a progressive cognitive and functional decline associated with neuropathologic 
lesions and neurochemical alterations such as a cholinergic deficit and glutamatergic overstimulation 
of postsynaptic N-methyl-D-aspartate (NMDA) receptors. The neurochemical changes in AD are the 
basis for the symptomatic treatment with the four drugs currently used. Donepezil, galantamine and 
rivastigmine are inhibitors of the acetylcholinesterase, increasing the concentration and duration of 
action of acetylcholine in the brain, whereas memantine, an NMDA-antagonist, reduces the 
glutamatergic overstimulation.1,2 The chemical structures of the four drugs and the major metabolite of 
rivastigmine, NAP 226-90, are presented in Fig. 1. 
Even though the benefit of Therapeutic Drug Monitoring (TDM) of antidementia drugs still remains to 
be demonstrated, several factors indicate that TDM might be useful for these drugs.3 Patients taking 
antidementia drugs show a high inter-individual variability in their response to treatment,4-6 which might 
partly be due to the observed inter-individual differences in plasma concentrations triggered by 
variations in drug metabolism and elimination.7-9 Donepezil and galantamine are metabolized by the 
cytochrome P450 3A (CYP3A) and 2D6 (CYP2D6) enzymes, known for their high inter-individual 
differences in activity10-12. Genetic variations in the CYP2D6 have been shown to influence plasma 
levels of these two drugs.7,13 In contrast, variability in renal elimination accounts probably for the inter-
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individual differences in plasma concentrations of memantine, since it is mainly excreted unchanged 
by the kidneys.14 It is supposed that genetic variations in transporters involved in the active tubular 
secretion of the drug could have an impact on its plasma levels.15,16 Rivastigmine is extensively 
metabolized by cholinesterases to NAP 226-90, an inactive and non-toxic metabolite. However, this 
inactive metabolite is an indicator of the extent of metabolism of rivastigmine, in particular of the first 
pass effect, and therefore it might be beneficial to quantify NAP 226-90 in the plasma.17 Moreover, 
comorbidities, primarily renal and hepatic impairment, and polymedication leading to drug interactions, 
make elderly people susceptible to changes in plasma levels of the drugs. All these factors let assume 
that an individually adapted dosage through monitoring of the plasma concentrations might be 
beneficial for patients treated with antidementia drugs. Furthermore, non-adherence to the therapy 
due to the decline in cognitive function is a particular problem in geriatric patients.18 Detected by TDM, 
this problem could be overcome by supervision of drug intake. 
Up to now, no method has been published that allows the simultaneous quantification of the four 
commonly used antidementia drugs in plasma. However, different chromatographic methods are 
described to determine the single compounds in human blood, sometimes with their related 
metabolites. Although some methods are described using gas chromatography,19,20 the majority uses 
liquid chromatography coupled with tandem mass spectrometry,21-31 ultraviolet (UV)32,33 or 
fluorescence detection.12 In case of mass spectrometry (MS), the analysis is mostly done by 
electrospray in the positive mode (ESI+)21,23,26,27 rather than by atmospheric pressure chemical 
ionization.22,31 Several different extraction procedures are described in the literature comprising of 
liquid-liquid extraction,26,32 solid phase extraction (SPE)21,24,33 and protein precipitation.23 Moreover, 
one capillary electrophoresis method using UV detection has been published, describing the 
simultaneous determination of galantamine, rivastigmine and NAP 226-90 for drug monitoring.34 The 
use of isotope-labeled internal standards to increase the robustness of the method is described in two 
of the published methods.25,29 Since most of these analytical methods are developed for 
pharmacokinetic studies after single doses,21,22,26-28,32,33 the covered concentration ranges are narrow 
and would not be adequate for TDM in steady state conditions of different dosages, where a large 
range of plasma concentrations is expected. 
The objective of the present work was to develop and validate a rapid and sensitive LC-MS method for 
the simultaneous determination of antidementia drugs in human plasma for the routine use in a TDM 
laboratory. The compounds were detected by MS in ESI+ mode, which is reported to be sensitive to 
matrix effects.35,36 Therefore, a mixed-mode cation exchange SPE, a powerful clean-up procedure, 
was chosen to isolate the drugs from the plasma prior to analysis. Furthermore, for three of the five 
compounds isotope-labeled standards were used for quantification, known to effectively normalize 
matrix effects.37 The method was successfully validated according to the guidelines of the Food and 
Drug Administration (FDA) and applied to samples of a real population treated with antidementia 
drugs. 
 
Chapter 3: Methods   
64 
 
2. Experimental 
2.1 Chemicals and reagents 
The drugs were kindly provided by their manufacturers: donepezil HCl by Eisai Co., Ltd (Tokyo, 
Japan), galantamine HBr by Janssen-Cilag (Beerse, Belgium), memantine HCl by Merz 
(Frankfurt/Main, Germany), rivastigmine hydrogen tartrate and its metabolite NAP 226-90 by Novartis 
(Basel, Switzerland). The internal standards (IS) [2H7]-donepezil, [13C,2H3]-galantamine HCl, [13C2,2H6]-
memantine HCl and [2H6]-rivastigmine hydrogen tartrate (not used in the final method) were purchased 
from Alsachim (Strasbourg, France). Lichrosolv® HPLC-grade acetonitrile, hydrochloric acid (37%) and 
ortho-phosphoric acid (85%) were purchased from Merck (Darmstadt, Germany). Ammonium 
hydroxide (25%), ammonium acetate for MS, formic acid for MS and physostigmine hemisulfate 
(eserine) were bought from Sigma-Aldrich (Steinheim, Germany). Ultrapure water was obtained from a 
Milli-Q® RG with a QPAQ2 column system (Millipore, Billerica, MA, USA). All chemicals were of 
analytical grade. For the preparation of calibration standards (CS) and quality control (QC) samples 
and the evaluation of matrix effects, more than 10 different batches of human plasma from outdated 
blood  donation   units  were   obtained   from   the  Hospital’s   blood   transfusion   center   (CHUV,   Lausanne,  
Switzerland). 
2.2 Equipment 
The liquid chromatography system consisted of an Agilent Series 1100 LC equipped with a binary 
pump and a 100-vial autosampler (Agilent Technologies, Waldbronn, Germany), with a measured 
dwell volume of 1.05 mL. Data handling and instrument control were performed by the Chemstation 
software B.01.01 (Agilent Technologies). The chromatographic system was coupled to an Agilent 
Series 110 MSD single quadrupole mass spectrometer (Agilent Technologies) equipped with an 
electrospray ionization interface operated in positive ionization mode (ESI+). Chromatographic 
separations  were  performed  on  an  XBridge  C18  column  (2.1  x  100  mm;;  3.5  μm)  (Waters,  Milford,  MA,  
USA)  equipped  with  an  XBridge  C18  cartridge  (2.1  x  10  mm;;  3.5  μm).  Analyses  were  carried  out  in  an  
air conditioned room at 22°C. 
2.3 Stock and working solutions 
Stock solutions of the analytes were prepared at 1 mg/mL (as base) by dissolving the adequate 
amount of the pure analyte in methanol and were stored at -20°C. By dilution of the stock solutions 
with 0.01 N HCl,  working  solutions  at  100  μg/mL  were  obtained  and  were  stored  at  -20°C. Calibrators 
(CS) and quality control (QC) samples were prepared independently by spiking blank plasma at 
different concentrations with freshly made dilutions of the working solution at 0.1, 1 and 10 g/mL. CS 
and QC were analyzed immediately or stored at -20°C until analysis. The stock solutions of the IS 
were prepared at 1 mg/mL in methanol and stored at -20°C. They were combined to give a single IS 
working  solution  at  0.5  μg/mL  that was likewise stored at -20°C. 
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To competitively inhibit the enzymatic in-vitro hydrolysis of rivastigmine to its metabolite NAP 226-90 
by  plasma  cholinesterases,  50  μL  of  a  0.002  M physostigmine solution was added to every 1 mL of 
plasma and used for the preparation of CS and QC samples.29 
2.4 Sample preparation 
Plasma  samples  (500  μL)  were mixed  with  50  μL  of  IS  solution  and  diluted  with  500  μL  of  a  4%  ortho-
phosphoric   acid   solution.   1000   μL   of   the  mixture   were   loaded   onto   an   Oasis   MCX   10  mg   96-well 
extraction plate (Waters, Milford, MA, USA) previously conditioned and equilibrated with 500 μL  
acetonitrile  and  500  μL  water.  Subsequently,  two  washing  steps  were  performed  with  500  μL  of  a  2%  
formic   acid   solution   followed   by   500   μL   acetonitrile.   The   compounds  were   then   eluted  with   500   μL  
acetonitrile/ammonium hydroxide 25% (80:20, v/v). After each step a low vacuum was applied until the 
wells were dry. The extracted samples were evaporated (N2 flow,  40°C)  and  reconstituted  in  250  μL  of  
the mobile phase at initial conditions, namely 50 mM ammonium acetate at pH 9.3 and acetonitrile 
(80:20, v/v), prior to injection into the chromatographic system. 
2.5 LC-MS conditions 
To set up the parameters for chromatographic separation, the HPLC modeling software OSIRIS 
Version 4.1 (Datalys, Grenoble, France) was used. The most suitable separation was achieved at a 
flow rate of 0.3 mL/min with a mobile phase composed of 50 mM ammonium acetate in ultrapure water 
adjusted to pH 9.3 (solution A) and acetonitrile (solution B) using the following stepwise elution 
program with an overall run time of 15 min: 20% of B maintained for 1 min, 33% of B at 1.4 min, 41% 
of B at 2.4 min, 56% of B at 4.2 min and a hold of 80% of B from 4.9 min to 6.5 min. The gradient was 
followed by rinsing with 90% of B from 6.7 to 8.2 min and a reconditioning step at the initial conditions 
from  9.2  to  15  min.  Of  each  sample  5  μL  were  injected. 
Detection was performed in the selected ion monitoring (SIM) mode for the singly charged positive 
ions at m/z 380.1 (donepezil), 288.1 (galantamine), 206.1 (rivastigmine), 121.1 (NAP 226-90), 180.1 
(memantine), 387.2 [2H7]-donepezil, 292.1 [13C,2H3]-galantamine and 188.2 [13C2,2H6]-memantine. 
Nitrogen was used as nebulizing gas at 20 psi and as drying gas at a temperature of 350°C and a flow 
rate of 12 L/min. Capillary voltage was set at 1250 V and the fragmentor voltage at 150 V, 130 V, 160 
V, 140 V and 100 V for donepezil, galantamine, rivastigmine, NAP 226-90 and memantine, 
respectively. Dwell time for each ion was 24 ms. In Table 1 the optimized individual fragmentor 
settings are listed together with the m/z-ratios of the compounds.  
2.6 Method validation 
The method validation was based on the guidelines for Bioanalytical Method Validation published 
online by the FDA,38 as well as on the recommendations of   the  “Société  Française  des  Sciences  et  
Techniques   Pharmaceutiques”.39 The draft version of the guidelines for method validation of the 
European Medicines Agency (EMEA) was also taken into consideration.40 
2.6.1 Selectivity, carry-over and psychiatric co-medication 
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Method selectivity was ascertained by analyzing 10 blank plasma batches for interfering peaks at 
retention times of the analytes. Possible carry-over effects were assessed by injecting blank plasma 
samples after the highest calibration standard at 300 ng/mL. 
Additionally, the following psychiatric drugs, and some of their metabolites, were extracted and 
analyzed with the same method to investigate the influence of potential co-medication: amitriptyline, 
amisulpride, aripiprazole, atomoxetine, dehydro-aripiprazole, bupropion, 3-hydroxy-bupropion, 
caffeine, chlorpromazine, citalopram, desmethyl-citalopram, clomipramine, desmethyl-clomipramine, 
clopenthixol, clozapine, N-oxid-clozapine, norclozapine, desipramine, duloxetine, fluoxetine, 
norfluoxetine, flupenthixol, fluvoxamine, haloperidol, imipramine, loxapine, maprotiline, mianserin, 
desmethyl-mianserin, midazolam, 1-hydroxy-midazolam, mirtazapine, 8-hydroxy-desmethyl-
mirtazapine, moclobemide, N-oxid-moclobemide, 3'-oxo-moclobemide, morphine, nicotine, 
nortriptyline, olanzapine, paroxetine, quetiapine, reboxetine, risperidone, 9-hydroxy-risperidone, 
sertindole, dehydro-sertindole, sertraline, desmethyl-sertraline, sulpiride, trimipramine, desmethyl-
trimipramine, trazodone, venlafaxine, O-desmethyl-venlafaxine, N-desmethyl-venlafaxine, N-O-di-
desmethyl-venlafaxine and ziprasidone. In case of similar retention times as the antidementia drugs, 
suppression of the signal was assessed by comparing peak area of the analyte at 100 ng/ml alone 
with the peak area of the analyte when injected with the potential interfering compound at a high 
therapeutic concentration. 
2.6.2 Matrix effects and recovery 
Primarily, matrix effects were investigated qualitatively by simultaneous post-column infusion of the 
analytes and IS into the MS detector during chromatographic analyses of 6 different blank plasma 
extracts, water and mobile phase.35,41 The analytes and their IS were infused at a concentration of 1 
μg/mL   and   a   flow   rate   of   2   μL/min.   The   chromatographic   signal   of   each   analyte   was   carefully  
examined to ascertain that there is no signal suppression or enhancement at the retention time due to 
interfering substances. 
Subsequently, matrix effects and recovery were assessed quantitatively at low (10 ng/mL) and high 
concentration levels (150 ng/mL for donepezil, rivastigmine and NAP 226-90, 300 ng/mL for 
galantamine and memantine) and at 50 ng/mL for the IS based on the approach of Matuszewski.42 
The following three sets of samples were prepared:  
(A): Pure standard solution samples of the analytes and IS in the SPE reconstitution solvent 
(acetonitrile/buffer 20:80) injected directly onto the column 
(B): Duplicates of plasma extract samples from 6 different sources spiked with the analytes and IS 
after extraction 
(C): Duplicates of plasma samples from 6 different sources (same as B) spiked with the analytes and 
IS before extraction. 
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The matrix effect (ME) was evaluated for each analyte and IS by calculating the ratio of the peak area 
in the presence of the matrix (samples spiked after extraction) to the peak area in absence of the 
matrix (pure standard) and expressed in percentage (ME = B/A). The recovery of extraction (RE) in 
the matrix was determined by comparing the peak area of the pre-extraction spiked (C) to the post-
extraction spiked samples (B) (RE = C/B). The overall process efficiency (PE), taking into account ME 
and RE, was assessed by calculating the ratio of the peak area of the pre-extraction spiked samples 
to the peak area of the pure standard (PE = C/A). Of all three parameters, the variability between the 
different plasma batches was evaluated and expressed as coefficient of variation (CV %). 
2.6.3 Trueness and precision 
Three validation series were carried out to examine trueness and precision of the method. CS were 
set in duplicate at 4 levels and QC samples in quadruplicate at 8 different levels covering the expected 
range of concentrations in patients.9,11,17,43 CS 1, 20, 100, 300 ng/mL for memantine and rivastigmine 
and 2, 20, 100, 300 ng/mL for donepezil, galantamine and NAP 226-90; QC 2, 5, 20, 50, 100, 200, 
300 ng/mL for donepezil, 1, 2, 5, 20, 50, 100, 200, 300 ng/mL for memantine and rivastigmine and 2, 
4, 10, 20, 50, 100, 200, 300 ng/mL for galantamine and NAP 226-90. Calibration curves were freshly 
prepared and established for each batch considering the peak area ratio of the analytes and their IS. 
[2H7]-donepezil, [13C,2H3]-galantamine and [13C2,2H6]-memantine were used as IS for their target 
analyte, whereas [13C,2H3]-galantamine was also found to be a suitable IS for rivastigmine and NAP 
226-90. The QC samples were analyzed against the calibration curve of the same run and the 
trueness of the obtained value was expressed as percentage of the nominal value. Repeatability 
(intra-day variance) and intermediate precision (sum of intra-day and inter-day variances) were 
calculated and expressed as coefficients of variation (CV %).44 In accordance to the above-mentioned 
guidelines, the lower limit of quantification (LLOQ) for each analyte was determined by the lowest QC 
concentration  with  a  trueness  and  precision  of  ≤20%. 
To  establish  a  procedure  if  patients’  plasma  levels  exceed  the  concentration of the highest calibration 
standard at 300 ng/mL, the trueness and precision of a three-fold dilution of spiked plasma at 600 
ng/mL was assessed. The dilution was carried out with blank plasma. 
2.6.4 Stability 
Stability of the compounds in plasma was assessed by spiking 5 different blank plasma batches at low 
(2ng/mL for memantine and rivastigmine, 4 ng/mL for donepezil, galantamine and NAP 226-90) and 
high concentration (250 ng/mL). Different sets of aliquots were quantified after storage at ambient 
temperature and at 5°C up to 72 hours, at -20°C for 3 months, and after one to three freeze-thaw 
cycles. The variations in drug concentrations were expressed as percentage of the initial concentration 
found in the samples analyzed immediately after preparation.  
Furthermore, the post-preparative stability was assessed by leaving the processed samples up to 24 h 
at room temperature as well as 48 h at 5°C before reanalysis. The calculated concentrations after 
immediate analysis and after storage of the same samples were compared. 
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Finally, the stability in spiked whole K-EDTA blood was tested at 100 ng/mL for donepezil, 
galantamine and memantine and at 10 ng/mL and 250 ng/mL for rivastigmine and NAP 226-90 by 
leaving the samples up to three days at room temperature. To stop the in vitro degradation of 
rivastigmine  by  plasma  cholinesterases,  10  μL  of  a  physostigmine  solution  at  0.01  M was added to 
every 1 mL of blood. 
 
3. Results and Discussion 
3.1 Solid-phase extraction 
To extract the basic drugs from the plasma, a solid phase extraction procedure with a mixed-mode 
sorbent was chosen, since the combination of hydrophobic interactions and cation-exchange leads to 
an enhancement of selectivity. The use of different organic solvents as well as different washing steps 
was investigated. Satisfactory results regarding recovery, repeatability and selectivity were obtained 
by using a generic protocol with acetonitrile as organic solvent and formic acid as washing solution. 
The recoveries, presented in Table 2, were comprised between 88 and 98% with good repeatability 
(CVs between 1 and 6%). By evaporation of the elution solvent and reconstitution of the drugs in the 
mobile phase, a twofold concentration step was performed, allowing the quantification of lower plasma 
concentrations. Moreover, the peak shape was thereby improved compared to the injection of the pure 
elution solvent or the elution solvent diluted with water (50:50). The selected SPE procedure is rapid 
and could be easily automatable,  using  500  μL  of  plasma. 
3.2 Optimization of chromatographic and MS conditions 
Different mobile phase compositions were assessed on reverse phase columns using acetonitrile or 
methanol and buffers ranging from pH 3 to pH 10. For the studied drugs, acidic conditions were less 
suitable than basic conditions, as the more polar bases, namely NAP 226-90 and galantamine, were 
eluted rapidly therefore increasing the risk of interferences with unretained matrix components. 
Moreover, the peak shapes were better in basic conditions. These observations are in agreement with 
literature reports.45,46 The most suited chromatographic separation of the five compounds was 
achieved by a gradient elution using as mobile phase an ammonium acetate buffer 50 mM at pH 9.3 
and acetonitrile as organic solvent. As stationary phase, an XBridge C18 column was selected due to 
the satisfactory selectivity results and its stability under basic conditions. Three different 
concentrations of ammonium acetate buffer (20 mM, 50 mM and 100 mM) were tested. Interestingly, 
the concentration of the buffer had an important influence on the selectivity with the most satisfactory 
result at 50 mM. In addition, the higher concentration of ammonia acetate increased the reproducibility 
of the chromatographic separation with increasing age of the column. With the selected LC conditions, 
the overall run time was 15 min. The typical retention times of the analytes are listed in Table 1 and a 
chromatogram of a QC plasma sample of the 5 compounds and the IS at 50 ng/mL is shown in Fig. 2. 
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The use of pure isotope-labeled internal standards is highly recommended in LC-MS analysis in order 
to compensate signal suppression or enhancement due to matrix components and variability in 
extraction procedure.37,47 In the described method the isotope-labeled IS [2H7]-donepezil, [13C,2H3]-
galantamine and [13C2,2H6]-memantine were used for quantification of their corresponding co-eluting 
analytes, whereas [13C,2H3]-galantamine was also chosen as IS for rivastigmine and NAP 226-90 for 
the following reasons: the fragment ions of rivastigmine and NAP 226-90 were used for quantification 
as they had a higher intensity than the molecule ions, allowing an increase in sensitivity for the two 
compounds. Since [2H6]-rivastigmine and rivastigmine have the same fragment ion at m/z 206, the 
deuterated   standard   couldn’t   be   used   as   IS   for   rivastigmine.   Moreover,   for   the   metabolite   of  
rivastigmine, NAP 226-90, no isotope-labeled standard was commercially available. Thus, after having 
verified that there is no signal suppression from galantamine on [13C,2H3]-galantamine at the highest 
CS at 300 ng/mL, [13C,2H3]-galantamine was used as IS for rivastigmine and NAP 226-90. The 
following MS settings were evaluated to find the optimal ionization conditions: nebulizing gas pressure 
(20-60, selected 20 psi), drying gas temperature (200-350, selected 350°C), drying gas flow rate (7-
13, selected 12 L/min) and capillary voltage (1250-4000, selected 1250 V).  
3.3 Validation 
3.3.1 Selectivity, carry-over and psychiatric co-medication 
No peaks from endogenous compounds were observed at the drugs retention time in any of the 10 
blank plasma extracts evaluated. However, a slight carry-over effect of 0.1% for donepezil was 
observed. With the highest CS at 300 ng/mL, this memory effect is acceptable as it corresponds to 
less than 20% of the concentration at LLOQ. For the other compounds, no carry-over was detected.  
Due to several co-morbidities, patients taking antidementia drugs often receive multiple co-
medications that could potentially lead to analytical interferences. Therefore, the influence of possible 
psychiatric co-medication on the determination of plasma levels of antidementia drugs was assessed. 
For this purpose, several antidepressant and antipsychotic drugs, and some of their metabolites, were 
extracted with the same method and their retention time was recorded. Four substances co-eluted 
with the compounds of interest, namely donepezil with bupropion, rivastigmine with risperidone, and 
memantine with 3-hydroxy-bupropion and 9-hydroxy-risperidone. However, they were distinguished by 
MS detection and no clinically significant signal suppression was observed for the antidementia drugs 
when injected with these compounds. Since the co-medication of elderly patients is not restrained to 
psychiatric drugs, the present assessment of interferences is not exhaustive and during routine use of 
the method, special attention should be paid to this issue. Nevertheless, it is supposed that, for 
donepezil, galantamine and memantine, the co-eluting isotope-labeled internal standards normalize 
the signal suppression. 
3.3.2 Matrix effects  
By means of direct infusion of the drug substances and the IS into the MS detector during analysis of 
6 different blank plasma batches, qualitative signal suppression and enhancement was assessed. No 
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interferences were apparent at the retention times of the analytes and IS. In Fig. 3 the corresponding 
chromatograms are presented. 
In the quantitative assessment of interfering plasma components, slight matrix effects were observed 
ranging from 85 to 114%. When normalized by their co-eluting isotopic-labeled IS, the matrix effects 
were considerably smaller ranging from 91 to 104% (data not shown). However, even more important 
than having low matrix effects, is having a low variability of these effects between the different plasma 
batches. With the selected extraction procedure this aim was achieved, as the variability between the 
6 different plasma sources never exceeded 5%. The results are reported in Table 2. 
Finally, the process efficiencies, describing the overall recovery taking the extraction recovery and the 
matrix effects into account, were comprised within 82 and 111% with CVs ranging from 1 to 6%.  
3.3.3 Trueness and precision 
Three validation series were performed on three different days. Eight CS were used for each 
compound covering the range from 1 to 300 ng/mL for donepezil, memantine and rivastigmine and 
from 2 to 300 ng/mL for galantamine and NAP 226-90. Different calibration curve models were tested 
and the following four point calibration curves were selected: 1, 20, 100 and 300 ng/mL for 
rivastigmine and memantine using a quadratic regression model and a linear regression weighted by 
1/x, respectively; 2, 20, 100, 300 ng/mL for donepezil, NAP 226-90 and galantamine using a quadratic 
regression model for donepezil and linear regression models for NAP and galantamine weighted by 
1/x2 and 1/x, respectively.  
The trueness, repeatability and intermediate precision of the back calculated QC samples are reported 
in Table 3. For all QC samples, the determined trueness met the acceptance criterion of ±15% (LLOQ 
±20%); except for donepezil at 1 ng/mL the trueness was 128%. However, the criterion for donepezil 
was met at 2 ng/mL. Overall, the repeatability and intermediate precision did not exceed the required 
limit   of   ≤15%   (LLOQ   ≤20%).   Consequently,   the   LLOQ   was   set   at   1   ng/mL   for   rivastigmine   and  
memantine and at 2 ng/mL for donepezil, NAP 226-90 and galantamine. For rivastigmine and its 
metabolite a low LLOQ is mandatory given the short half life of the drug.17 By contrast, for the other 
three drugs the LLOQ is well below the expected therapeutic concentrations of patients. The 
corresponding accuracy profiles with acceptance limit (= 30%), and with upper and lower -
expectation tolerance intervals ( = 90%) calculated for each compound in the dosing range are 
shown in Fig. 4. 
Three-fold dilutions of spiked plasma at concentrations exceeding by two-fold the highest calibration 
levels were found to be in the accepted range of the accuracy profile (not shown in Fig. 4). This 
indicates that plasma samples containing antidementia drugs above the highest level of calibration 
can be adequately diluted with blank plasma prior to LC-MS analysis. 
To assess linearity of the method, a linear regression model was applied to the recalculated QC 
concentrations vs. theoretical concentrations. The following slopes 0.983, 0.983, 1.024, 0.986 and 
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0.990, and intercepts 0.389, 1.745, -0.721, 2.302 and 1.445 were found for donepezil, galantamine, 
rivastigmine, NAP 226-90 and memantine, respectively. The corresponding determination coefficients 
were 0.991, 0.998, 0.996, 0.995, 0.999, indicating that the developed method was linear for the tested 
compounds. 
3.3.4 Stability 
As reported in Table 4, the stability of the analytes in plasma was confirmed at room temperature and 
at 4°C up to 72 h as well as at -20°C for three months. The variation over time of each analyte was 
well within the required range of ±15% of the initial concentration. Furthermore, all of the analytes 
were found to have a good stability in plasma even after three freeze and thaw cycles. The stability of 
the compounds in the extracted samples was ascertained by leaving the vials for 24 h at room 
temperature and for 48 h at 5°C. 
To establish shipping conditions, the stability of the drugs in whole K-EDTA blood left at room 
temperature up to three days was investigated. The stability up to 72 h was confirmed for donepezil 
and galantamine, as well as for rivastigmine when physostigmine was immediately added to the blood 
samples to inhibit enzymatic breakdown. In contrast, NAP 226-90 was found to be unstable in whole 
blood with a mean decrease for the high concentration of -15% after 8 h and -38% after three days. 
For the determination of the metabolite NAP 226-90, a rapid centrifugation is necessary to stop the 
degradation process. Interestingly, for memantine an increase of 17% and 20% was observed after 
two and three days, respectively. Therefore, a centrifugation step within 24 h is preferable for the 
precision of the measurement. A possible explanation of this raise could be the hemolysis of blood 
cells during storage and therefore a release of drug substance into the plasma. A deeper investigation 
of this phenomenon would be outside the scope of the present work. 
 
4. Clinical Application 
The presence of several comorbidities, drug interactions due to polypharmacy, and variations in drug 
metabolism are possible factors leading to the high inter-individual variability in plasma levels 
observed in patients treated with antidementia drugs. Since a lack of clinical response or the presence 
of adverse events could be due to non-optimal plasma levels of the drugs, TDM might be a valuable 
tool to individually adapt the dosage of antidementia drugs. The developed analytical method showed 
to be reliable and sensitive for monitoring plasma concentrations of antidementia drugs. It is currently 
applied to samples from participants of a pharmacogenetic study investigating the influence of genetic 
variations in drug metabolizing enzymes and drug transporters on the plasma concentrations of 
antidementia drugs. Some examples of measured plasma levels are shown in Table 5. Additionally, a 
representative  patient’s  chromatogram  for  each  drug  is  shown  in  Fig.  5. 
 
 
Chapter 3: Methods   
72 
 
5. Conclusion 
A simple LC-MS method for the simultaneous quantification of donepezil, galantamine, rivastigmine 
and its metabolite, and memantine was developed and validated according to the FDA guidelines. The 
drugs were extracted from plasma by a simple SPE procedure, hereby removing efficiently 
endogenous interfering components from the matrix. The HPLC-MS method allows a fast 
quantification of the five compounds over a concentration range usually measured in patients, which 
was confirmed by applying the method to real  patients’  samples.   
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Figure 1: Chemical structures of the antidementia drugs and the metabolite NAP 226-90. 
 
 
Figure 2: Selected ion monitoring chromatogram of a QC plasma sample at 50 ng/ml for all 
compounds and IS.  
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Figure 3: Chromatogram of 6 blank plasma extracts with post-column infusion of the analytes.  
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Figure 4: Accuracy profiles within the acceptance limit (=  30%), and with upper and lower -
expectation tolerance intervals ( = 90%) for each compound in the dosing range. 
Chapter 3: Methods   
79 
 
 
Figure 5: Representative chromatograms of patients receiving different antidementia drugs a) 
donepezil (60 ng/ml), b) galantamine (73 ng/ml), c) rivastigmine (5 ng/ml, NAP 226-90 3 ng/ml) and d) 
memantine (108 ng/ml).  
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Table 1: Indivual MS settings and typical retention times of the analytes. 
 [M+H]+ 
(m/z) 
Fragment 
ion (m/z) 
Fragmentor 
Voltage (V) 
tR (min)b 
Donepezil 380.1a   150 9.0 
Rivastigmine 251.1 206.1a 160 7.8 
     
NAP 226-90 166.1 121.1a 140 3.7 
Galantamine 288.1a  130 4.8 
Memantine 180.1a 163.1 100 7.4 
[2H7]-donepezil 387.2a  150 8.9 
[13C,2H3]-galantamine 292.1a  130 4.7 
[13C2,2H6]-memantine 188.2a 171.2 100 7.4 
a) Used for quantification of the compound 
b) tR: Retention time 
 
 
Table 2: Matrix effects (ME), extraction recovery (RE), process efficiency (PE) 
 Nominal 
conc. (n=6) 
ME % 
(%CV) 
RE % 
(%CV) 
PE% 
(%CV) 
Donepezil 10 104 (2) 95 (3) 98 (2) 
 150 114 (5) 97 (6) 111 (2) 
Rivastigmine 10 101 (1) 93 (1) 95 (1) 
 150 107 (2) 90 (4) 97 (3) 
NAP 226-90 10 104 (1) 96 (3) 99 (3) 
 150 107 (2) 96 (3) 103 (2) 
Galantamine 10 85 (2) 96 (1) 82 (2) 
 300 106 (1) 93 (1) 98 (2) 
Memantine 10 98 (2) 88 (2) 86 (3) 
 300 103 (2) 93 (5) 96 (5) 
[2H7]-donepezil 50 99 (2) 98 (3) 97 (3) 
[13C,2H3]-galantamine 50 106 (1) 94 (2) 100 (2) 
[13C2,2H6]-memantine 50 101 (3) 93 (4) 94 (6) 
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Table 3: Trueness and precision of QC samples determined by repeated analysis in quadruplicates 
in three different series 
 Nominal conc 
(ng/ml) 
Trueness 
(%) 
Precision (%)  
  Repeatability Intermediate 
precision 
Donepezil 2 110.7 2.7 5.5 
 5 104.3 1.8 6.3 
 20 105.3 4.4 6.3 
 50 100.1 2.9 4.0 
 100 97.6 1.5 6.2 
 200 97.7 1.7 8.3 
 300 98.8 4.9 8.5 
 600/3 91.9 4.6 7.2 
Rivastigmine 1 99.7 2.0 4.3 
 2 98.0 2.0 5.3 
 5 99.6 1.8 2.1 
 20 100.4 2.7 3.1 
 50 100.2 2.6 3.8 
 100 99.6 2.1 3.6 
 200 101.2 3.3 4.9 
 300 102.7 4.9 6.4 
 600/3 92.6 6.2 7.2 
NAP 226-90 2 103.2 3.7 8.0 
 4 103.1 3.0 3.9 
 10 103.6 2.1 3.9 
 20 104.4 3.8 4.1 
 50 103.8 2.8 2.7 
 100 103.1 1.6 4.6 
 200 102.2 2.4 6.5 
 300 95.2 2.6 3.4 
 600/3 93.6 4.9 5.3 
Galantamine 2 92.0 3.1 6.4 
 4 92.1 3.4 3.1 
 10 100.4 2.9 7.2 
 20 109.7 4.1 4.7 
 50 105.7 1.9 2.6 
 100 107.2 1.7 4.6 
 200 105.7 2.5 3.1 
 300 100.2 2.3 3.1 
 600/3 98.4 5 4.4 
Memantine 1 94.1 4.0 4.1 
 2 99.3 2.9 3.7 
 5 102.8 3.1 3.7 
 20 106.3 3.3 5.1 
 50 103.8 1.8 1.8 
 100 103.9 1.1 1.3 
 200 101.4 2.4 2.1 
 300 98.4 2.1 2.1 
 600/3 94.0 4.7 5.3 
 
Table 4: Plasm
a, post-preparative and w
hole blood stability expressed as percentage of the initial concentration (C
V%
) 
Plasm
a 
Donepezil 
 
Rivastigm
ine
b 
 
NAP 226-90
b 
 
Galantam
ine 
 
M
em
antine 
N
om
inal conc [ng/m
l] 
4 
250 
 
2 
250 
 
4 
250 
 
4 
250 
 
2 
250 
 
n=5 
n=5 
 
n=5 
n=5 
 
n=5 
n=5 
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Table 5: Examples of plasma levels measured in three patients per drug dosage. 
 Calibrated range (ng/ml) 
Therapeutic 
range (ng/ml) 
Plasma level  
Median (range) 
(ng/ml) 
Daily dose 
 (mg/d) 
Donepezil 2 - 300 30 – 753 27 (19 – 29) 5 
   58 (34 - 59) 10 
Rivastigmine 1 - 300 unknown 5 (5 – 14) 9.5 (patch) 
NAP 226-90   5 (3 – 12)  
Rivastigmine   5 (1 – 22) 9 (capsule) 
NAP 226-90   3 (2 – 7)  
Galantamine 2 - 300 30 – 1003 44 (38 – 84) 16 
   73 (35 – 103) 24 
Memantine 1 - 300 Unknown9 63 (15 – 75) 10 
   146 (82 – 163) 20 
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3.5 Article III: Simultaneous determination of antidementia drugs in human plasma: Procedure 
transfer from HPLC-MS to UPLC-MS/MS 
 
Summary 
In this article, the transfer of the HPLC-MS method for the simultaneous determination of antidementia 
drugs to UPLC-MS/MS is described. The UPLC-MS/MS procedure allows to reduce the required 
amount of plasma, to use a simplified sample preparation, and to obtain a higher sensitivity and 
specificity with a much shortened run-time. The UPLC-MS/MS method was successfully validated. 
Moreover, a method comparison was performed with patients’   samples, showing similar results 
between the HPLC-MS and UPLC-MS/MS procedures.  
Plasma concentration measurements of antidementia drugs have recently been added to the 
accredited analyses proposed by our TDM service. Because of its numerous advantages, the 
analyses are performed by the UPLC-MS/MS procedure reported in this article. However, the HPLC-
MS method can be used as a backup method.  
 
 
 
 
 
 
Article accepted for publication in Journal of Pharmaceutical and Biomedical Analysis
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Abstract 
A previously developed high performance liquid chromatography mass spectrometry (HPLC-MS) 
procedure for the simultaneous determination of antidementia drugs, including donepezil, 
galantamine, memantine, rivastigmine and its metabolite NAP 226-90, was transferred to an ultra 
performance liquid chromatography system coupled to a tandem mass spectrometer (UPLC-MS/MS). 
The drugs and their internal standards ([2H7]-donepezil, [13C,2H3]-galantamine, [13C2,2H6]-memantine, 
[2H6]-rivastigmine) were  extracted  from  250  μL  human  plasma  by  protein  precipitation  with  acetonitrile.  
Chromatographic separation was achieved on a reverse phase column (BEH  C18  2.1x50mm;;  1.7μm)  
with a gradient elution of an ammonium acetate buffer at pH 9.3 and acetonitrile at a flow rate of 0.4 
mL/min and an overall run time of 4.5 min. The analytes were detected on a tandem quadrupole mass 
spectrometer operated in positive electrospray ionization mode, and quantification was performed 
using multiple reaction monitoring. The method was validated according to the recommendations of 
international guidelines over a calibration range of 1-300 ng/mL for donepezil, galantamine and 
memantine, and 0.2-50 ng/mL for rivastimgine and NAP 226-90. The trueness (86-108%), 
repeatability (0.8-8.3%), intermediate precision (2.3-10.9%) and selectivity of the method were found 
to be satisfactory. Matrix effects variability was inferior to 15% for the analytes and inferior to 5% after 
correction by internal standards. A method comparison was performed  with  patients’  samples  showing  
similar results between the HPLC-MS and UPLC-MS/MS procedures. Thus, this validated UPLC-
MS/MS method allows to reduce the required amount of plasma, to use a simplified sample 
preparation, and to obtain a higher sensitivity and specificity with a much shortened run-time. 
 
1. Introduction 
Four drugs are currently used for the symptomatic treatment of dementia, the acetylcholinesterase 
inhibitors donepezil, galantamine and rivastigmine, and the N-methyl-D-aspartate (NMDA) receptor 
antagonist memantine. The chemical structures of the four antidementia drugs and the major 
metabolite of rivastigmine, NAP 226-90, are presented in Figure 1. 
Therapeutic drug monitoring (TDM) is a well known tool for optimization of pharmacotherapy. By 
maintaining  patients’  drug  plasma  concentrations  in  the  target  range  through  individual  dose  adaption,  
efficacy and safety of many treatments, including psychotropic drugs, can be improved.1,2 Even though 
little evidence exists, several factors indicate that TDM might also be beneficial for antidementia 
drugs.1 A high inter-individual variability in response to treatment has been shown,3-5 which might 
partly be due to the high inter-individual variabilites in plasma concentrations.6-8 In elderly people, the 
presence of comorbidities and multiple comedication leading to drug-drug interactions, as well as 
genetic variations in metabolizing enzymes and transporters, might be causes of the observed inter-
individual variabilities in plasma concentrations. Moreover, non-adherence to the treatment could be 
revealed by TDM, which is a particular problem in patients with cognitive deficits.9 
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We previously published a high performance liquid chromatography mass spectrometry (HPLC-MS) 
procedure for the simultaneous determination of the four antidementia drugs in human plasma for 
TDM.10 To our knowledge, no other analytical methods allowing the simultaneous quantification of all 
four drugs have been published. However, several HPLC-MS/MS methods are described quantifying 
single compounds, sometimes with their metabolites, in human plasma.11-21 Sample preparation was 
performed using solid phase extraction (SPE), liquid-liquid extraction (LLE) or protein precipitation. 
In the present study, we aimed to transfer the previously developed HPLC-MS method to an ultra 
performance liquid chromatography system coupled to a tandem mass spectrometer (UPLC-MS/MS) 
to analyze the compounds by the most sensitive and specific methodology today available with a 
minimized run time per sample and a simplified extraction procedure of the drugs from plasma. UPLC 
technology has demonstrated significant advantages with respect to speed, sensitivity and 
resolution,22 and detection by tandem MS further increases the sensitivity and specificity of the 
method. The UPLC-MS/MS procedure was fully validated and its performance evaluated by 
comparing   the   results   of   patients’   plasma   concentration   measurements   obtained   by   UPLC-MS/MS 
with the results previously obtained by HPLC-MS. The UPLC-MS/MS procedure is presently used in 
our laboratory for TDM in patients receiving antidementia drugs. 
 
2. Experimental 
2.1 Chemicals and Reagents 
The drugs were kindly provided by their manufacturers: donepezil HCl by Eisai Co., Ltd (Tokyo, 
Japan), galantamine HBr by Janssen-Cilag (Beerse, Belgium), memantine HCl by Merz 
(Frankfurt/Main, Germany), rivastigmine hydrogen tartrate and its metabolite NAP 226-90 by Novartis 
(Basel, Switzerland). The internal standards (IS) [2H7]-donepezil, [13C,2H3]-galantamine HCl, [13C2,2H6]-
memantine HCl and [2H6]-rivastigmine hydrogen tartrate were purchased from Alsachim (Strasbourg, 
France). Biosolv® UPLC-grade acetonitrile, ammonium acetate (puriss p.a. for mass spectrometry) and 
physostigmine hemisulfate (eserine) were bought from Sigma-Aldrich (Buchs, Switzerland). Ultrapure 
water was obtained from a Milli-Q® RG with a QPAQ2 column system (Millipore, Billerica, MA, USA). 
All chemicals were of analytical grade. For the preparation of calibration standards (CS) and quality 
control (QC) samples and the evaluation of matrix effects, more than 10 different batches of human 
plasma  from  outdated  blood  donation  units  were  obtained  from  the  hospital’s  blood  transfusion  center  
(CHUV, Lausanne, Switzerland). 
2.2 Equipment 
The liquid chromatography system consisted of a Waters Acquity UPLC instrument equipped with a 
binary pump and a 96-vial autosampler (Waters, Milford, MA, USA). Chromatographic separation was 
performed  on  a  BEH  C18  column  (2.1  x  50  mm;;  1.7  μm)  (Waters)  equipped  with  a  BEH  C18  cartridge  
(2.1   x   5   mm;;   1.7   μm).   Analyses   were   carried   out   in   an   air   conditioned   room at 22°C and the 
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autosampler was kept at 8°C. The chromatographic system was coupled to a tandem quadrupole MS 
(TQD) (Waters) equipped with an electrospray ionization interface operated in positive ionization mode 
(ESI+). Data acquisition handling and instrument control were performed by the Masslynx software 
version V4.1 (Waters). 
2.3 Stock and Working Solutions 
Stock solutions of the analytes were prepared at 1 mg/mL (as base) in methanol and stored at -20°C. 
By dilution of the stock solutions with 0.01  N  HCl,  working  solutions  at  100  μg/mL  were  obtained  and  
likewise stored at -20°C. CS and QC samples were prepared independently by spiking blank plasma 
at different concentrations with freshly made dilutions of the working solution at 0.01, 0.1, 1 and 10 
g/mL in 0.01 N HCl. CS and QC samples were analyzed immediately or stored at -20°C until 
analysis. The stock solutions of the IS were prepared at 1 mg/mL in methanol and stored at -20°C. 
They were diluted with acetonitrile to give a single IS working solution  at  0.25  μg/mL  ([2H7]-donepezil, 
[13C,2H3]-galantamine, [13C2,2H6]-memantine)   and   0.075   μg/mL   ([2H6]-rivastigmine), respectively. To 
inhibit the enzymatic in-vitro hydrolysis of rivastigmine to its metabolite NAP 226-90 by plasma 
esterases,  100  μL  of  a 0.001 M physostigmine solution was added to every 1 mL of plasma used for 
the preparation of CS and QC samples.19 
2.4 Sample Preparation 
Plasma  samples  (250  μL)  were  mixed  with  50  μL  of  IS  solution  and  750  μL  acetonitrile  were  added  for  
protein precipitation. The samples were vortex-mixed, sonificated for 30 s, and centrifuged for 10 min 
at 16000 x g (12610 rpm) on an Eppendorf Centrifuge 5430 (Eppendorf AG, Hamburg, Germany). The 
supernatants  (900  μL)  were  transferred  into  polypropylene  tubes  and  evaporated  to  dryness  (N2 flow, 
45°C).  The  solid  residues  were  reconstituted  in  100  μL  of  the mobile phase at initial conditions (buffer-
acetonitrile 80:20, v/v), vortex-mixed and again centrifuged for 10 min at 16000 x g. Finally, the 
supernatants  (90  μL)  were  transferred  into  glass  vials  prior  to  injection  into  the  UPLC  MS/MS  system. 
2.5 UPLC-MS/MS conditions 
The stationary phase used in HPLC and UPLC method development was based on the same 
technology. Thus, the established HPLC gradient, using an ammonium acetate buffer (pH 9.3; 50 mM 
for HPLC and 20 mM for UPLC) (solution A) and acetonitrile (solution B) as mobile phase, was 
translated to UPLC conditions by means of the HPLC calculator tool of the University of Geneva, 
Switzerland.23 The obtained UPLC conditions were further improved and a suitable separation was 
achieved at a flow rate of 0.4 mL/min using the following stepwise elution program with an overall run 
time of 4.5 min: 20% of B maintained for 1.7 min, gradient to 35% of B from 1.7 to 1.75 min, hold at 
35% of B from 1.75 to 2.2 min, gradient to 80% of B from 2.2 to 2.9 min, hold at 80% of B from 2.9 min 
to 3.5 min. The gradient was followed by rinsing with 95% of B from 3.7 to 4.0 min and a 
reconditioning  step  at  initial  conditions  from  4.2  to  4.5  min.  Of  each  sample  5  μL  were  injected. 
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Detection was performed using three multiple reaction monitoring (MRM) functions with the following 
transitions (Table 1): function 1 m/z 166.0→121  (NAP  226-90),  288.1→213  (galantamine),  292.1→213  
([13C,2H3]-galantamine); function 2 m/z 180.1→163  (memantine),  188.1→171  ([13C2,2H6]-memantine), 
251.0→206   (rivastigmine),   257.0→206   ([2H6]-rivastigmine); function 3 m/z 380.2→91   (donepezil),  
387.2→98  ([2H7]-donepezil). For each function the dwell times were automatically assigned (Table 1). 
Nitrogen was used as desolvation gas at a flow rate of 800 L/h and a temperature of 400°C, and argon 
as collision gas at a flow rate of 0.35 mL/min. Source temperature was set at 150°C and capillary 
voltage at 3 kV. The cone voltage and the collision energy were optimized for all of the compounds 
separately  by  direct  infusion  of  a  solution  at  1  μg/mL  in  0.01  N  HCl  into  the  MS/MS  at  a  flow  rate  of  10  
μL/min   and   in   combined mode with the mobile phase (60% solution A/40% solution B). The cone 
voltage was tested in MS scan mode (values from 10 to 60 eV) and the collision energy in product 
scan mode (values from 5 to 50 eV). The settings producing the highest signal intensities of parent 
and product ions were retained (Table 1).  
2.6 Method Validation 
The  method  validation  was  based  on  the  recommendations  of  the  “Société  Française  des  Sciences  et  
Techniques  Pharmaceutiques”  and  on  the  two  guidelines  for  bioanalytical  method  validation published 
online by the US Food and Drug Administration and by the European Medicines Agency.24-26 
2.6.1 Selectivity, carry-over and psychiatric comedication 
Method selectivity was ascertained by analyzing plasma extracts from 10 batches of blank plasma for 
interfering peaks at the retention time of the analytes and IS. Moreover, carry-over effects were 
investigated by determining the peak area of the compounds in blank plasma injected after spiked 
samples at three different concentrations over the calibration range (donepezil, galantamine, 
memantine at 75, 150 and 300 ng/mL; rivastigmine, NAP 226-90 at 12, 24 and 50 ng/mL). 
Additionally, blank plasma was spiked with the following psychiatric drugs and some of their 
metabolites, and analyzed by the same procedure to investigate the influence of potential 
comedication: amitriptyline, amisulpride, aripiprazole, atomoxetine, dehydro-aripiprazole, bupropion, 3-
hydroxy-bupropion, caffeine, chlorpromazine, citalopram, desmethyl-citalopram, clomipramine, 
desmethyl-clomipramine, clopenthixol, clozapine, N-oxid-clozapine, norclozapine, desipramine, 
duloxetine, fluoxetine, norfluoxetine, flupenthixol, fluvoxamine, haloperidol, imipramine, loxapine, 
maprotiline, mianserin, desmethyl-mianserin, midazolam, 1-hydroxy-midazolam, mirtazapine, 8-
hydroxy-desmethyl-mirtazapine, moclobemide, N-oxid-moclobemide, 3'-oxo-moclobemide, morphine, 
nicotine, nortriptyline, olanzapine, paroxetine, quetiapine, reboxetine, risperidone, 9-hydroxy-
risperidone, sertindole, dehydro-sertindole, sertraline, desmethyl-sertraline, sulpiride, trimipramine, 
desmethyl-trimipramine, trazodone, venlafaxine, O-desmethyl-venlafaxine, N-desmethyl-venlafaxine, 
N-O-di-desmethyl-venlafaxine and ziprasidone. In the case of a similar retention time to the 
antidementia drugs, suppression of the signal was assessed by comparing the peak area of the 
analyte at 100 ng/mL (donepezil, galantamine, memantine) and 10 ng/mL (rivastigmine, NAP 226-90) 
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alone with the peak area of the analyte when injected with the potential interfering compound at a high 
therapeutic concentration. 
2.6.2 Matrix Effects, Extraction Recovery and Process efficiency 
Primarily, matrix effects were examined qualitatively by simultaneous post-column infusion of the 
analytes and IS into the MS/MS detector during chromatographic analyses of 6 different blank plasma 
extracts and mobile phase.27,28 The compounds were infused at a concentration of 50 ng/mL 
(donepezil, galantamine, memantine), 10 ng/mL (rivastigmine, NAP 226-90) and 100 ng/mL (IS) with a 
flow  rate  of  10  μL/min,  corresponding  to  the  lower  end  concentration  signal  response  of  the  analytes.  
Signal suppression or enhancement at the retention time of the analytes was investigated. 
Subsequently, matrix effects, recoveries of extraction and process efficiencies were assessed 
quantitatively at low (donepezil, galantamine, memantine at 3 ng/mL; rivastigmine, NAP 226-90 at 0.6 
ng/mL) and high (donepezil, galantamine, memantine at 250 ng/mL; rivastimine, NAP 226-90 at 40 
ng/mL) concentration based on the approach of Matuszewski.29 Three sets of samples were 
processed as follows:  
(A): Pure standard solution samples of the analytes and IS in the reconstitution solvent (buffer-
acetonitrile 20:80, v/v) injected directly onto the column. 
(B): Duplicates of plasma extract samples from 6 different sources spiked with the analytes and IS 
after extraction. 
(C): Duplicates of plasma samples from 6 different sources (same as B) spiked with the analytes and 
IS before extraction. 
For calculations, the mean peak area of the duplicates was used. The matrix effect (ME) was 
evaluated for each analyte and IS by calculating the ratio of the peak area in the presence of the 
matrix (samples spiked after extraction) to the peak area in absence of the matrix (pure standard) and 
expressed in percentage (ME = B/A). The recovery of extraction (RE) was determined by comparing 
the peak area of the pre-extraction spiked (C) to the post-extraction spiked samples (B) (RE = C/B). 
The overall process efficiency (PE), taking into account ME and RE, was assessed by calculating the 
ratio of the peak area of the pre-extraction spiked samples to the peak area of the pure standard (PE = 
C/A). Of all three parameters, the variability between the different plasma batches was evaluated and 
expressed as coefficient of variation (CV%). A value   ≤15%  was   considered   satisfactory.   The   same  
parameters and respective CVs were calculated considering the IS-normalized peak areas for each 
analyte. 
2.6.3 Trueness and Precision 
Three validation series were performed on independent days to determine the trueness and precision 
of the method. Duplicates of CS and quadruplicates of QC samples were set at 8 different levels 
covering the expected range of concentrations in patients:8,30-32 1, 2, 5, 20, 50, 100, 200, 300 ng/mL 
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for donepezil, galantamine and memantine, and 0.2, 0.5, 1, 2, 5, 10, 20, 50 ng/mL for rivastigmine and 
NAP 226-90. Results were based on the peak area ratio of the analytes and their IS. [2H7]-donepezil, 
[13C,2H3]-galantamine, [2H6]-rivastigmine and [13C2,2H6]-memantine were used as IS for their respective 
analyte, whereas [2H6]-rivastigmine was additionally used for the metabolite of rivastigmine NAP 226-
90. The QC samples were analyzed against the calibration curve of the same run and the trueness of 
each concentration level was expressed as percentage of the theoretical value. Precision was 
estimated by means of repeatability (intra-day variance) and intermediate precision (sum of intra-day 
and inter-day variances) and expressed as coefficients of variation (CV%).33 Accuracy profiles within 
the  acceptance  limits  (λ=±30%)  and  with  β-expectation  tolerance  intervals  (β=90%)  were  established  
for each compound.33,34 Moreover, the linearity of the method was assessed applying a regression 
model to the recalculated QC concentrations versus theoretical concentrations. 
In each validation run, four QC samples at 600 ng/mL (donepezil, galantamine, memantine) and 100 
ng/mL (rivastigmine, NAP 226-90)   were   included   to   assess   dilution   integrity   in   case   of   a   patient’s  
plasma concentration exceeding the highest CS. The trueness and precision of these samples were 
determined carrying out a two-fold dilution with blank plasma prior to extraction.  
2.6.4 Stability 
The stability of all compounds in plasma and whole blood was assessed previously using the HPLC-
MS procedure.10 The in vitro degradation of rivastigmine was stopped by addition of the esterase 
inhibitor physostigmine to the samples. In the present study, additional tests were performed to 
investigate the stability of rivastigmine and NAP 226-90 in whole blood and plasma collected in 
commercially available blood sampling tubes containing sodium fluoride (1 mg NaF, 1.2 mg K-EDTA 
per mL), another esterase inhibitor.35 Whole blood and plasma of 5 different persons were spiked with 
rivastigmine and NAP 226-90 at low (2 ng/mL) and high (20 ng/mL) concentration and different sets of 
aliquots were prepared. The stability was assessed after storage at ambient temperature for 24 h, 48 h 
and 72 h. In addition, a set of plasma aliquots was stored for 2 weeks at -20°C to investigate a longer 
storage in the freezer before analysis. The stability was evaluated by calculating the percentage of the 
initial concentration in the different aliquots. 
 Furthermore, the post-preparative stability was assessed for all compounds by leaving the processed 
samples up to 48 h on the autosampler at 8°C before reanalysis.  
2.7 Method comparison between HPLC-MS and UPLC-MS/MS 
Several   patients’   samples   (33   for   galantamine,   40   for   donepezil,   memantine   and   rivastigmine),  
previously quantified by HPLC-MS, were reanalyzed in different series by the described UPLC-MS/MS 
procedure. For NAP 226-90,  instability  was  observed  in  patients’  samples after storage for more than 
one year and multiple thaw/freeze cycles, therefore, aliquots of 28 spiked plasma samples with 
concentrations covering the dosage range were analyzed with both procedures to perform the 
comparison. For all analytes, the correlation between the two methods was tested by a Passing-
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Bablok fit36,37 and the mean bias was assessed by Bland-Altman plots38 (Analyze-it, Microsoft Excel 
2007). 
 
3. Results and Discussion 
3.1 Sample preparation 
In the original HPLC-MS  method,   the   drugs  were   isolated   from  500  μL  plasma  by  SPE,  which   is   a  
powerful procedure to obtain clean extracts. However, the higher specificity of the UPLC-MS/MS 
compared to HPLC-MS allows the analysis of less clean extracts with satisfactory results. Therefore, 
the extraction procedure was simplified and a protein precipitation with acetonitrile was used with the 
advantages of a faster sample preparation and lower costs. In addition, the amount of required plasma 
was  reduced   to  250  μL.  The  extraction  recoveries  were  comprised  between  77%  and  96%,  with   the  
exception of memantine and [13C2,2H6]-memantine for which the recoveries were between 46% and 
54% (Table 2). Moreover, the repeatability was good for all compounds with CVs below 11% for the 
analytes and IS alone, and below 6% when the analyte/IS ratios were considered.  
3.2 Transfer of Chromatographic Conditions and Optimization of MS/MS Conditions 
The chromatographic conditions of the HPLC method with an overall run time of 15 min were 
translated to the UPLC system using the HPLC calculator tool from the University of Geneva.23 The 
gradient was then optimized to achieve a satisfactory separation of the compounds. Compared to the 
original method, the concentration of the ammonium acetate buffer at pH 9.3 was reduced from 50 
mM to 20 mM and instead of an X-Bridge column (2.1x100  mm;;  3.5  μm),  a  BEH  C18  column  (2.1  x  50  
mm;;  1.7  μm)  was  used,  which  is  based  on  the  same  stationary  phase  technology  but  packed  with  sub-
2  μm  particles.  Elution  was  realized  at  a  flow  rate  of  0.4  mL/min  and  the  overall  run  time  was  4.5  min.  
The retention times of the analytes are listed in Table 1 and a chromatographic profile of a QC plasma 
sample at the lower limit of quantification (LLOQ) is shown in Figure 2. 
To improve the robustness of an analytical method, it is highly recommended to use isotope-labeled IS 
for quantification.39,40 They compensate for signal alterations due to matrix effects and for variability in 
the extraction procedure. In the described method, isotope-labeled IS were used for donepezil, 
galantamine, rivastigmine and memantine, co-eluting with their respective analyte. For NAP 226-90, 
[2H6]-rivastigmine was used as IS after verification of the absence of signal suppression of rivastigmine 
on [2H6]-rivastigmine at the highest calibration level. 
To find optimal ionization conditions, different settings of the cone voltage and of the collision energy 
were evaluated for each analyte. Satisfactory results were obtained with cone voltage values between 
20 and 45 eV and collision energy values between 15 and 35 eV (Table 1). The detection was 
performed in MRM mode using three different functions, each of which monitored one or two analytes 
with their respective IS. Compared to the method using a unique MRM function, the variability of 
replicate injections was improved and the sensitivity was increased due to the higher dwell times. 
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3.3 Validation 
3.3.1 Selectivity, Carryover and Comedication with Psychoactive Drugs 
No  peaks  from  endogenous  compounds  were  observed  at  the  analytes’  retention  times  in  any  of  the  
10 blank plasma extracts evaluated. Moreover, no significant cross talk was observed between the 
isotope-labeled IS and the parent compounds. Injection of blank plasma after three different 
concentrations over the calibration range revealed no significant carry-over effects for all substances 
with the exception of donepezil. Even though different needle washes were investigated, a carry-over 
of 0.15% persisted for this analyte. The peak area of the carry-over should quantitatively represent 
less than 20% of the peak area of the analyte at LLOQ.26 To meet this criterion, a blank sample has to 
be   injected   after   the   highest   CS   and   between   two   subsequent   injections   of   donepezil   patients’  
samples. 
Patients taking antidementia drugs frequently receive multiple comedication due to several 
comorbidities. Since comedication may potentially lead to analytical interferences, the influence of 
psychoactive drugs on the determination of antidementia drugs was assessed. For this purpose, 
plasma samples spiked with several antidepressant and antipsychotic drugs, and some of their 
metabolites, were analyzed with the same procedure. The retention times of the psychoactive drugs 
were recorded. Six substances coeluted with the compounds of interest, namely donepezil with 
bupropion, clopenthixol and dehydro-sertindole, rivastigmine with desmethyl-citalopram and 1-
hydroxy-midazolam and NAP 226-90 with nicotine. All coeluting substances were distinguished by 
MS/MS detection and no significant signal suppression was observed for the antidementia drugs when 
injected with these compounds. However, the use of comedication in elderly patients is not restrained 
to psychoactive drugs, thus, special attention has to be paid to this issue during routine use of the 
method. Nevertheless, by the use of the highly specific UPLC-MS/MS technology and of isotope-
labeled IS compensating for potential signal suppression, the risk of analytical inferences with 
comedication has been minimized. 
3.3.2 Matrix Effects 
The detection by MS in ESI mode is known to be sensitive to matrix effects, which refers to signal 
enhancement or suppression by endogenous compounds present in the biological matrix.22,28 Matrix 
effects were qualitatively studied by the means of direct infusion of the analytes and IS into the MS/MS 
detector during analysis of six different blank plasma extracts. At the retention time of the analytes, 
signal suppression was observed for donepezil and [2H7]-donepezil, and signal enhancement for 
memantine and [13C2,
2H6]-memantine, whereas no interferences were detected for the other 
compounds (data not shown). Additionally, matrix effects were assessed quantitatively by comparing 
the peak area of the analytes and IS in the pure standard solution and in six different plasma batches 
spiked at low (3 times LLOQ) and high (80% upper limit of quantification (ULOQ)) concentration. The 
findings of the post-column infusion experiment were confirmed by the quantitative assessment, which 
revealed matrix effects of 79% and 81% for donepezil and [2H7]-donepezil, and 110% and 105% for 
memantine and [13C2,2H6]-memantine, respectively, at low concentration (Table 2). However, when the 
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ratios analyte/IS were used for calculation, the matrix effects were considerably smaller for donepezil 
and memantine (98%-105%), showing the compensating effect of the isotope-labeled IS. For the other 
compounds, the matrix effects were comprised between 92% and 103%, and between 95% and 102% 
when the analyte/IS ratios were considered (Table 2). Even more important than absolute matrix 
effects, is to have a low variability of these effects between the different plasma batches. This aim was 
achieved with CVs inferior to 15% for the compounds alone and inferior to 5% for the ratios analyte/IS 
(Table 2). 
Finally, the process efficiencies, representing the combined effects of extraction recovery and matrix 
effects, were also found to be satisfactory with values ranging from 93% to 109% and CVs inferior to 
7% for the analyte/IS ratios (Table 2). 
3.3.3 Trueness and Precision 
Three different validation series were performed on independent days. Eight CS were initially used for 
each compound covering the range from 1 to 300 ng/mL for donepezil, galantamine and memantine, 
and from 0.2 ng/mL to 50 ng/mL for rivastigmine and its metabolite NAP 226-90. Different calibration 
models were tested and the following four-point calibration curves were selected: 1, 20, 100 and 300 
ng/mL for donepezil (quadratic regression model weighted 1/x), galantamine (linear regression model 
weighted 1/x2) and memantine (linear regression model weighted 1/x), and 0.2, 2, 20 and 50 ng/mL for 
rivastigmine and NAP 226-90 (linear regression model weighted 1/x in both cases).  
The QC samples were analyzed against the calibration curve of the same run and the trueness, 
repeatability and intermediate precision at each concentration level were determined (Table 3). In 
accordance to the above-mentioned guidelines, the QC samples were within the specifications. The 
determined trueness met the acceptance criterion of 10015% (LLOQ 20%) with values comprised 
between 86% and 108%. Moreover, the values for repeatability and intermediate precision met the 
requirements of CVs 15% (LLOQ 20%) with values inferior to 8.3% and 10.9%, respectively. 
Consequently, the LLOQs were set at 1 ng/mL for donepezil, galantamine and memantine, and at 0.2 
ng/mL for rivastigmine and NAP 226-90. The higher sensitivity of the UPLC-MS/MS technology 
compared to the HPLC-MS allowed to reduce the LLOQs of rivastigmine and NAP 226-90. Therefore, 
the calibration ranges were modified as follows to better correspond to the low concentrations 
observed in patients: from 1 to 300 ng/mL (rivastigmine) and 2 to 300 ng/mL (NAP 226-90) in HPLC-
MS to 0.2 to 50 ng/mL (both analytes) in UPLC-MS/MS. 
The accuracy  profiles   for  each  compound   in   the  dosing   range  with  β-expectation tolerance intervals 
(β=90%)  are  presented  in  Figure  3.  All  accuracy  profiles  are  within  the  set  acceptance  limits  of  ±30%  
with the exception of NAP 226-90. A possible reason for the larger profile of NAP 226-90 might be the 
lack of a coeluting isotope-labeled IS which would compensate for variabilities in the extraction 
procedure and matrix effects. The larger accuracy profile of NAP 226-90 is probably not of clinical 
significance as NAP 226-90 is an inactive and non-toxic metabolite. However, NAP 226-90 was 
introduced in the method because it is an indicator of the extent of rivastigmine metabolism. 
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The dilution integrity was confirmed by a twofold dilution of QC samples at concentrations exceeding 
twofold the highest calibration level. The trueness and precision of the diluted samples met the 
acceptance criteria of 10015%   and   CVs   ≤15%,   therefore,   plasma   sample   of   patients   containing  
antidementia drugs at concentrations exceeding the ULOQ can be adequately diluted with blank 
plasma before analysis. 
Furthermore, a linear regression model was applied to the recalculated QC concentrations versus 
theoretical concentrations to assess the linearity of the method. The following slopes 0.995, 0.973, 
0.953, 1.005 and 0.867 and intercepts 0.200, 2.223, 0.332, 0.270 and 0.037 were obtained for 
donepezil, galantamine, memantine, rivastigmine and NAP 226-90, respectively. The corresponding 
determination coefficients were 0.997, 0.994, 0.953, 0.996 and 0.989, indicating that the developed 
method was linear for the tested compounds. 
3.3.4 Stability 
As previously described, the analytes were stable in plasma for 72 h at room temperature, up to 3 
months at -20°C and after three freeze/thaw cycles. Moreover, the drugs were stable in K-EDTA whole 
blood for at least 24 h at room temperature, with the exception of NAP 226-90 for which a rapid 
degradation was observed.10 Rivastigmine is metabolized to NAP 226-90 by esterases that are 
present in blood and plasma. To stop the in-vitro degradation of rivastigmine after blood sampling, the 
esterase inhibitor physostigmine was added to the samples. NaF is another known esterase inhibitor35 
and, in contrast to physostigmine, it is used in commercial blood sampling tubes to inhibit glucose 
degradation. For TDM of rivastigmine, using commercially available blood sampling tubes would be 
more convenient. Therefore, the stability of rivastigmine and NAP 226-90 in whole blood and plasma 
collected in NaF containing blood sampling tubes was tested over a period of 72 h at room 
temperature. The degradation of rivastigmine remained below 20% under the following conditions: up 
to 72 h in whole blood and 48 h in plasma at room temperature, and up to 2 weeks in plasma at -20°C 
(Table 4). The concentration of the metabolite NAP 226-70 increased proportionally to the decrease in 
rivastigmine concentration. Compared to physostigmine, the inhibition by NaF is less strong and thus 
the degradation of rivastigmine more rapid. For reasons of convenience, blood sampling tubes 
containing NaF could be used. However, to assure better precision of the measurement, the samples 
should be frozen as soon as possible. 
Since a new extraction procedure was used, the post-preparative stability was retested with the 
UPLC-MS/MS method. All analytes were found to be stable in the injection solution up to 48 h at 8°C 
with values between 86% and 110% of the initial concentration (Table 4). 
3.4 Method comparison between HPLC-MS and UPLC-MS/MS 
A method comparison was performed by analyzing samples previously measured by HPLC-MS by the 
newly developed UPLC-MS/MS procedure. The Passing-Bablok regression equations and 
corresponding plots are presented in Figure 4. The 95% CI included the value 1 for the slope and the 
value zero for the intercept for donepezil, galantamine and memantine, indicating no statistically 
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significant difference between the methods. In contrast, the slope of rivastigmine and NAP 226-90 did 
not include the value 1, meaning that there is a proportional difference between the two methods. 
However, the mean bias obtained by the Altman-Bland plots were found to be small with 10.9% (95% 
CI 5.9% to 15.9%) and -5.6% (95% CI -7.3% to -3.9%) for rivastigmine and NAP 226-90, respectively. 
These differences may not be of clinical relevance and are possibly due to the time difference 
between the tests, the use of different stock solutions and the modified calibration ranges for 
rivastigmine and NAP 226-90. 
 
4. Conclusion 
The procedure developed on HPLC-MS for the determination of antidementia drugs in human plasma 
was successfully transferred to UPLC-MS/MS. Sample preparation was simplified by using protein 
precipitation instead of SPE and, due to the higher sensitivity of the tandem MS, the required amount 
of  plasma  was  reduced  from  500  μL  to  250  μL.  The  calibration  ranges  of  rivastigmine  and  NAP  226-90 
were modified, with a decreased LLOQ of 0.2 ng/mL, to better correspond to plasma concentrations 
observed in patients. Moreover, the run time was shortened from 15 min to 4.5 min. The procedure 
was fully validated according to the recommendations of international guidelines. A method 
comparison between HPLC-MS and UPLC-MS/MS was performed showing similar results between 
the two procedures. Both methods are reliable and can be used for TDM in patients receiving 
antidementia drugs. However, the UPLC-MS/MS method is preferable with respect to specificity, 
sensitivity and speed and is presently used in the routine TDM service in our laboratory. 
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Figure 1: Chemical structures of the analytes. 
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Figure 2: Chromatogram of a QC plasma sample at LLOQ (1 ng/mL donepezil, galantamine, 
memantine, 0.2 ng/mL rivastigmine, NAP 226-90, 50 ng/mL [2H7]-donepezil, [13C,2H3]-galantamine, 
[13C2,2H6]-memantine and 15 ng/mL [2H6]-rivastigmine). 
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Figure 3: Accuracy   profiles   within   the   acceptance   limit   (λ=±30%)   and   with   upper   and   lower   β-
expectation  tolerance  intervals  (β=90%)  for  each  compound  in  the  dosing  range. 
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Figure 4: Passing-Bablok fits of the comparison between UPLC-MS/MS and HPLC-MS. In the plots 
the regression lines (solid line), the 95% confidence intervals for the regression line (dashed lines, 
values in brackets) and the identity lines (x=y, gray line) are shown. 
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Table 1: MRM parameters and retention times of the analytes and IS. 
 Parent 
(m/z) 
Fragment 
(m/z) 
Cone  
voltage  
(eV) 
Collision  
energy  
(eV) 
Dwell time 
(ms) 
tR  
(min)a 
Function 1 (0-2.4 min)       
NAP 226-90 166 121 20 15 171 1.5 
Galantamine 288 213 30 25 171 1.9 
[13C,2H3]-galantamine 292 213 30 25 171 1.8 
Function 2 (2.5-3.2 min)       
Memantine 180 163 30 15 128 2.9 
[13C2,2H6]-memantine 188 171 30 15 128 2.8 
Rivastigmine 251 206 20 15 128 3.0 
[2H6]-rivastigmine 257 206 20 15 128 3.0 
Function 3 (3.2-4.5 min)       
Donepezil 380 91 45 35 261 3.4 
[2H7]-donepezil 387 98 45 35 261 3.4 
a tR: Retention time. 
 Table 2: M
atrix effects (M
E
), recovery of extraction (R
E) and process efficiency (PE) 
 
Concentration 
(ng/m
L) 
M
E %
 (CV%
a) 
n=6 
RE %
 (CV%
 a) 
n=6 
PE %
 (CV%
 a) 
n=6 
 
Low 
High 
Low 
High 
Low 
High 
Low 
High 
Donepezil 
3 
250 
79 (4) 
90 (4) 
95 (6) 
79 (4) 
75 (9) 
72 (7) 
[ 2H
7 ]-donepezil 
50 
50 
81 (7) 
86 (7) 
96 (7) 
77 (5) 
78 (11) 
66 (10) 
Galantam
ine 
3 
250 
97 (2) 
92 (2) 
80 (1) 
85 (2) 
77 (2) 
79 (1) 
[ 13C, 2H
3 ]-galantam
ine 
50 
50 
95 (2) 
98 (2) 
83 (3) 
84 (2) 
79 (2) 
82 (1) 
Rivastigm
ine 
0.6 
40 
102 (2) 
102 (1) 
80 (2) 
80 (2) 
82 (2) 
81 (2) 
[ 2H
6 ]-rivastigm
ine 
15 
15 
103 (1) 
101 (1) 
81 (1) 
82 (1) 
83 (2) 
83 (2) 
NAP 226-90 
0.6 
40 
99 (1) 
97 (1) 
78 (3) 
78 (1) 
77 (3) 
76 (1) 
M
em
antine 
3 
250 
110 (14) 
104 (7) 
46 (7) 
53 (9) 
51 (16) 
55 (15) 
[ 13C
2 , 2H
6 ]-m
em
antine 
50 
50 
105 (9) 
100 (4) 
47 (6) 
54 (10) 
49 (12) 
54 (12) 
 
 
 
 
 
 
 
 
 
Donepezil/[ 2H
7 ]-donepezil 
3 
250 
98 (4) 
105 (3) 
99 (3) 
103 (1) 
96 (3) 
109 (3) 
Galantam
ine/[ 13C, 2H
3 ]-galantam
ine 
3 
250 
102 (3) 
95 (2) 
96 (3) 
102 (3) 
98 (2) 
106 (2) 
Rivastigm
ine/[ 2H
6 ]-rivastigm
ine 
0.6 
40 
99 (2) 
101 (2) 
99 (3) 
98 (2) 
98 (3) 
98 (2) 
NAP 226-90/[ 2H
6 ]-rivastigm
ine 
0.6 
40 
96 (2) 
96 (1) 
96 (3) 
95 (1) 
93 (3) 
93 (2) 
M
em
antine/[ 13C
2 , 2H
6 ]-m
em
antine 
3 
250 
105 (4) 
104 (3) 
97 (5) 
98 (3) 
102 (6) 
103 (4) 
aC
V%
: C
oefficient of variation. 
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Table 3: Trueness and precision of quality control samples in quadruplicates determined in three 
different validation series. 
 Nominal 
Concentration 
(ng/mL) 
Trueness (%) 
Precision (%) 
 Repeatability Intermediate precision 
Donepezil 1 95.5 3.3 4.0 
 2 99.2 2.3 2.3 
 5 93.1 2.9 9.1 
 20 104.0 2.8 4.1 
 50 100.8 1.8 5.0 
 100 98.3 0.8 4.7 
 200 101.0 2.1 6.1 
 300 99.1 2.1 3.8 
Galantamine 1 99.2 5.5 7.2 
 2 100.0 6.0 6.0 
 5 99.6 3.3 5.1 
 20 103.4 3.7 5.0 
 50 104.7 3.0 3.3 
 100 105.1 4.9 6.4 
 200 102.0 3.2 4.6 
 300 95.8 4.7 6.0 
Rivastigmine 0.2 92.0 6.5 6.5 
 0.5 96.0 4.5 4.5 
 1 101.8 3.6 4.4 
 2 105.9 3.1 5.7 
 5 107.2 2.4 5.9 
 10 105.9 4.1 7.9 
 20 107.7 4.0 5.7 
 50 100.0 2.4 5.5 
NAP 226-90 0.2 89.0 4.6 6.4 
 0.5 88.2 6.1 8.0 
 1 91.2 5.1 5.7 
 2 88.7 2.6 7.1 
 5 86.4 1.8 6.7 
 10 86.2 1.9 6.0 
 20 88.7 4.7 10.9 
 50 89.6 1.8 4.3 
Memantine 1 106.8 4.1 6.9 
 2 102.6 8.3 8.3 
 5 97.5 3.3 3.3 
 20 100.0 4.5 4.9 
 50 94.9 2.1 3.2 
 100 93.2 2.6 3.7 
 200 95.5 3.8 4.3 
 300 95.4 2.2 2.4 
 Table 4: Postpreparative stability of all com
pounds and stability of rivastigm
ine and N
A
P 226-90 in sodium
 fluoride containing blood sam
pling tubes 
expressed as the percentage of the initial concentration (coefficient of variation %
). 
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4.1 Article IV: Relationship of genetic variants in CYP2D6, CYP3A, POR, NR1I2 and ABCB1 
genes with steady-state donepezil plasma concentrations 
 
Summary 
In this article, the results of the pharmacogenetic study in patients treated with donepezil are 
described. The large inter-individual variability in donepezil plasma concentrations, reported in 
previous studies, was confirmed. The relationship of genetic variations in CYP2D6, CYP3A, POR, 
NR1I2 and ABCB1, and of other clinical factors, with donepezil steady-state plasma concentrations 
was investigated in 129 older patients treated with this drug. The CYP2D6 genotype appeared to be 
the major genetic factor contributing to the variability in plasma concentrations. Thus, CYP2D6 
homozygous extensive metabolizers demonstrated significantly lower plasma concentrations than 
heterozygous extensive metabolizers and poor metabolizers, and higher plasma concentrations than 
ultrarapid metabolizers. Moreover, significantly higher plasma concentrations were observed in NR1I2 
rs1523130T carriers, which might be due to a lower CYP3A expression in these patients. Finally, the 
POR*28T allele was associated with lower donepezil concentrations in CYP2D6 extensive 
metabolizers, which is in line with the higher CYP3A activity described in carriers of this allele. These 
findings contribute to a better understanding of donepezil pharmacokinetics and might help, with 
further research, to improve clinical effectiveness and tolerance of the treatment. 
 
 
 
Article in preparation 
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ABSTRACT 
Background: A large interindividual variability in plasma concentrations was observed in patients 
treated with donepezil, the most frequently prescribed antidementia drug. Donepezil is mainly 
metabolized by the enzymes CYP2D6 and CYP3A, and it is a substrate of the P-glycoprotein. We 
aimed to study the relationship of genetic variants influencing the activity of these enzymes and 
transporter, and of other clinical factors, with donepezil steady state plasma concentrations. 
Methods: In this naturalistic cross-sectional study, 129 older patients treated with a constant dose of 
donepezil were included. The patients were genotyped for polymorphisms in CYP2D6, CYP3A, POR, 
NR1I2 and ABCB1 genes, and donepezil steady state plasma concentrations were determined. 
Results: The CYP2D6 genotype appeared to be the major genetic factor contributing to the variability 
in plasma concentrations. Thus, significant differences were found between CYP2D6 homozygous 
extensive metabolizers and heterozygous extensive metabolizers, poor metabolizers and ultrarapid 
metabolizers with median dose-adjusted plasma concentrations of 4.7 versus 5.3 (p=0.037), 6.3 
(p=0.005) and 2.6 (p=0.005) ng/ml·mg, respectively. Significantly higher plasma concentrations were 
observed in NR1I2 rs1523130T carriers (p=0.005), potentially having a lower CYP3A expression. 
Moreover, the POR*28 was associated with lower donepezil concentrations in CYP2D6 extensive 
metabolizers (p=0.018).  
Conclusions: Genetic variations, primarily in CYP2D6, significantly influenced donepezil plasma 
concentrations and might therefore have an impact on the efficacy and safety of the treatment.  
 
INTRODUCTION 
Donepezil is an acetylcholinesterase inhibitor widely used in the symptomatic treatment of Alzheimer’s  
disease (AD). The inhibition of the acetylcholinesterase increases the level of acetylcholine in the 
synaptic cleft and thus compensates the cholinergic deficit observed in the AD pathology. Cholinergic 
adverse events (AE) are common and include gastrointestinal problems, dizziness, insomnia, fatigue 
and muscle cramps.1 Several studies reported a large variability in drug response to donepezil among 
AD patients,2,3 which might partly be due to the observed interindividual differences in plasma 
concentrations of the drug.4 On one hand, these differences could be triggered by genetic variations in 
enzymes and transporters implicated in drug metabolism and elimination. On the other hand, in elderly 
patients, the presence of multiple comorbidities and polypharmacy resulting in drug-drug interactions 
might lead to changes in plasma concentrations. 
Donepezil is metabolized in the liver by the cytochromes P450 (CYP) 2D6 and 3A. 6-O-desmethyl-
donepezil is the only active metabolite with a comparable potency in AChE inhibition as donepezil. It 
is, however, only present at around 20% of the concentration of the parent drug.5 Coadministration of 
drugs inhibiting CYP2D6 and CYP3A has been found to increase plasma concentrations of donepezil, 
showing the importance of these two enzymes in donepezil metabolism.6,7  
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Phenotypically, four types of CYP2D6 metabolizers can be distinguished: poor (PM), intermediate 
(IM), extensive (EM) and ultrarapid metabolizers (UM). Underlying genetic variations defining the 
CYP2D6 phenotypes are well known.8 One clinical trial reported a non significant influence of the 
CYP2D6 genotype on donepezil plasma concentrations.4 However, this study enrolled a small number 
of subjects (n=42) without any PM. Several studies also investigated the influence of genetic variations 
in CYP2D6 on response to donepezil treatment. Although discrepant, results from these studies 
suggest that patients with CYP2D6 genotypes associated with no or low activity (i.e. leading to higher 
plasa concentrations) may have better clinical outcomes.9-12 
The predictive information of genetic variations in CYP3A on enzyme activity is more limited.13 CYP3A 
stands for a group of isozymes, namely CYP3A4, CYP3A5 and CYP3A7, which have a large overlap 
in substrate specificity. A clinical trial investigated the association of different CYP3A4/5 
polymorphisms on plasma concentrations and therapeutic outcome of donepezil. The results suggest 
no major impact of genetic variants in CYP3A4/5 on donepezil metabolism.14 Furthermore, donepezil 
is a substrate of the P-glycoprotein (P-gp),15 a membrane transporter implicated in drug absorption, 
distribution and excretion. Several polymorphisms in the ABCB1 gene, coding for P-gp, have been 
shown to influence its activity.16 In the above mentioned study, patients homozygous for the ABCB1 
1236T/2677T/3435T haplotype showed a tendency toward lower plasma concentrations.14 
Genetic variations in other genes than CYP3A4/5/7 could influence CYP3A activity. The cytochrome 
P450 oxidoreductase (POR) is a protein that transfers electrons from NADPH to microsomal CYP 
enzymes and might, therefore, be a general limiting factor for drug metabolizing capacity.17 Many 
polymorphisms in the POR have been described, some of them changing the activity of the enzyme in 
vitro. The results of an in vivo study suggest a 1.6-fold increase in CYP3A activity among homozygous 
carriers of the common POR*28 allele.17 Furthermore, the Pregnane X receptor (PXR) regulates the 
expression of detoxifying drug-metabolic enzymes and transporters, including CYP3A4 and P-gp.18 
PXR is a nuclear receptor encoded by the NR1I2 gene and is activated by a variety of xenobiotics and 
endogenous ligands. In vitro studies revealed genetic variants in the regulatory region of NR1I2 
associated with inducible and constitutive CYP3A4 expression.19,20 
In the present study, we investigated the effect of genetic variations in CYP2D6, CYP3A4/5/7, POR, 
NR1I2 and ABCB1 on steady state donepezil plasma concentrations in a group of 129 older patients 
treated with donepezil. The relationship between plasma concentrations and genotypes on recorded 
side effects was also investigated. 
 
METHODS 
Study design and participants 
This cross-sectional study was conducted at four hospitals (Lausanne, Geneva, Marsens, Aigle) and 
in affiliated nursing homes. A total of 129 patients treated with donepezil for at least one month with a 
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stable dose were included. 89% of the participants were inpatients and 11% were outpatients. One 
blood sampling was performed to measure donepezil plasma concentration, to evaluate renal and 
hepatic function (standard clinical laboratory tests: ALT, ASP, AP, GGT, bilirubin, urea, creatinine), 
and to extract DNA for the genetic analyses. The presence of adverse events, reported by the 
patients, doctors and/or nurses, was registered. Additionally, concomitant diseases, comedication, 
consumption of grapefruit, alcohol and tobacco were recorded. 
The study was approved by the local ethics committees (Lausanne University Hospital, Geneva 
University Hospital, Cantonal Ethic Committee Fribourg) and conducted according to the Good Clinical 
Practices. Written informed consent, including consent for genetic analysis, was obtained from all 
patients or their legal representative. 
Plasma concentration determination and estimation of trough concentration 
Blood samples were collected on average 14 hours after medication intake (range: 1-28 hours) in 
EDTA blood tubes. After centrifugation, the plasma was stored at -20°C until analysis. Donepezil 
plasma concentrations were determined by high performance liquid chromatography coupled with 
mass spectrometry, as previously described.21 
Trough concentrations at 24 hours after drug intake were estimated by the means of the following 
equation: Ctrough=Cmeasured*e-((ln2/t1/2)*dt). According to literature, t1/2 was considered as 70 hours 22-25 and 
dt as the time between medication intake and blood sampling. The maximal plasma concentration is 
reached around four hours after drug intake.23-25 In patients in the first two hours of the absorption 
phase (n=12), the measured plasma concentration was regarded as trough concentration. In patients 
in the second part of the absorption phase (n=9), the above-mentioned equation was used to calculate 
the trough concentration assuming that most of the drug substance was already absorbed. Since 
linear pharmacokinetics of donepezil has been demonstrated, the estimated trough concentration was 
corrected for each patient by the daily donepezil dose.23 
Genotyping 
Genomic DNA was extracted from EDTA blood samples with the FlexiGene DNA extraction kit and the 
QIAamp DNA Blood Mini Kit (QIAGEN, Hombrechtikon, Switzerland) according to the manufacturer’s  
protocols. The following SNPs were detected by real-time  polymerase  chain  reaction  with  5’-nuclease 
allelic discrimination assays (ABI PRISM 7000; Applied Biosystems, Rotkreuz, Switzerland) according 
to   previous   studies   or   manufacturer’s   instructions:17,26 CYP2D6*3 (rs35742686), CYP2D6*4 
(rs3892097), CYP2D6*6 (rs5030655), CYP3A4*1B (rs2740574), CYP3A4 rs4646437C>T, CYP3A5*3 
(rs776746), CYP3A7*1C (2262T>A and 2270T>G), POR*28 (rs1057868), NR1I2 rs1523130, NR1I2 
rs2472677, NR1I2 rs7643645, ABCB1 2677G>T (rs2032582), ABCB1 3435C>T (rs1045642), ABCB1 
1236C>T (rs1128503). Gene deletion (CYP2D6*5) and duplication/multiplication (CYP2D6*xN) were 
analyzed by TaqMan copy number assay and long PCR, respectively, as previously described.26 
Internal quality control samples of known genotype were included in all analyses.  
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Statistical Analysis 
Group comparisons were performed with the non-parametric Wilcoxon and Kruskal-Wallis rank sum 
tests   for  continuous  variables  and  with   the  Fisher’s  exact   test   for  categorical  variables.  Associations  
between continuous variables were tested with the Spearman rank-order correlation coefficients (rs). 
Multiple regression analyses were performed using the log-transformed value of the dose-adjusted 
estimated trough concentration as dependent variable whereas age, gender, comedication and 
genetic polymorphisms were considered as independent variables. The adjusted values of R2 obtained 
from the regression models are reported as a measure of the explained variability. Haplotypes were 
inferred using the R software (version 2.11.1).27 All tests were two-sided  and   a  P   value   ≤0.05  was  
considered statistically significant. Analyses were performed using STATA software (version 11.2; 
StataCorp, College Station, Texas, USA). 
 
RESULTS 
Study population 
A total of 129 patients fulfilled the inclusion criteria of one month treatment with a stable daily dose of 
5 mg (n=45) or 10 mg (n=84) donepezil. Of these, 127 were taking the drug once daily whereas two 
were splitting it into two intakes. The sample consisted of 37 (29%) men and 92 (71%) women with a 
mean (±SD) age of 84±6 years (range 62-99 years). All but one of the participants were Caucasians. 
The patients were diagnosed with AD (n=85), mixed dementia (n=24), vascular dementia (n=5) and 
Lewy body dementia (n=2). In 13 subjects, the type of dementia was not specified. The patients 
received on average (±SD) 7±3 (range 0-13) concomitant drugs. No patient had moderate or severe 
hepatic impairment. Demographic and clinical characteristics are shown in Table 1. 
Donepezil concentration variability and relationship with demographic factors 
The calculated trough plasma concentrations ranged from 8-72 ng/ml and 13-105 ng/ml among 
patients receiving 5 mg and 10 mg donepezil per day, respectively. The estimated trough plasma 
concentration  corrected  by  the  dose  ranged  between  1.3  and  14.4  ng/ml•mg,  with  a  11-fold variability 
(Table 1). Female patients displayed significant higher dose-adjusted plasma concentrations 
compared to males   (median   5.3   versus   4.4   ng/ml•mg,   p<0.001)   (Table   2).   Age   (rs=0.12, p=0.2), 
smoking (p=0.4), elevated alcohol consumption (p=0.5) and impaired renal function (rs=-0.05, p=0.6) 
were not significantly associated with dose-adjusted donepezil concentrations. 
Six patients (4.7%) were taking strong CYP2D6 inhibitors (paroxetine n=3, levopromazine n=2 and 
fluoxetine n=1) and two patients (1.6%) strong CYP3A inhibitors (amiodarone n=1, diltiazem n=1).28,29 
All but one of these patients were CYP2D6 EMs. The subject taking fluoxetine as comedication was 
genotyped as CYP2D6 PM and was, therefore, not considered as receiving a CYP2D6 inhibitor in the 
statistical analyses. Interestingly, this patient had the highest dose-adjusted donepezil concentration of 
the  group   (14.4  ng/ml•mg),  a   finding   that  might  be   related   to   the  additive  effect  of   the  CYP2D6  PM  
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status and the moderate inhibition of CYP3A by fluoxetine. Subjects receiving strong CYP2D6 and 
CYP3A inhibitors demonstrated higher dose-adjusted donepezil concentrations compared to the rest 
of the cohort, although the difference was at the limit of significance for CYP2D6 inhibitors (median 6.9 
versus   5.0   ng/ml•mg,   p=0.059)   and   not   significant   for   CY3A   inhibitors   (5.8   versus   5.0   ng/ml•mg,  
p=0.391) (Table 2). Four patients, among one CYP2D6 PM, taking CYP3A inducers (prednisone n=3, 
pioglitazone n=1) had lower dose-adjusted   plasma   concentrations   (median   3.8   versus   5   ng/ml•mg,  
p=0.15), but this difference did not reach statistical significance.  
Relationship between genotypes and donepezil plasma concentrations 
CYP2D6 genotypes 
Genotype frequencies are shown in Table 3. Allele and genotype frequencies are in agreement with 
previous reports in Caucasians.26,30 CYP2D6 homozygous EMs (homEMs) (n=65) displayed 
significantly lower dose-adjusted plasma concentrations compared to heterozygous EMs 
(hetEMs)(n=55)  and  PMs  (n=7)  (median  4.7  versus  5.3,  p=0.031  and  versus  6.3  ng/ml•mg,  p=0.026,  
respectively). Moreover, the UMs (n=2) presented significantly lower dose-adjusted plasma 
concentrations  than  homEMs  (median  2.6  versus  4.7  ng/ml•mg,  p=0.03)  (Figure  1,  Table 2).  
CYP3A4/5/7, POR, NR1I2 genotypes 
The observed genotype frequencies are presented in Table 3. They are in agreement with reported 
results17,19,31 and no deviation from Hardy-Weinberg equilibrium was observed (p>0.05). In the 
Caucasian subsample (n=128), linkage disequilibrium was observed between CYP3A4*1B and 
CYP3A4 rs4646437   (D’=1,   r2=0.18), CYP3A4*1B and CYP3A5*3 (D’=1,   r2=0.32), and between 
CYP3A4 rs4646437 and CYP3A5*3 (D’=0.76,  r2=0.34), which is in line with previous studies.31 NR1I2 
rs2472677 was moderately linked to NR1I2 rs1523130   (D’=0.24, r2=0.05) and NR1I2 rs7643645 
(D’=0.57,  r2=0.27). 
No association was found between CYP3A4/5/7 single nucleotide polymorphisms (SNP) or haplotypes 
and dose-adjusted donepezil plasma concentrations. Similarly, no influence was observed when the 
sample was stratified by CYP2D6 metabolizer status to take into account the potential confounding 
effect of this genotype. In contrast, a tendency toward lower plasma concentrations was observed in 
patients carrying one or two POR*28 alleles (p=0.105). When only CYP2D6 EMs were considered, the 
difference reached statistical significance (median CC 5.2 versus CT/TT   4.7   ng/ml•mg,   p=0.038)  
(Table 2). Interestingly, the effect was more pronounced in CYP2D6 hetEMs than in homEMs (data 
not shown). 
Carriers of the NR1I2 rs1523130 CC genotype had significantly lower dose-adjusted drug 
concentrations than carriers of CT/TT  genotypes  (median  4.5  versus  5.2  ng/ml•mg,  p=0.021)   (Table  
2). The relationship was also observed taking only CYP2D6 EMs into account (p=0.038) (Table 2). 
Neither NR1I2 rs2472677 and NR1I2 rs7643645 polymorphisms nor NR1I2 haplotypes were 
associated with donepezil kinetics, even when considering the different CYP2D6 genotypes. 
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ABCB1 genotypes 
The ABCB1 genotype frequencies are presented in Table 3. No deviation from Hardy-Weinberg 
equilibrium was observed (p>0.05). Linkage disequilibrium was noted between ABCB1 3435CT and 
2677GT   (D’=0.80,   r2=0.47),   3435CT   and   1236CT   (D’=0.75,   r2=0.40) and between 2677GT and 
1236CT   (D’=0.86,   r2=0.72). Genotype frequencies and linkage disequilibrium are consistent with 
previous reports.31,32 
The SNPs ABCB1 3435C>T and 2677G>T were not found to be significantly related to dose-adjusted 
donepezil concentrations (p=0.927 and p=0.141). However, a trend toward lower plasma 
concentrations was observed in patients carrying the ABCB1 1236CT/TT genotypes (median CC 5.6 
versus  CT/TT  4.8  ng/ml•mg,  p=0.084).  Moreover,   a   trend   toward  higher  plasma  concentrations  was  
measured in patients carrying the haplotype ABCB1 3435T/2677G/1236C (n=29) compared to non-
carriers   (n=100)   (median   5.2   versus   5.0   ng/ml•mg,   p=0.084).   When   the   sample   was   stratified   by  
CYP2D6 EM status, the associations between donepezil concentrations and the ABCB1 2677G>T and 
1236G>T polymorphisms, as well as the haplotype 3435T/2677G/1236C, reached statistical 
significance (median 2677G>T GG 5.7  versus  GT/TT  4.7  ng/ml•mg,  p=0.046;; 1236C>T CC 5.7 versus 
CT/TT   4.7   ng/ml•mg, p=0.024; carriers 3435T/2677G/1236C 5.4 versus non-carriers   4.9   ng/ml•mg,  
p=0.021) (Table 2). 
Multivariate genotype analysis 
In multiple regression analyses, the combined effect of different covariates (age, gender, comedication 
with CYP2D6/CYP3A inhibitors and/or CYP3A inducers) and genotypes on dose-adjusted donepezil 
concentrations was assessed. Age, female gender and moderate and strong CYP2D6 inhibitors were 
significantly related to higher dose-adjusted donepezil plasma concentrations (p=0.014, p=0.005, 
p=0.007, respectively) (Table 4). For CYP3A inducers, a trend toward lower plasma concentrations 
was observed (p=0.072) while the influence of CYP3A inhibitors was not significant (p=0.287). 
Moreover, the CYP2D6 genotypes and the SNP NR1I2 rs1523130 were significantly related to the 
plasma concentrations (homEMs versus hetEMs, PMs and UMs, p=0.037, p=0.005, p=0.005, 
respectively, NR1I2 rs1523130 p=0.005). Neither the investigated polymorphisms in ABCB1 and 
CYP3A4/5/7, the allele POR*28 nor the SNPs NR1I2 rs2472677 and NR1I2 rs7643645 had a 
significant impact. The model explained 25% of the variability of dose-adjusted donepezil 
concentrations. 
When excluding CYP2D6 PMs and UMs and considering only CYP2D6 EMs in the model, the 
covariates age, gender and CYP2D6 inhibitors and the SNP NR1I2 rs1523130 were significantly 
related to donepezil plasma concentrations (p=0.048, p<0.001, p=0.009 and p<0.001, respectively), 
which is in agreement with the multivariate model including all CYP2D6 genotypes (Table 4). In 
addition, the relationship of the allele POR*28 with plasma concentrations was significant in the 
CYP2D6 EM subgroup (p=0.018), which is in line with the univariate analysis. The model explained 
22% of the variability of dose-adjusted donepezil concentrations in CYP2D6 EMs.  
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Furthermore, multiple regression analyses were performed including the haplotype ABCB1 
3435T/2677G/1236G instead of the ABCB1 polymorphisms. The influence of the haplotype was 
significant in the CYP2D6 EM subgroup analysis (p=0.024), but not in the whole sample (p=0.081), 
which is in agreement with the univariate analyses. Both models explained 26% of the variability of 
dose-adjusted donepezil concentrations. 
Finally, the proportions of explained variability by models including all analyzed genetic 
polymorphisms and models including only CYP2D6 genotypes were compared. The explained 
variabilities were only slightly higher in the complete models with values of 25% (all genetic 
polymorphisms and covariates) versus 23% (CYP2D6 genotypes and covariates) and, excluding the 
covariates, with 8% (all genetic polymorphisms) versus 6% (CYP2D6 genotypes). This suggests that 
the functional alleles of CYP2D6 accounted for the major part of the genetically determined variability 
in donepezil pharmacokinetics. 
Relationship between plasma concentration and genotypes on adverse events (AE) 
57% of the patients reported no AE while 43% experienced at least one AE. Among them 14% had 
gastrointestinal problems (nausea, vomiting, diarrhea, anorexia), 16% dizziness, 11% headache, 8% 
insomnia, 20% fatigue, 6% muscle cramp, 13% accidents (falls) and 11% pain. No difference in 
frequencies was seen between patients receiving 5 mg and 10 mg donepezil per day. No significant 
association was found between donepezil plasma concentrations and the presence of AEs. However, 
when CYP2D6 PMs or patients with strong CYP2D6 inhibitors were compared with the rest of the 
cohort,  the  former  had  significantly  more  AEs  (75%  (n=9)  versus  40%  (n=46)  ≥1  AE,  p=0.029),  which  
might be due to the trend toward higher donepezil trough plasma concentrations in this group (median 
(IQR) 55 (40-68) versus 41 (25-56) ng/ml, p=0.078). Additionally, a tendency toward more AEs was 
observed in carriers of the ABCB1 3435T/2677G/1236C haplotype (59% (n=17) versus 38% (n=38) 
with  ≥1  AE,  p=0.059), which might as well be due to higher donepezil trough plasma concentrations 
(median (IQR) 50 (30-63) ng/ml versus 41 (25-56) ng/ml, p=0.102). 
 
DISCUSSION 
There is a large interindividual variability in the response to acetlycholinesterase inhibitors, with 
responder rates as low as 15-35%.3,33,34 Since a concentration-response effect has been reported for 
donepezil,35 differences  in  therapeutic  outcome  could  be  related,  to  some  extent,  to  the  drugs’  plasma  
concentrations. In this study, an 11-fold variability in dose-adjusted donepezil plasma concentrations 
was observed, which confirmed the results of a previous report.4  
The CYP2D6 genotype appeared to be the major genetic factor influencing dose-adjusted donepezil 
plasma concentrations. In the study sample, 7 CYP2D6 PMs, 55 hetEMs, 65 homEMs and 2 UMs 
were included. Even though considerable overlaps were measured between the groups, hetEMs and 
PMs demonstrated significantly higher dose-adjusted plasma concentrations than homEMs, with a 
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13% and 34% increase in the median values. Moreover, the two UMs had lower dose-adjusted plasma 
concentrations than the median value of homEMs. Although CYP2D6 genotypes have been shown to 
influence the plasma concentrations of many drugs,8,36 only one previous study, to our knowledge, 
examined the relationship between CYP2D6 genotypes and donepezil plasma concentrations.4 
Results showed a tendency toward lower plasma concentrations in homEMs compared to hetEMs, 
and in UMs compared to EMs,4 but the limited sample size (n=42) and statistical power precluded a 
formal conclusion. The current study broadens our knowledge in showing for the first time these 
significant relationships.  
Further accentuating the importance of CYP2D6 in donepezil metabolism, a 1.4-fold increase in 
plasma concentrations was measured in patients receiving strong inhibitors of CYP2D6. In the 
multivariate analysis, even moderate CYP2D6 inhibitors were significantly related to higher dose-
adjusted donepezil concentrations. The clinical significance of these interactions remains to be 
determined, but careful monitoring of these patients might be beneficial. 
In contrast to CYP2D6, genetic variations in CYP3A do not appear to play a significant role as our 
results showed no associations between CYP3A4/5/7 genetic polymorphisms and dose-adjusted 
donepezil concentrations. These results are consistent with a previous study analyzing polymorphisms 
in CYP3A4/5 and the fact that the current knowledge of genetic variations in CYP3A4/5/7 only 
marginally explains the large interindividual variability in CYP3A activity.37 
To our knowledge, the present study is the first to examine the relationship between POR, PXR, and 
donepezil pharmacokinetics. Interest in the electron transferring enzyme POR and the nuclear 
receptor PXR resulted from the search on polymorphisms of genes influencing CYP3A expression and 
activity. The most common studied POR polymorphism is the exonic SNP rs1057868C>T, defining the 
allele *28. Our group showed the influence of this polymorphism on CYP3A activity in two independent 
cohorts, with POR*28 TT carriers presenting a 1.6-fold higher CYP3A activity than carriers of the C 
allele.17 In line with these findings, the current study demonstrates that patients carrying at least one 
POR*28 allele have a tendency toward lower dose-adjusted donepezil plasma concentrations. In 
CYP2D6 EMs, the difference reached statistical significance, which suggests a confounding of the 
effect by CYP2D6 PMs and UMs when considering the whole cohort. Moreover, stratification of the 
sample by CYP2D6 genotype revealed a pronounced effect of the POR*28 in hetEMs. The decreased 
CYP2D6 activity in hetEMs, partly compensated by CYP3A, might explain the distinct impact of the 
POR*28 in these subjects.  
Recently, attention was drawn on three polymorphisms in the regulatory region of NR1I2, which were 
associated with PXR and CYP3A4 expression in vitro, namely rs1523130, rs2472677 and rs7643645. 
In this study, a significant association of the NR1I2 rs1523130 was found with dose-adjusted 
donepezil concentrations, with patients carrying at least one T allele having higher plasma 
concentrations compared to subjects carrying two C alleles. In vitro studies demonstrated decreased 
CYP3A4 mRNA concentrations in liver tissue with the NR1I2 rs1523130 CT/TT genotypes.19,20 
Therefore, the observation of higher donepezil concentrations in NR1I2 rs1523130 CT/TT carriers 
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could be due to a lower CYP3A4 activity. Because PXR mediates the induction of several phase I and 
II drug-metabolizing enzymes as well as transporters including P-pg, the influence of the NR1I2 
rs1523130 might also be mediated by other factors than CYP3A expression. 
Finally, the three common P-gp polymorphisms were investigated: ABCB1 3435C>T, 2677G>T and 
1236C>T. Although these SNPs were tested in many in vitro and in vivo studies, the literature bears 
no consensus on the phenotypic associations with these SNPs.16 A trend toward lower dose-adjusted 
plasma concentrations was found in T allele carriers of the ABCB1 2677G>T and 1236C>T SNPs, but 
was no more significant in the multivariate analysis. Interestingly, carriers of the haplotype ABCB1 
3435T/2677G/1236C showed higher plasma concentrations compared to non-carriers, however, the 
difference reached statistical significance in the multivariate analysis only if CYP2D6 EMs were taken 
into account. Results of a recent study showed a tendency toward lower donepezil plasma 
concentrations in patients carrying two alleles of the haplotype 3435T/2677T/1236T. However, the 
difference did not reach statistical significance,14 and could not be confirmed by the present results. It 
should be mentioned that P-gp polymorphisms might influence donepezil plasma concentrations 
through altered absorption, distribution and/or excretion. On the other hand, it has also been shown 
that individuals homozygous for the ABCB1 2677 T allele have enhanced constitutive CYP3A4 
expression in liver and intestine compared with those homozygous for the G allele.38 This difference in 
CYP3A activity might therefore explain the higher donepezil dose-adjusted plasma concentrations in 
carriers of the ABCB1 2677 G allele and of the haplotype ABCB1 3435T/2677G/1236C. 
Overall, 43% of the patients reported at least one AE when receiving 5 mg or 10 mg donepezil daily. 
This prevalence is lower than in other studies, where incidences of 65% (5 mg/day) and 83% (10 
mg/day) have been reported.2 This discrepancy might be due to the fact that most of the patients 
included in the present study had already been treated for several months with donepezil. Therefore, 
at inclusion the transient AEs were no more present and intolerant patients would already have 
discontinued the treatment and be ineligible. Because of the higher incidence of AEs in patients 
treated with 10 mg donepezil daily, a relationship between plasma concentrations and frequency of 
AEs has been suggested.2 In our study population, the frequency of subjects experiencing at least one 
AE was significantly higher in CYP2D6 PMs or patients taking comedications which are strong 
CYP2D6 inhibitors. This could be due to the higher trough concentrations measured in these subjects, 
even though the difference did not reach statistical significance. Furthermore, a similar trend toward a 
higher incidence of AEs was noticed in patients carrying the haplotype ABCB1 3435T/2677G/1236G, 
also displaying slightly higher trough concentrations. These results suggest that future prospective 
studies should be performed to determine whether therapeutic monitoring of donepezil could be useful 
to reduce AEs. 
This naturalistic cross-sectional study has several limitations. The patients included in the study are 
very heterogeneous thus confounding by different factors, such as comobidities or comedication, 
cannot be excluded. Blood sampling for plasma concentration determination was performed at any 
time of the day, thus, trough plasma concentrations had to be estimated in order to be able to 
compare the patients. Because of the long half-life of the drug (70 hours), resulting in small differences 
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between peak and trough concentrations, our estimation of the trough concentrations is considered to 
be suitable for the objectives of the study. Prevalent AEs were recorded at inclusion and, as previously 
mentioned, most patients were already receiving donepezil for several months. This might have 
complicated differentiating between donepezil related AEs and effects of concomitant diseases or 
medication. Considering these limitations, confirmation of the presented findings in other study cohorts 
is required.  
In summary, the present study shows a large interindividual variability in donepezil plasma 
concentrations. Functional alleles of CYP2D6 accounted for a major part of the genetically determined 
variability. However, genetic variations in POR, NR1I2 and ABCB1 were also related to donepezil 
pharmacokinetics. These findings are an important contribution to a better understanding of donepezil 
pharmacokinetics and, potentially, clinical effectiveness and tolerance. 
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Figure 1: Influence of the CYP2D6 genotype on dose-adjusted donepezil plasma concentrations. In 
the box plots median and interquartile ranges are shown. 
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Table 1: Characteristics of the study population (n=129) 
Characteristic Category    
Age (years)  (mean±SD; range) 84 ± 6 62-99 
     
Gender male (n; %) 37  28.6 
 female (n; %) 92 71.3 
Duration of treatment (years)a (mean±SD; range) 2 ± 1.7 0.1-8 
Smoking  (n; %) 9 7.0 
Alcoholb  (n; %) 3 2.3 
Renal impairment eGFRc ≥  60 (n; %) 59 45.7 
 eGFRc 30-59 (n; %) 67 51.9 
 eGFRc <30 (n; %) 3 2.3 
Dose per day  5 mg (n; %) 45 34.9 
 10 mg (n; %) 84 65.1 
Estimated C0d (ng/ml) 5 mg (median (IQR); range) 23 (19-29) 8-72 
 10 mg (median (IQR); range) 52 (43-64) 13-105 
C0/De (ng/ml•mg)  (median (IQR); range) 5.0 (4.1-6.2) 1.3-14.4 
Comedication     
CYP2D6 inhibitors moderate (n; %) 65 50.4 
 strong (n; %) 6 f 4.7 
CYP3A inhibitors moderate (n; %) 37 28.7 
 strong (n; %) 2 1.6 
CYP3A inducers  (n; %) 4 3.1 
a)  n=120, in 9 subjects the duration of treatment is unknown 
b)   >40 g per day in men and >20 g per day in women 
c)   Estimated glomerular filtration reat with MDRD (Modification of Diet in Renal Disease) formula 
in ml/min/1.73m2 39 
d)  C0: trough plasma concentration 
e)  Co corrected by the daily dose 
f)  Includes one CYP2D6 PM who was not considered as receiving a CYP2D6 inhibitor in the 
statistical analyses. 
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Table 2: Univariate analyses of the influence of demographic factors and genotypes on dose-adjusted 
donepezil concentrations 
   all CYP2D6 genotypes  CYP2D6 EMs     
   n Dose-
adjusted 
plasma 
levela 
P 
valuesb 
 n Dose-
adjusted 
plasma 
levela 
P 
valuesb 
          
Demographic factors category        
          
Gender  male 37 4.4 (3.7-4.9) >0.001     
  female 92 5.3 (4.3-6.5)      
Strong CYP2D6 inhibitors yes 5 6.9 (5.8-7.6) 0.059     
  no 124 5.0 (4.0-6.1)      
Strong CYP3A inhibitors yes 2 5.8 (5.8-5.8) 0.391     
  no 127 5.0 (4.0-6.3)      
CYP3A inducers yes 4 3.8 (2.4-5.2) 0.150     
  no 125 5.0 (4.1-6.2)      
          
Genetic factors genotype        
          
CYP2D6   
UM 
 
2 
 
2.6 (2.1-3.2) 
 
0.030c 
    
  homEM 65 4.7 (4.0-5.8)      
  hetEM 55 5.3 (4.5-6.8) 0.031c     
  PM 7 6.3 (5.2-8.4)  0.026c     
CYP3A4  
allele *1B 
 
*1/*1 
 
123 
 
5.0 (4.1-6.2) 
 
0.878 
  
11
6 
 
5.0 (4.1-6.1) 
 
0.804 
  *1/*1B 6 4.6 (3.2-8.8)   4 4.6 (3.6-7.0)  
 rs4646437 CC 103 5.0 (4.1-6.3) 0.603  99 5.0 (4.1-6.2) 0.344 
  CT 26 4.7 (4.0-6.2)   21 3.6 (4.4-5.3)  
CYP3A5 
 
 
allele *3 
 
*1/*3 
 
16 
 
5.0 (4.2-6.3) 
 
0.803 
  
15 
 
5.0 (4.5-6.2) 
 
0.756 
  *3/*3 113 5.0 (4.1-6.2)   10
6 
5.0 (4.1-6.1)  
CYP3A7  
allele *1C 
 
*1/*1 
 
123 
 
5.0 (4.1-6.3) 
 
0.712 
  
11
4 
 
5.0 (4.1-6.1) 
 
0.756 
  *1/*1C 5 5.0 (4.4-6.2)   5 5.0 (4.4-6.2)  
  *1C/*1C 1 3.8   1 3.8  
POR  
allele *28 
 
CC 
 
74 
 
5.2 (4.2-6.6) 
 
0.105 
  
69 
 
5.2 (4.6-6.6) 
 
0.038 
  CT 46 4.8 (3.9-6.0)   42 4.7 (3.9-5.8)  
  TT 9 4.6 (3.5-5.8)   9 4.6 (3.5-5.8)  
NR1I2  
rs1523130 
 
CC 
 
47 
 
4.5 (3.7-5.8) 
 
0.021 
  
43 
 
4.5 (3.8-5.8) 
 
0.038 
  CT 56 5.2 (4.4-6.7)   52 5.0 (4.4-6.1)  
  TT 26 5.2 (4.2-6.4)   25 5.3 (4.5-6.4)  
 rs2472677 TT 50 5.0 (4.0-5.9) 0.691  47 5.0 (4.2-5.9) 0.996 
  TC 67 5.0 (4.1-6.4)   62 5.0 (4.1-6.2)  
  CC 12 5.0 (4.1-7.2)   11 5.0 (4.1-6.9)  
 rs7643645 AA 61 5.1 (4.2-6.3) 0.718  55 5.0 (4.2-6.3) 0.658 
  AG 56 5.0 (4.1-6.1)   54 5.0 (4.1-6.0)  
  GG 12 4.6 (3.7-7.2)   11 4.2 (3.7-6.9)  
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ABCB1  
3436C>T 
 
CC 
 
36 
 
5.2 (3.8-6.3) 
 
0.927 
  
35 
 
5.3 (4.0-6.3) 
 
0.603 
  CT 55 4.9 (3.9-6.1)   54 4.9 (3.9-6.1)  
  TT 38 5.2 (4.3-6.4)   31 4.8 (4.3-5.9)  
 2677G>T GG 45 5.6 (4.1-6.4) 0.141   44 5.7 (4.3-6.6) 0.046 
  GT 56 4.8 (3.9-5.7)   54 4.8 (4.0-5.7)  
  TT 28 5.0 (4.3-6.5)   26 4.7 (4.3-5.8)  
 1236C>T CC 45 5.6 (4.4-6.8) 0.084   44 5.7 (4.5-6.9) 0.024 
  CT 58 4.7 (3.9-5.5)   56 4.7 (3.9-5.5)  
  TT 26 5.3 (4.2-6.2)   20 5.0 (4.1-5.8)  
 3435T/2677G/ 
1236C carriers 29 5.2 (4.5-7.1) 0.084  92 4.9 (3.9-5.8) 0.021 
  non-carriers 
100 5.0 (3.9-6.0)   28 5.4 (4.6-7.1)  
 
a) Dose-adjusted plasma levels are  expressed  as  median  (interquartile  range)  in  ng/ml•mg 
b) P values determined by Wilcoxon test; dominant model grouped by the presence of at least one 
variant allele versus wild type 
c) P value refers to homozygous extensive metabolizers (homEM) versus ultrarapid metabolizers 
(UM), heterozygous extensive metabolizers (hetEM) and poor metabolizers (PM), respectively. 
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ABCB1 3435CT 
 
 
 
CYP3A4 *1B 
 
 
 
NR1I2 rs2472677 
 
C
C
 
36 
28 
20-36 
 
*1/*1 
123 
95 
90-98 
 
TT 
50 
39 
30-48 
C
T 
55 
43 
34-52 
 
*1/*1B
 
6 
5 
2-10 
 
TC
 
67 
52 
43-61 
TT 
38 
29 
22-38 
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12 
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5-16 
ABCB1 2677GT 
 
 
 
CYP3A5 *3 
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35 
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12 
7-19 
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47 
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88 
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Table 4: Multivariate analyses of the influence of genotypes on dose-adjusted donepezil concentrations 
in all CYP2D6 genotypes and in CYP2D6 EMs 
 
a) Coefficients and P values obtained from the linear multiple regression analysis using the log-
transformed dose-corrected donepezil trough concentrations as dependent variable and genotypes, age, 
gender, comedication with CYP2D6 inhibitors, CYP3A inhibitors and CYP3A inducers as independent 
variables.  
 all CYP2D6 genotypes  CYP2D6 EM 
 Coefficient (SE)a P valuea  Coefficient (SE)a P valuea 
Demographic factors      
Age 0.012 (0.005) 0.014  0.010 (0.005) 0.048 
Female Gender 0.197 (0.068) 0.005  0.258 (0.063) <0.001 
CYP2D6 inhibitors 0.178 (0.065) 0.007  0.157 (0.059) 0.009 
CYP3A inhibitors 0.071 (0.067) 0.287  0.092 (0.062) 0.138 
CYP3A inducers -0.330 (0.182) 0.072  0.231 (0.192) 0.231 
      
Genetic factors      
CYP2D6 homEM versus hetEM 0.130 (0.061) 0.037    
 homEM versus PM 0.417 (0.145) 0.005    
 hom EM versus UM -0.721 (0.252) 0.005    
CYP3A4 allele *1B 0.051 (0.178) 0.774  -0.026 (0.180) 0.887 
 rs4646437 0.018 (0.091) 0.846  -0.032 (0.090) 0.718 
CYP3A5 allele *3 -0.050 (0.124) 0.687  -0.098 (0.116) 0.400 
CYP3A7 allele *1C 0.014 (0.142) 0.919  -0.073 (0.130) 0.575 
POR allele *28 -0.050 (0.060) 0.401  -0.136 (0.056) 0.018 
NR1I2 rs1523130 0.185 (0.064) 0.005  0.234 (0.062) <0.001 
 rs2472677 -0.039 (0.107) 0.720  -0.033 (0.101) 0.749 
 rs7643645 -0.034 (0.062) 0.577  -0.002 (0.058) 0.979 
ABCB1 3436C>T 0.089 (0.101) 0.377  0.071 (0.093) 0.447 
 2677G>T -0.207 (0.160) 0.198  -0.156 (0.145) 0.285 
 1236C>T 0.059 (0.141) 0.676  0.064 (0.129) 0.619 
 Intercept 0.265 (0.462) 0.568  0.531 (0.450) 0.241 
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4.2 Article V: Population pharmacokinetic study of memantine: effects of clinical and genetic 
factors 
 
Summary 
In this article, the results of the pharmacogenetic study in patients treated with memantine are 
described. Memantine is mainly eliminated unchanged by the kidneys with implication of active renal 
secretion by cation transporters. Moreover, considerable inter-individual variability in plasma 
concentrations has been reported in previous studies. A population pharmacokinetic study, using 
NONMEM, was performed, which included clinical and genetic data from 108 patients. Common 
polymorphisms in renal cation transporters (SCL22A1/2/5, SLC47A1, ABCB1) and nuclear receptors 
(NR1I2, NR1I3, PPAR) involved in transporter expression were investigated. An average clearance of 
5.2 l/h with a 27% inter-individual variability (CV%) was found. In line with the primarily renal 
elimination, the glomerular filtration rate markedly influenced memantine clearance. Moreover, female 
patients showed a slower elimination with a 20% lower clearance. No significant relationship between 
genetic variations in cation transporter genes and memantine clearance was found. In contrast, the 
polymorphism NR1I2 rs1523130 was significantly associated with memantine clearance, with carriers 
of the NR1I2 rs1523130 CT/TT genotypes presenting a 16% slower memantine elimination than 
carriers of the CC genotype. To date, this is the first study that comprehensively evaluated the effect 
of polymorphisms in renal transporters and nuclear receptors on memantine pharmacokinetics. The 
better understanding of inter-individual variability in memantine pharmacokinetics might be beneficial 
in the context of individual dose optimization. 
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ABSTRACT 
Memantine, a frequently prescribed antidementia drug, is mainly eliminated unchanged by the 
kidneys, partly via tubular secretion. Considerable interindividual variability in plasma levels has been 
reported. To investigate clinical and genetic factors influencing memantine disposition, a population 
pharmacokinetic study was performed including data from 108 patients recruited in a naturalistic 
setting. Patients were genotyped for common polymorphisms in renal cation transporters 
(SCL22A1/2/5, SLC47A1, ABCB1) and nuclear receptors (NR1I2, NR1I3, PPAR) involved in 
transporter expression. The average clearance was 5.2 l/h with a 27% interindividual variability (CV%). 
Glomerular filtration rate (p=0.007) and gender (p=0.001) markedly influenced memantine clearance. 
NR1I2 rs1523130 was identified as the unique significant genetic covariate for memantine clearance 
(p=0.006), with carriers of the NR1I2 rs1523130 CT/TT genotypes presenting a 16% slower 
memantine elimination than carriers of the CC genotype. The better understanding of interindividual 
variability might be beneficial in the context of individual dose optimization. 
 
INTRODUCTION 
Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, which is indicated 
for  the  treatment  of  moderate  to  severe  Alzheimer’s  disease.  Memantine  has  generally  been  shown  to  
be a well-tolerated drug,1 the most common adverse events (AE) include dizziness, somnolence, 
headache and constipation.1,2 The major part of an administered memantine dose is excreted 
unchanged by the kidneys (75-90%) with the remaining memantine converted to numerous 
metabolites.3 The total renal clearance (CL) substantially exceeds glomerular filtration rate, indicating 
that a significant part of memantine is eliminated via active tubular secretion by renal transporters.3 
Steady-state plasma levels of 70-150 ng/ml with large interindividual variations have been reported in 
patients receiving the recommended daily dose of 20 mg.2 Moreover, a relationship between clinical 
outcome and frequency of AEs with memantine plasma levels has been suggested.4  
There is growing evidence that, for some drugs, genetic variations in membrane transporters 
contribute to interpatient variability in disposition and/or response.5 Memantine is a known substrate of 
the human organic cation transporter 2 (OCT2).6 However, as an organic cation at physiological pH, 
memantine is probably also handled by other transporters of the renal organic cation transport system, 
including the organic cation transporters (OCT1-3), the carnitine transporters (OCTN1-3), the 
multidrug and toxin extrusion proteins (MATE1-2) and the P-glycoprotein (P-gp).7 Numerous 
polymorphisms have been described in their respective genes SLC22A1-3, SLC22A4-5, SLC47A1-2 
and ABCB1, some of them are known to alter protein function and expression.8-13 To our knowledge, 
no studies investigating the influence of genetic variants in cation transporters on memantine 
pharmacokinetics have been published. However, several single nucleotide polymorphisms (SNP) in 
SLC22A1/2 and SLC42A1 have been suggested to affect metformin CL.13,14 Similar effects might be 
anticipated for memantine, as metformin is an organic cation drug that is mainly eliminated unchanged 
by the kidneys with implication of active secretion by renal transporters. In addition, in vitro and in vivo 
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studies have demonstrated the involvement of the following nuclear receptors in gene expression 
regulation of cation transporters in different tissues: pregnane X receptor (PXR), constitutive 
androstane receptor (CAR) and peroxisome proliferator-activated receptor (PPAR).15-19 There is 
emerging evidence that polymorphisms in nuclear receptors influence the expression of cytochrome 
P450 (CYP) drug metabolizing enzymes,20,21 thus affecting pharmacokinetics of drugs. A similar effect 
of these polymorphisms on renal drug transporter expression might therefore be hypothesized, which 
could potentially lead to interindividual variability in drug elimination. Thus, the identification of clinical 
and genetic factors underlying the interindividual variability in memantine pharmacokinetics may help 
to improve the understanding of variation in drug response.  
The aim of the present study was to quantify the effects of genetic variations in genes of renal cation 
transporters and nuclear receptors, and of other clinical factors, on memantine plasma levels. In 
addition, simulations were performed to predict and compare the average steady-state plasma levels 
(Cav)   associated   with   20  mg,   15  mg   and   10  mg   once   daily   dosage   regimens   for   relevant   patients’  
characteristics. Finally, an analysis of the memantine concentration-toxicity relationship was 
conducted. 
 
RESULTS 
A total of 108 patients were included in the study, receiving a daily memantine dose of 5 mg (n=5), 10 
mg (n=24), 15 mg (n=4) or 20 mg (n=75). The average (±SD) duration of memantine treatment was 
1.8 (±1.7) years (range 1 month to 10 years). Memantine plasma levels measured at steady-state 
ranged from 11 to 314 ng/ml. The characteristics of the study population are presented in Table 1.  
 
Structural model 
A one-compartment model with first-order absorption from the gastro-intestinal tract fitted the data at 
best. Owing to few data at early time points after drug intake, rendering the estimation of the 
absorption rate constant ka imprecise, ka was fixed to the mean of the bootstrap resampling analysis 
(0.3 h-1 CI95:0.04-1.11-1). In addition to CL, interpatient variability on the volume of distribution of the 
central compartment (V) and ka did not further improve the description of the data (change in the 
objective function (ΔOF) ≤0.9;;   p>0.3).   The estimates and the variability (CV%) of the basic 
pharmacokinetic model were: CL 5.2 l/h (27%), V 172.8 L and ka 0.3 h-1. 
 
Influence of non-genetic covariates  
Table 2 summarizes the model-building steps performed for the covariate analysis. In univariate 
analyses, sex, age and creatinine CL (CLcreat) were identified as significant covariates on memantine 
CL (ΔOF)  ≤-7; p<0.01). Ethnicity, memantine formulation, smoking, grapefruit juice (P-gp inhibitor) or 
elevated alcohol consumption were not associated with memantine CL (ΔOF≥-12.7; p>0.1). Interacting 
medications were classified as drugs eliminated via tubular secretion, OCT inhibitors, PXR agonists, 
and P-gp inhibitors or inducers (Supplementary Table 1). Among those, P-gp inhibitors (ΔOF=-11; 
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p<0.01) and PXR agonists (ΔOF=-5; p<0.05) increased memantine CL by about 20%. Since the 
classification of drugs as P-gp inhibitors and PXR agonists was mainly based on in vitro data, the 
clinical significance for pharmacokinetic drug interactions at therapeutic concentrations is unknown. 
Therefore, the analyses on these covariates were considered to be exploratory and they were not kept 
in the reported final model to avoid bias. Nevertheless, similar results were found with and without 
these covariates (data not shown). The model incorporating all relevant non-genetic covariates was 
built up and further refined by setting them one by one to their null values. This step eliminated the 
influence of age on CL, but sex and CLcreat remained  statistically  significant  (ΔOF=-17.6; p<0.001) and 
explained altogether 7% of the interindividual variability on CL.  
 
Influence of genetic covariates 
A total of 27 polymorphisms in renal transporters and nuclear receptors were analyzed (Table 3). The 
minor allelic frequencies are in line with the reported frequencies for Caucasians in the SNP database 
of the National Center for Biotechnology Information.22 No deviation from Hardy-Weinberg equilibrium 
was observed (p>0.08), with the exception of CAR rs4073054 (p=0.04). 
No significant relationship was found between the investigated SNPs in the genes SLC22A1/2/5, 
SLC47A1 and ABCB1 of renal transporters and memantine CL. In contrast, univariate analyses testing 
the effects of polymorphisms in the nuclear receptors NR1I2, NR1I3, RXRA, PPARGC and PPARG 
revealed a significant association of the SNP NR1I2 rs1523130 with memantine CL (rich model Eq 2 
ΔOF=-6.3; p<0.05), explaining 9% of its interindividual variability. 
Several models were used to test the relationships between the NR1I2 rs1523130 genotypic groups 
and memantine CL (Table 2). Compared to the rich model, linear, power, square root or square 
models provided similar description of the data using an activity score (Eq 3, 4, 5 and 6 ΔOF<-4; 
p<0.05). Furthermore, no statistical significant difference in CL in NR1I2 rs1523130 CT and TT 
genotypic groups was observed compared to the other models (ΔOF=0.5;;  p=0.5). CL was 5.87 l/h in 
NR1I2 rs1523130 CC individuals and reduced to 4.96 l/h in carriers of the CT or TT alleles.  
The final model included sex, CLcreat and NR1I2 rs1523130 polymorphism on memantine CL (ΔOF=-
25; p<0.001). These covariates explained 17% of the overall variability in memantine CL. The final 
model  parameters’  estimates,  together  with  their  bootstrap  estimations,  are  given  in  Table  4.  Figure  1  
shows the dose-normalized concentration-time plots of memantine with their 95% prediction intervals. 
 
Simulations 
Model-based simulations were performed to evaluate the impact of genetic polymorphism and 
impaired renal function on memantine Cav and to compare these concentrations to the suggested 
therapeutic range of 90-150 ng/ml.23  
Individuals with normal renal function carrying the NR1I2 rs1523130 CT/TT genotypes had a modest 
19% increase in median Cav after daily doses of 20 mg, with a mean Cav increasing from 115 ng/ml 
(CI95% 55-174 ng/ml) to 137 ng/ml (CI95% 66-208 ng/ml). The model predicted an additional 28% 
increase in Cav in individuals with impaired renal function (CLcreat 30 ml/min) in combination with the 
genetic polymorphism, leading to a mean Cav of 169 ng/ml (CI95% 82-256 ng/ml). While considering 
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the interindividual variability in CL, it is expected that 13%, 32%, 36% and 63% of individuals would 
exceed the 150 ng/ml upper limit in NR1I2 rs1523130 CC individuals with normal renal function, 
CT/TT carriers with normal renal function, CC individuals with reduced renal function and CT/TT 
carriers with reduced renal function, respectively.  
Additionally, simulations were performed to evaluate which dose adjustment would be required in 
patients with a CLcreat of 30 ml/min under assumption of reference alleles for NR1I2. For daily doses of 
10 mg and 15 mg, the respective predicted mean Cav were 38% and 8% inferior to patients with 
normal renal function receiving 20 mg memantine per day (71 ng/ml and 106 ng/ml vs. 115 ng/ml). 
Moreover, while accounting for interindividual variability, the dose reductions would lead to Cav below 
the 90 ng/ml limit in 84% and 30% of the individuals after 10 mg and 15 mg daily, respectively. Figure 
2 shows the average and 95% predicted interval (PI) of Cav obtained for memantine 10 mg, 15 mg and 
20 mg daily regimens under various assumptions of NR1I2 rs1523130 genotypes and renal function. 
Concentration-side effect relationships 
A total of 54% (n=58) patients reported no AE while 46% (n=50) experienced at least one AE. 
Constipation was present in 25%, dizziness in 14%, headache in 13% and somnolence in 17% of the 
patients. Logistic regression analyses between Cav or area under the curve (AUC0-) and the 
presence/absence of AEs revealed no significant relationship. In contrast, chi-square analyses 
between dichotomized Cav values and the presence/absence of AEs showed that patients with Cav 
above 150 ng/ml had a significantly higher risk to experience at least one AE (38% (n=26) Cav<150 
ng/ml vs. 60% (n=24) Cav>150 ng/ml, p=0.028). Regarding specific AEs, constipation (16% vs. 40%, p 
= 0.006) and dizziness (7% vs. 25%, p=0.01) were significantly related to the 150 ng/ml cut-off value, 
whereas other AEs (headache p = 0.095) and somnolence (p=0.075) were non-significant.  
 
DISCUSSION 
Comorbidities, polypharmacy and non-compliance are particular problems in elderly patients with 
cognitive impairment. It would therefore be of special importance for this population to avoid multiple 
medication changes due to non-response or side effects. Thus, optimization of memantine treatment 
through an individual dose-adaption might be beneficial. In this naturalistic cross-sectional study, 108 
dementia patients were included receiving a treatment with memantine. A population pharmacokinetic 
model was developed, integrating genetic and non-genetic factors, to study the interindividual 
variability in memantine pharmacokinetics. To our knowledge, this is the first pharmacogenetic study 
on memantine. The CL estimate and its variability are in good accordance with a previous population 
pharmacokinetic study.24 As expected, renal function had a marked impact on memantine elimination. 
The dominant influence of the renal function is in agreement with the extensive renal elimination of 
memantine and has previously been shown in a single dose study in elderly volunteers.25 Age and sex 
were also correlated to memantine elimination, but their influence was integrated in the MDRD 
(Modification of Diet in Renal Disease) formula used to estimate CLcreat.26 However, the influence of 
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sex remained beyond correction, which could be related to a lower OCT expression in female, as 
observed in rats and mice.27,28 
It is suggested that comedication eliminated via renal tubular secretion or inhibiting organic cation 
transporters could lead to pharmacokinetic interactions with memantine.3 To date, only few clinical 
trials addressed this issue. On one hand, one study reported a decreased memantine CL in patients 
taking comedication eliminated via renal tubular secretion.24 On the other hand, no significant effect of 
a combination of glibenclamid/metformin on single-dose memantine pharmacokinetics was found in 
another study, even though metformin is a substrate of organic cation transporters.29 A large 
proportion of our study population received drugs eliminated via tubular secretion and/or OCT 
inhibitors, but no interactions were revealed. The classification of OCT inhibitors was mostly based on 
in vitro data, thus, the in vivo consequences are difficult to predict. Further studies are required to 
elucidate the interaction potential between OCT inhibitors and memantine. 
In the current study, PXR agonists and P-gp inhibitors showed a moderate increase on memantine 
CL. The enhancement by PXR agonists might be explained by an increased expression of OCTs, as it 
has been reported for rifampicin.19 The enhancement by P-gp inhibitors is somewhat counterintuitive, 
as a slower elimination would be expected from a diminished transport function. Since P-gp is involved 
in the drug distribution process, an altered distribution of memantine could be a possible explanation. 
However, as many P-gp inhibitors are also PXR agonists (e.g., simvastatin, omeprazole), the effects 
of these comedications could not be clearly distinguished. The involvement of P-gp in memantine CL 
must therefore be examined in further studies. A limitation of these covariate analyses is the 
classification of the drugs mainly based on in vitro data. 
It has become evident that membrane transporters are important determinants of drug disposition, and 
genetic variations altering the function or expression of transporters are interesting targets for 
pharmacogenetic investigations.30 In this study, we examined the relationship of polymorphisms in 
genes of renal cation transporters with memantine elimination. Although the selected SNPs were 
associated in vitro and/or in vivo with altered transport, pharmacokinetics or pharmacodynamics of 
OCT substrates,10,13,31-34 they did not affect memantine CL. Several explanations for the lack of 
association are conceivable. On one hand, the naturalistic approach of the study, including patients 
with comorbidities and several comedications, might have masked subtle effects of genetic variations. 
The in vivo impact of cation transporter polymorphisms has most extensively been studied with 
metformin. Supporting our hypothesis, the effect of genetic variants on metformin pharmacokinetics 
appears small and the subsequent effects on clinical response are also limited, above all in studies 
involving patients.13,14 On the other hand, it is likely that several redundant cation transporters are 
implicated in the renal elimination of memantine. A diminished activity of one transporter might 
therefore be compensated by the other ones. Finally, considerable intersubject differences in OCT 
expression have been reported suggesting that other mechanisms regulating the expression of renal 
transporters might be predominant.13  
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Recently, attention has been drawn on genetic variations in nuclear receptors, implicated in the control 
of drug metabolizing enzyme and transporter expression. In this study, we investigated several 
polymorphisms in the following nuclear receptors known to be involved in cation transporter 
expression:  PXR,  RXRα,  PPARγ  and  CAR.15-18 A significant relationship between memantine CL with 
the SNP NR1I2 rs1513023 was found, with a 16% decreased CL in patients carrying at least one T 
allele. In vitro, this SNP was associated with decreased hepatic CYP3A4 expression.20 Expecting the 
same effect, the reduced CL would be a result of lower transporter expression in the kidneys. For 
further insights into the mechanistic basis underlying the alteration in memantine pharmacokinetics, in 
vitro studies on renal transporter expression related to NR1I2 rs1513023 genotypes are required.  
To date, no prospective studies have been conducted to establish a therapeutic range of memantine 
for efficacy and tolerability optimization. However, in recently published consensus guidelines, a 
therapeutic range of 90-150 ng/ml was proposed.23 In patients, receiving the recommended dose of 20 
mg memantine daily and reference alleles for NR1I2, the predicted Cav levels were in good agreement 
with the therapeutic range. The proportion of patients exceeding the therapeutic range increased 
considerably in carriers of the NR1I2 rs1513023 T allele and/or in case of renal insufficiency with a 
CLcreat of 30 ml/min. According to the prescription information,2 half of the normal daily dose is 
recommended for patients with severe renal impairment. The simulations predicted a Cav inferior to the 
therapeutic range for the majority of patients with a Clcreat of 30 ml/min and NR1I2 reference alleles. 
On the other hand, a dose of 15 mg per day leaded to similar Cav than a 20 mg daily dose in patients 
with normal renal function and might thus be more appropriate. In accordance with the proposed 
therapeutic range, patients with memantine Cav levels above 150 ng/ml had a significant increased 
occurrence of AEs. Thus, a dose reduction might be useful if the threshold of 150 ng/ml is exceeded, 
especially in case of AEs that might limit adherence to the treatment. Due to the cross-sectional study 
design, AEs were recorded at inclusion when most participants were already receiving memantine for 
several months. Therefore, it was difficult to differentiate between memantine related AEs and effects 
of concomitant diseases or medication, and confirmation of the result in other study cohorts is 
required. With respect to a possible benefit of individual memantine dose-adaption, further studies on 
the concentration-effect relationship are necessary to establish an evidence-based therapeutic range. 
In conclusion, the pharmacokinetic parameters of memantine were adequately described by our 
population model, showing a predominant role of renal function and gender on memantine CL. To 
date, this is the first study that comprehensively evaluated the effect of polymorphisms in renal 
transporters and nuclear receptors on memantine pharmacokinetics. No significant relationship 
between genetic variations in renal cation transporter genes and memantine CL was found. In 
contrast, the polymorphism NR1I2 rs1523130, that potentially alter the expression of transporters in 
the kidney, was significantly related to slower memantine elimination. However, replication of these 
results in another group of patients is necessary. These findings are an important contribution to the 
understanding of interindividual variability in memantine pharmacokinetics and might be useful to 
improve clinical outcome and tolerability of the treatment. 
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MATERIALS AND METHODS 
Study Population 
A total of 108 subjects receiving memantine for at least one month at stable dose were included in this 
cross-sectional study. Patients were recruited at four hospitals in Switzerland (Lausanne, Geneva, 
Marsens, Aigle) and in affiliated nursing homes. The sample consisted of 94% inpatients and 6% 
outpatients. One blood sampling was performed to measure the memantine plasma level, to evaluate 
the renal function (standard laboratory tests of creatinine, urea), and to extract DNA for the genetic 
analyses. The presence of adverse events, reported by the patients, doctors and/or nurses, was 
registered. Additionally, concomitant diseases, comedication, consumption of grapefruit, alcohol and 
tobacco were recorded. 
The study was approved by the local ethics committees (Lausanne University Hospital, Geneva 
University Hospital, Cantonal Ethic Committee Fribourg) and conducted according to the Good Clinical 
Practices. Written informed consent, including consent for genetic analysis, was obtained from all 
patients or their legal representative. 
Drug concentration measurement  
Blood samples were collected on average 12 hours after medication intake (range: 1-25 hours) in 
EDTA blood tubes. After centrifugation, the plasma was stored at -20°C until analysis. Memantine 
plasma levels were determined by high performance liquid chromatography coupled with mass 
spectrometry, as previously described.35  
Genotyping 
Genomic DNA was extracted from EDTA blood samples with the FlexiGene DNA extraction kit or the 
QIAamp  DNA  Blood  Mini  Kit  (QIAGEN,  Hombrechtikon,  Switzerland)  according  to  the  manufacturer’s  
protocols. The following functional and tagging SNPs were selected for genotyping based on 
previously published in vitro or in vivo pharmacogenetic studies and on their frequency in the 
Caucasian population.10,13,20,21,31-34,36,37 Genotyping was performed by real-time polymerase chain 
reaction   with   5’-nuclease allelic discrimination assays (ABI PRISM 7000; Applied Biosystems, 
Rotkreuz,   Switzerland)   according   to   manufacturer’s   instructions   or   previous   studies:38 SLC22A1 
rs628031 (C__8709275_60), rs72552763 (C__34211613_10), rs622342 (C__928527_20), 
rs34130495 (Custom TaqMan SNP Genotyping Assay), rs34059508 (C__30634080_20), rs12208357 
(C__30634096_10), SLC22A2 rs2279463 (C__8703416), rs316003 (C__928498_30), rs316019 
(C__3111809_20), rs624249 (Custom TaqMan SNP Genotyping Assay); SLC22A5 rs2631367 
(C__26479161_30); SLC47A1 rs2289669 (C__15882280_10); ABCB1 rs2032582, ABCB1 rs1045642, 
ABCB1 rs1128503 (C__7586662_10), ABCB1 rs2229109 (C__15951365_20); NR1I2 rs1523130 
(C__9152783_20), rs2472677 (C__26079845_10), rs7643645, (C__1834250_10), NR1I3 rs2307424, 
rs4073054 (C__25741543_10), rs2502815, RXRA rs3132297 (C__9199894_10), rs3818740 
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(C__27521184_10), PPARGC1A rs8192678 (C__1643192_20), PPARG rs1801282 
(C__1129864_10), rs3856806 (C__11922961_30). 
Model-based pharmacokinetic analysis 
Structural model. The pharmacokinetic analysis was performed using NONMEM (version 7.1) 39 with 
the PsN-Toolkit (version 3.2.4).40  
A stepwise procedure was employed to identify the model that fitted the data the best, comparing one- 
vs. multi-compartment models with several absorption types. Memantine CL and V were estimated 
during the analysis, while ka was fixed to the mean of the bootstrap resampling analysis, because of 
the limited data collected during the absorption phase. Since memantine was only administered orally, 
the estimated pharmacokinetic parameters represent apparent values. 
Exponential errors following a log-normal distribution were used to describe interpatient variability of 
the pharmacokinetic parameters. Proportional, additive and mixed error models were compared to 
describe the intrapatient (residual) variability. 
Covariate model. Covariates potentially influencing the kinetic parameters were incorporated 
sequentially in the model. The typical value of a given parameter θ  was modeled to depend linearly on 
the non-genetic covariate X, as shown by the equation: 
θ=θ0∙  (1+θ1∙X) Eq 1 
where θ0 is the mean estimate and θ1 is the relative deviation of the mean due to the X covariate. Age 
and CLcreat were included in the model as relative deviation respectively from the population mean and 
the limit value of normal renal function in case of CLcreat, i.e., 80 ml/min and categorical variables were 
coded as 0 and 1. CLcreat was calculated based on the MDRD formula.26 In order to characterize the 
impact of genetic polymorphisms on memantine CL, patients were categorized into genotypic groups 
as well as according to the number of functional alleles. Activity scores of 2, 1 and 0 were assigned 
respectively to the fully functional reference (Hom-Ref), heterozygous (Het-LOF), and homozygous 
(Hom-LOF) diminished/loss of function alleles.41 CL values were then estimated for each genotype 
(rich model) and/or for further regrouped (reduced model) sub-populations using the equation: 
CL=෍CLiIi
i
 Eq 2 
where CLi is the typical value for the ith genetic group and Ii is an indicator variable taking the value of 
1 if an individual carries the ith genotype, 0 otherwise. Reduced models, in which the same genotyping 
group was assigned to Het-LOF and Hom-LOF, as well as those relating CL with the activity score, 
were tested and compared to the rich model. Competitive models evaluated in this study were linear, 
power, square root and square equations, as follows:  
CL=CL0+θ1∙n Eq 3 
CL=CL0∙θ1
n Eq 4 
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CL=CL0+θ1∙√n Eq 5 
CL=CL0+θ1∙n2 Eq 6 
where n = 0, 1 or 2 is the activity score and θ1 is the average contribution per allele above that of the 
Hom-Ref CL (CL0).  
At the end of the univariate analysis, all patient characteristics that showed an influence on the 
pharmacokinetic parameters were evaluated again by comparing a model containing all the significant 
covariates with a model from which each factor was deleted sequentially.   
Parameter estimation and model selection. The data were fitted by use of the first-order conditional 
method. As a goodness-of-fit statistics, NONMEM uses an objective function value (OF), which 
corresponds approximately to minus twice the maximum logarithm of the likelihood of the data. The 
ΔOF   between   two  models   approximates   a   χ2 distribution and, along with diagnostic goodness-of-fit 
plots, is used for models comparison. In the model-building step, a decrease of the OF is considered 
statistically significant (p<0.05) if it exceeds 3.8 for 1 additional parameter. An increase of 5.9 points in 
the OF (p<0.01) was used to test for covariate significance during the backward deletion procedure.   
Model validation and Simulation. The bootstrap method with replacement was used to assess the 
stability of the final model and to construct the confidence intervals (CIs) of the pharmacokinetic 
parameters using PsN-Toolkit (Version 3.2.4).40 Five hundred data sets were reconstructed by re-
sampling from the original data. The mean values of the parameters obtained were compared with 
those estimated from the original data. The 95% CIs were calculated for each parameter. In addition, 
simulations based on the final pharmacokinetic estimates were performed with NONMEM using 1,000 
individuals in order to calculate 95% prediction intervals and the Cav for individuals with different NR1I2 
rs1523130 genotypes and renal function (CLcreat 30 or 80 ml/min) after the administration of 10 mg, 15 
mg and 20 mg daily. The concentrations including the 5th and 95th percentiles at each time point were 
retrieved to construct the prediction intervals. The figures were generated with GraphPad Prism 
(Version 5.0 for Windows, GraphPad Software, San Diego California USA).  
Concentration-side effect analysis 
The relationship between log-transformed individual estimates of memantine Cav and AUC0-  and AEs 
(constipation, dizziness, headache, somnolence) was investigated by logistic regression analyses. 
AUC0-  was obtained using Dose/CL and Cav derived as AUC0- /, with  = 12 or 24 h. The 
association between different memantine Cav cut-off levels (100 ng/ml, 150 ng/ml, 200 ng/ml) and the 
occurrence of AEs was assessed with chi-square tests. The analyses were performed on STATA 
software (Version 11.2, StataCorp, College Station, Texas, USA) and a p-value  ≤0.05  was  considered  
statistically significant. 
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Figure 1: Memantine dose-normalized plasma level-time plots of male (black circles) and female 
(white circles) patients. Simulations were performed for male patients carrying the NR1I2 rs1523130 
CC genotype and receiving 20 mg of memantine per day (solid line represents average population 
prediction value; dashed lines, 95% prediction intervals).  
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Figure 2: Predicted average concentrations (bars) with 95% prediction interval for male patients with 
various NR1I2 rs1523130 genotypes and renal function (CLcreat = 80 or 30 ml/min) administered 20 
mg, 15 mg or 10 mg memantine per day. The suggested therapeutic range between 90 and 150 ng/ml 
is indicated.23 
Chapter 4: Results   
151 
 
Table 1: Characteristics of 108 model-building patients evaluated in the 
population pharmacokinetic analysis of memantine. 
Baseline characteristic  
Model-building patients 
Value % or range 
Demographic characteristics   
Sex (men/women) (no.) 34/74 31/69 
Median age (yr) 83 59-100 
Ethnicity (no. of patients)   
Caucasian  106 98 
Asian  2 2 
Environmental characteristics   
Drug formulation (tablet/solution) 101/7 94/6 
Alcohol Consumption 
(normal/high/no information) 
 
104/2/2 
 
96/2/2 
Grapefruit consumption (yes/no) 1/107 1/99 
Smoking Status (yes/no) 3/105 3/97 
Physiologic characteristics   
CLcreat 
a
 (ml/min) 63 27-147 
Creatinine  (μmol/l) 90 37-168 
Urea (mmol/l) 7.8 3.3-45.8 
Concomitant medications (no/yes)    
OCT inhibitors 75/33 69/31 
Drug eliminated via tubular secretion 38/70 35/65 
PXR agonists 78/30 72/28 
P-gp inhibitors   49/59 45/55 
P-gp inductors 94/14 87/13 
a CLcreat, creatinine clearance estimated by glomerular filtration rate.26
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Table 2: Summary of the models used to examine the influence of patient covariates on memantine oral 
CL. 
Non-genetic covariates Model θ0 θ1 θ2 ΔOF
c P 
Individual characteristics       
Does SEX influence CL?  
(male: SEX=1; female: SEX=2) 
θ0 (1+  θ1·(SEX-1)) 6.30 -0.22  -11.7 < 0.01 
Does AGE influence CL? θ0 (1+  θ1 ·AGEb) 5.34 -1.12  -9.3 < 0.01 
Does ethnicity influence CL? 
(Caucasian: q1=1; q2=0 
 Asian         : q1=0; q2=1) 
θ0 ·q1+  θ1·q2 5.21 7.15  -1.0 NS 
Does memantine formulation influence CL? 
(tablet: FORM=1; solution: FORM=2)          θ0 (1+  θ1 ·(FORM-1)) 
5.29 -0.12  -0.7 NS 
Does CLcreat
a
 influence CL?                              θ0 (1+  θ1 · CLcreat
b
 ) 5.65 -0.34  -7.3 < 0.01 
Does Urea influence CL? θ0 (1+  θ1 ·UREA) 5.43 -5·10-3  0.5 NS 
Does alcohol consumption influence CL? 
(Normal/no info: q1=1; q2=0 
 high                 : q1=0; q2=1) 
θ0 ·q1+  θ1·q2 5.24 6.02  -2.8 NS 
Does grapefruit consumption influence CL? 
(NO  : q1=1; q2=0 
 YES: q1=0; q2=1) 
θ0 ·q1+  θ1·q2 5.27 3.45  -2.2 NS 
Does smoking influence CL? 
(NO  : q1=1; q2=0 
 YES: q1=0; q2=1) 
θ0 ·q1+  θ1·q2 5.20 6.44  -0.9 NS 
Concomitant medications on CL  
(DRUG=1 if administered) 
θ0 (1+  θ1 ·DRUG)      
OCT Inhibitors  5.20 0.03  -0.1 NS 
Drug eliminated via tubular secretion  5.11 0.04  -0.3 NS 
PXR agonists  5.00 0.18  -5.0 0.02 
P-gp Inhibitors  4.67 0.23  -11.0 < 0.01 
P-gp Inductors  5.24 5·10-3  0.0 NS 
Genetic covariates Model θ0 θ1 θ2 ΔOFc P 
SLC22A2 rs316019  
Rich model  (Eq 2): I0: TT; I1: GT; I2: GG 
θ0I0+θ1I1+θ2I2  6.94 5.63 5.11 -2.0 NS 
SLC22A2 rs316003  
Rich model  (Eq 2): I0: CC; I1: TC; I2: TT 
θ0I0+θ1I1+θ2I2  6.55 5.17 5.12 -3.1 NS 
SLC22A2 rs2279463 
Rich model  (Eq 2): I0: GG; I1: AG; I2: AA  
θ0I0+θ1I1+θ2I2  6.20 5.30 5.21 -0.30 NS 
SLC22A2 rs624249 
Rich model  (Eq 2): I0: AA; I1: CA; I2: CC   
θ0I0+θ1I1+θ2I2 5.32 4.99 5.58 -2.4 NS 
SLC22A1 rs628031 
Rich model  (Eq 2): I0: AA; I1: GA; I2: GG   
θ0I0+θ1I1+θ2I2  5.64 5.30 5.03 -1.4 NS 
SLC22A1 rs72552763 
Rich model  (Eq 2): I0: deldel; I1:GATdel; 
I2:GATGAT 
θ0I0+θ1I1+θ2I2  4.60 5.29 5.22 -0.2 NS 
SLC22A1 rs622342 
Rich model  (Eq 2): I0: CC; I1: AC; I2: AA 
θ0I0+θ1I1+θ2I2 6.19 5.09 5.11 -3.6 NS 
SLC22A1 rs34059508 
Rich model  (Eq 2): I1:GA; I2: GG 
θ1I1+θ2I2  4.72 5.25 -0.3 NS 
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a CLcreat, creatinine clearance estimated by glomerular filtration rate,26 
b Age and CLcreat are expressed as the relative deviation of the individual age and CLcreat 
from the population mean and normal renal function limit value (80 ml/min). 
c Differences in the NONMEM objective function   (ΔOF)   compared   to   the   basic   structural  
model, without covariates and with parameters estimates of CL of 5.2 l/h, a V of 172.8 l and 
a ka of 0.3 h-1  
d n =0, 1 or 2, number of functional alleles respectively for the TT, CT and CC patients. 
SLC22A1 rs12208357 
Rich model  (Eq 2): I1: CT; I2: CC 
θ1I1+θ2I2  5.70 5.16 -1.0 NS 
SLC22A1 rs34130495 
Rich model  (Eq 2): I1:GA; I2: GG 
θ1I1+θ2I2  4.54 5.26 -0.6 NS 
SLC22A5 rs2631367 
Rich model  (Eq 2): I0:GG; I1:CG; I2: CC 
θ0I0+θ1I1+θ2I2 4.97 5.21 5.61 -2.0 NS 
SLC47A1 rs2289669 
Rich model  (Eq 2): I0:AA; I1: GA; I2: GG 
θ0I0+θ1I1+θ2I2 5.26 5.39 4.98 -1.2 NS 
ABCB1 3435CT 
Rich model  (Eq 2): I0:TT; I1: CT; I2: CC 
θ0I0+θ1I1+θ2I2 5.27 5.12 5.39 -0.4 NS 
ABCB1 2677GT 
Rich model  (Eq 2): I0: TT; I1:GT; I2: GG 
θ0I0+θ1I1+θ2I2 4.97 5.23 5.39 -0.8 NS 
ABCB1 1236CT 
Rich model  (Eq 2): I0:TT; I1: CT; I2: CC 
θ0I0+θ1I1+θ2I2 5.17 5.16 5.40 -0.4 NS 
ABCB1 1199GA 
Rich model  (Eq 2): I0: AA; I1: GA; I2: GG 
θ0I0+θ1I1+θ2I2 3.71 5.05 5.27 -1.0 NS 
NR1I2 rs1523130 
Rich model (Eq 2):  I0:TT; I1:CT, I2: CC 
θ0I0+θ1I1+θ2I2 4.74 5.04 5.87 -6.3 0.04 
Recessive model (Eq 2):  q1=0 for 
CT/TT,  q1=1 for CC 
θ0 (1+  θ1 · q1) 5.87  -0.16 -5.8 0.02 
Linear model d (Eq 3) θ0+θ1∙n 4.59 0.57  -5.6  0.02 
Power model d (Eq 4) θ0∙θ1
n 4.59 1.12  -5.7  0.02 
Square root model d (Eq 5) θ0+θ1∙√n 4.59 0.68  -4.0  0.04 
Square model  d (Eq 6) θ0+θ1∙n2 4.75 0.28  -6.3 0.01 
NR1I2 rs2472677 
Rich model  (Eq 2): I0: CC; I1 TC; I2: TT 
θ0I0+θ1I1+θ2I2  5.15 5.34 5.16 -0.3 NS 
NR1I2 rs7643645 
Rich model  (Eq 2): I0: GG; I1 AG; I2: AA 
θ0I0+θ1I1+θ2I2 5.77 5.32 5.03 -2.0 NS 
NR1I3 rs2307424 
Rich model  (Eq 2): I0: TT; I1 CT; I2: CC 
θ0I0+θ1I1+θ2I2  4.60 5.31 5.19 -1.6 NS 
NR1I3 rs4073054 
Rich model  (Eq 2): I0: GG; I1 TG; I2: TT 
θ0I0+θ1I1+θ2I2  4.82 5.41 5.10 -1.6 NS 
NR1I3 rs2502815 
Rich model  (Eq 2): I0: TT; I1 CT; I2: CC  
θ0I0+θ1I1+θ2I2 4.23 5.25 5.27 -1.0 NS 
RXRA rs3132297  
Rich model  (Eq 2): I0: TT; I1 CT; I2: CC 
θ0I0+θ1I1+θ2I2 5.46 4.70 5.41 -3.2 NS 
RXRA rs3818740 
Rich model  (Eq 2): I0: CC; I1 TC; I2: TT 
θ0I0+θ1I1+θ2I2 4.78 5.09 5.45 -1.8 NS 
PPARGC1B rs8192678  
Rich model  (Eq 2): I0: TT; I1 CT; I2: CC 
θ0I0+θ1I1+θ2I2 4.85 5.36 5.20 -0.9 NS 
PPARG rs1801282 
Rich model  (Eq 2): I0: GG; I1 CG; I2: CC 
θ0I0+θ1I1+θ2I2 6.25 5.39 5.20 -0.7 NS 
PPARG rs3856806 
Rich model  (Eq 2): I0:  TT; I1 CT; I2: CC 
θ0I0+θ1I1+θ2I2 5.32 5.31 5.22 -0.7 NS 
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Table 3: Genotype frequencies in the study population (n=108). 
Genetic Polymorphisms Model-building patients 
 Genotypes Value Frequency (%) 
 
    
SLC22A2  
rs316019 (A270S) 
 
GG/GT/TT 
 
88/18/2 
 
81/17/2 
 
rs316003  TT/TC/CC 66/35/7 61/32/6 
 
rs2279463  AA/AG/GG 84/23/1 78/21/1 
 
rs624249  CC/CA/AA 38/53/17 35/49/16 
SLC22A1  
rs628031 (M408V) GG/GA/AA 39/53/16 36/48/15 
 
rs72552763 (M420del) GATGAT/GATdel/deldel 72/35/1 67/32/1 
 
rs34059508 (G465R) GG/GA/AA 104/4/0 96/4/0 
 
rs12208357 (R61C) CC/CT/TT 95/13/0 88/12/0 
 
rs34130495 (G401S) GG/GA/AA 105/3/0 97/3/0 
 
rs622342 AA/AC/CC 46/48/14 43/44/13 
 
Number of active allelesa 2 active/1 active/0 active 58/49/1 54/45/1 
SLC22A5  
rs2631367 
 
CC/CG/GG 
 
31/48/29 
 
29/44/27 
SLC47A1  
rs2289669 
 
GG/GA/AA 
 
34/54/20 
 
31/50/19 
ABCB1 
rs2032582 (3435C>T) 
 
CC/CT/TT 
 
29/46/33 
 
27/43/30 
  
rs1045642 (2677G>T) GG/GT/TT 38/51/19 35/47/18 
 
rs1128503 (1236C>T) CC/CT/TT 38/47/23 35/44/21 
 
rs2229109 (1199G>A) GG/GA/AA 102/5/1 94/5/1 
NR1I2  
rs1523130 
 
CC/CT/TT 
 
36/54/18 
 
33/50/17 
 
rs2472677 TT/TC/CC 42/45/21 39/42/19 
 
rs7643645 AA/AG/GG 54/40/14 50/37/13 
NR1I3  
rs2307424 
 
CC/CT/TT 
 
42/54/12 
 
39/50/11 
 
rs4073054 TT/TG/GG 34/62/12 32/57/11 
 
rs2502815 CC/CT/TT 62/44/2 57/41/2 
RXRA  
rs3132297 
 
CC/CT/TT 
 
81/24/3 
 
75/22/3 
 
rs3818740 TT/TC/CC 53/45/10 49/42/9 
PPARGC1B  
rs8192678 
 
CC/CT/TT 
 
38/57/13 
 
35/53/12 
PPARG  
rs1801282 
 
CC/CG/GG 
 
84/22/2 
 
78/20/2 
 
rs3856806 CC/CT/TT 81/26/1 75/24/1 
a Active alleles were defined by the absence of one or more of the following amino acid substitutions in SLC22A1, 
according to literature:31 M408V, M420del, G465R, R61C, G401S. 
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Table 4: Final population pharmacokinetic parameter estimates of memantine and their bootstrap 
evaluations (CL/F, mean apparent clearance for male wild-type NR1I2 rs1523130 patients with 
normal renal function; V/F, mean apparent volume of distribution; ka, mean absorption rate 
constant). 
 
Parameter 
Population mean Bootstrap evaluation 
Estimate SEa 
(%) 
IIVb 
(%) 
SEc 
(%) 
Estimate SEa 
(%) 
IIVb 
(%) 
SEc 
(%) 
CL/F (l/h) 7.51 8 22 57 7.57 9 21 61 
θ
d
NR1I2 rs1523130  -0.16 30   -0.16 34   
θ
e
CLcreat
 -0.30 40   -0.29 43   
θfemale -0.20 26   -0.21 27   
V/F (l) 194 30   242 72   
ka (h-1) 0.30 --   0.30    
f 25 19   25 21   
a Standard errors of the estimates (SE) are defined as SE/estimate and are expressed as 
percentages. 
b Interindividual variability defined as CVs (%). 
c Standard errors of the coefficient of variations, calculated as (SE/estimate) ^ 0.5, are expressed 
as percentages.  
d Relative deviation of CL/F due to NR1I2 rs1523130 individuals carrying of at least one T allele 
(Eq 1). 
e Relative deviation of CL/F as a function of CLcreat,  estimated  using  CL/F  *  (1+  θCLcreat * (80-
CLcreat)/80)), where 80ml/min is the limit value of normal renal function  
f Residual additive error, expressed as standard deviation (ng/ml). 
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Supplementary Table 1: Classification  of  patients’  comedication   
Classification Drugs Ref 
OCT inhibitors 
bisoprolol, carvedilol, diclofenac, fluoxetine, ibuprofen, metformin, 
metoprolol, O-desmethyl-tramadol, paroxetine, propanolol, quinine, 
ranitidine, spironolactone, trimethoprim 
1-6 
Drugs eliminated 
by tubular 
secretion 
acetyl salicylic acid, bisoprolol, candesartan, captopril, digoxine, 
furosemide, hydrochlorothiazide, ibuprofen, levetiracetam, lisinopril, 
morphine, metformine, methothrexate, quinine, trimethoprim 
7-12 
PXR agonists 
amoxicillin, atorvastatin, carbamazepine, fluvastatine, ginkgo biloba, 
isradipine, nifedipine, omeprazole, simvastatin, spironolactone, valproic 
acid 
13 
P-gp inhibitors 
atorvastatin, bisoprolol, candesartan, carvedilol, diltiazem, felodipine, 
fluoxetine, haloperidol, irbesartan, nifedipine, omeprazol, pantoprazol, 
paroxetine, propanolol, sertraline, simvastatin, spironolactone 
14-16 
P-gp inducers budenoside, morphine, trazodone, valproic acid, venlafaxine 14 
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3. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-66. 
4. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and 
biopharmaceutical implications. Pharm Res. 2007 Jul;24(7):1227-51. 
5. Bachmakov I, Glaeser H, Endress B, et al. Interaction of beta-blockers with the renal uptake transporter OCT2. 
Diabetes Obes Metab. 2009 Nov;11(11):1080-3. 
6. Tzvetkov MV, Saadatmand AR, Lotsch J, et al. Genetically polymorphic OCT1: another piece in the puzzle of the 
variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2011 
Jul;90(1):143-50. 
7. Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharmacotherapy: a naturalistic study using a population 
pharmacokinetic approach. Clin Pharmacokinet. 2007;46(7):599-612. 
8. Documed SA, Basel, Switzerland. Compendium Suisse des Medicaments. http://www.compendium.ch/ (last 
access Dec 2011). 
9. Tahara K, Kagawa Y, Takaai M, et al. Directional transcellular transport of bisoprolol in P-glycoprotein-expressed 
LLC-GA5-COL150 cells, but not in renal epithelial LLC-PK1 Cells. Drug Metab Pharmacokinet. 2008;23(5):340-6. 
10. Beermann B. Pharmacokinetics of lisinopril. Am J Med. 1988;85(3B):25-30. 
11. Van Crugten JT, Sallustio BC, Nation RL, Somogyi AA. Renal tubular transport of morphine, morphine-6-
glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. Drug Metab Dispos. 1991 Nov-
Dec;19(6):1087-92. 
12. Notterman DA, Drayer DE, Metakis L, Reidenberg MM. Stereoselective renal tubular secretion of quinidine and 
quinine. Clin Pharmacol Ther. 1986 Nov;40(5):511-7. 
13. PharmGkb. Agonists/ligands of hPXR. http://www.pharmgkb.org/gene/PA378?tabType=tabVip (last access Dec 
2011). 
14. Zhou SF, Xue CC, Yu XQ, et al. Clinically important drug interactions potentially involving mechanism-based 
inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 
Dec;29(6):687-710. 
15. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 
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4.3 Article VI: Relationship of CYP2D6, CYP3A5, POR and ABCB1 genotypes with galantamine 
plasma concentrations 
 
Summary 
In this article, the results of the pharmacogenetic study in patients treated with galantamine are 
described. Galantamine is extensively metabolized by the enzymes CYP2D6 and CYP3A and is a 
substrate of the P-glycoprotein. The relationship of genetic variants influencing the activity of these 
enzymes and transporter with galantamine steady-state plasma concentrations was investigated in 27 
patients treated with a constant dose of galantamine. The patients were genotyped for common 
polymorphisms in CYP2D6, CYP3A4/5, POR and ABCB1. The CYP2D6 genotype appeared to be an 
important determinant of galantamine pharmacokinetics, with CYP2D6 poor metabolizers presenting 
60% higher galantamine plasma concentrations than CYP2D6 extensive metabolizers. Moreover, the 
results suggest a potential influence of the ABCB1 2677G>T polymorphism on galantamine 
pharmacokinetics. Genetic variations, primarily in CYP2D6, might therefore be interesting for further 
prospective studies, investigating inter-individual variability in clinical outcome and tolerability of 
galantamine treatment. 
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ABSTRACT 
Background: The frequently prescribed antidementia drug galantamine is extensively metabolized by 
the enzymes CYP2D6 and CYP3A and is a substrate of the P-glycoprotein. We aimed to study the 
relationship of genetic variants influencing the activity of these enzymes and transporter with 
galantamine steady-state plasma concentrations.  
Methods: In this naturalistic cross-sectional study, 27 older patients treated with a constant dose of 
galantamine were included. The patients were genotyped for common polymorphisms in CYP2D6, 
CYP3A4/5, POR and ABCB1, and galantamine steady state plasma concentrations were determined.  
Results: The CYP2D6 genotype appeared to be an important determinant of galantamine 
pharmacokinetics, with CYP2D6 poor metabolizers presenting 60% higher dose-adjusted galantamine 
plasma concentrations than CYP2D6 extensive metabolizers (median 2.9 versus 1.8 ng/ml·mg, 
p=0.004).  
Conclusion: The CYP2D6 genotype significantly influenced galantamine plasma concentrations and 
might therefore be interesting for further studies investigating interindividual variability in clinical 
outcome and tolerability of the treatment. 
 
INTRODUCTION 
Alzheimer’s  disease  is  the  most  common  form  of  dementia,  characterized by progressive deterioration 
of cognition and global functioning. It is recognized that a loss of cholinergic activity significantly 
contributes to the cognitive decline.1 Galantamine, indicated for the symptomatic treatment of mild to 
moderate   Alzheimer’s   disease,   enhances   the cholinergic function trough inhibition of the enzyme 
acetylcholinesterase and allosteric modulation of nicotinic receptors.2 
It is widely accepted that genetic variations in drug metabolizing enzymes and transporters contribute 
to therapeutic failure and adverse drug reactions.3,4 Galantamine is mainly metabolized by the liver 
enzymes cytochrome P450 (CYP) 2D6 and CYP3A, which stands for the group of isozymes CYP3A4, 
CYP3A5 and CYP3A7.5,6 In addtion, galantamine is presumably a substrate of the membrane 
transporter P-glycoprotein (P-gp), implicated in drug absorption, distribution and excretion.7 Thus, 
genetic variations in these enzymes and transporter might influence galantamine disposition and 
clinical outcome. Moreover, polymorphisms in the cytochrome P450 oxidoreductase (POR), a protein 
that transfers electrons to the CYP enzymes, have been shown to alter CYP3A activity and might, 
therefore, affect galantamine pharmacokinetics as well.8,9 Phenotypically, four types of CYP2D6 
metabolizers can be distinguished: poor (PM), intermediate (IM), extensive (EM) and ultrarapid 
metabolizers (UM). Underlying genetic variations defining the CYP2D6 phenotypes are well known.10 
In previous studies, a 25% decreased galantamine clearance and an altered metabolite profile has 
been shown in CYP2D6 PMs compared to EMs.6,11 To our knowledge, no studies investigated the 
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impact of polymorphisms in CYP3A, POR or ABCB1 (encoding P-gp) genes on galantamine 
pharmacokinetics. 
The aim of this work was to study the effect of genetic variations in CYP2D6, CYP3A4/5, POR and 
ABCB1 on galantamine steady-state plasma concentrations in a cohort of 27 dementia patients from a 
naturalistic therapeutic setting. Moreover, the relationship between galantamine plasma 
concentrations and recorded side effects was assessed. 
 
METHODS 
Study design and participants 
In this cross-sectional study, 27 patients (23 inpatients and 4 outpatients) receiving galantamine at a 
constant dose for at least one week were included. Patients were recruited at four hospitals 
(Lausanne, Geneva, Marsens, Aigle) and in affiliated nursing homes. One blood sampling was 
performed to measure galantamine plasma concentration, to evaluate renal and hepatic function 
(standard clinical laboratory tests), and to extract DNA for the genetic analyses. The presence of 
adverse events, reported by the patients, doctors and/or nurses, was registered. Additionally, 
concomitant diseases, comedication, consumption of grapefruit, alcohol and tobacco were recorded. 
The study was approved by the local ethics committees (Lausanne University Hospital, Geneva 
University Hospital, Cantonal Ethic Committee Fribourg) and conducted according to the Good Clinical 
Practices. Written informed consent, including consent for genetic analysis, was obtained from all 
patients or their legal representative. 
Drug concentration measurement and estimation of trough concentration 
Blood samples were collected in EDTA blood tubes. After centrifugation, the plasma was stored at -
20°C until analysis. Galantamine plasma concentrations were determined by high performance liquid 
chromatography coupled with mass spectrometry, as previously described.12 
In 16 patients trough concentrations were measured, whereas in 11 patients the blood samples were 
drawn 1-7 hours after drug intake. In these patients, trough concentrations were estimated with 
NONMEM (Version 7.1) using the equation of a previously published population pharmacokinetic 
analysis including age and creatinine clearance (CLcreat) as covariates.11 Thus, the influence of these 
two covariates in our study population was only tested in the subgroup of 16 patients with measured 
trough concentration. Since linear pharmacokinetics of galantamine has been demonstrated,13 the 
trough concentration was corrected for each patient by the daily dose. 
Genotyping 
Genomic DNA was extracted from EDTA blood samples with the FlexiGene DNA extraction kit 
(QIAGEN,  Hombrechtikon,  Switzerland)  according  to  the  manufacturer’s  protocol.  The  following  SNPs  
were detected by real-time  polymerase   chain   reaction  with   5’-nuclease allelic discrimination assays 
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(ABI  PRISM  7000;;  Applied  Biosystems,  Rotkreuz,  Switzerland)  according  to  manufacturer’s  protocols  
and previous studies:14 CYP2D6*3 (rs35742686), CYP2D6*4 (rs3892097), CYP2D6*6 (rs5030655), 
CYP3A4 rs4646437, CYP3A5*3 (rs776746), ABCB1 2677G>T (rs2032582), ABCB1 3435C>T 
(rs1045642). Gene deletion (CYP2D6*5) and duplication/multiplication (CYP2D6*xN) were analyzed 
by TaqMan copy number assay and long PCR, respectively, as previously described.14 Internal quality 
control samples of known genotype were included in all analyses. 
Statistical Analysis 
Group comparisons were performed with the non-parametric Wilcoxon rank sum test for continuous 
variables  and  with  the  Fisher’s  exact   test   for  categorical  variables.  Associations  between  continuous  
variables were tested with the Spearman rank-order correlation coefficients. All tests were two-sided 
and a p-value  ≤0.05  was  considered  statistically  significant.  Analyses  were  performed  using  STATA  
software (version 12.0; StataCorp, College Station, Texas, USA). 
 
RESULTS 
Study population and influence of non-genetic factors 
A total of 27 Caucasian patients were included in the study, receiving a galantamine dose of 8 mg 
(n=7), 16 mg (n=12) or 24 mg (n=8). The sample consisted of 13 men and 14 women with a mean 
(±SD) age of 82±7 (range 67-91) years with mean (±SD) duration of treatment of 3.5 (±2.3) years. No 
patient had hepatic impairment, whereas 6 patients had a moderate renal insufficiency (CLcreat 30-59 
ml/min). Two patients were smokers and one patient had elevated alcohol consumption. The subjects 
received on average (±SD) 6±3 concomitant drugs. One patient was treated with the strong CYP2D6 
inhibitor paroxetine and was further considered as CYP2D6 PM. Weak or moderate CYP2D6 and 
CYP3A inhibitors were prescribed to respectively 19 and 9 patients.15 
Steady-state median (IQR) trough concentrations were 19 (12-26) ng/ml, 33 (27-38) ng/ml and 41 (23-
61) ng/ml for patients receiving 8 mg, 16 mg and 24 mg galantamine per day, respectively, and the 
dose-adjusted concentrations ranged between 0.66 and 4.0 ng/ml·mg. Age, gender, smoking, 
impaired renal function and comedication with weak or moderate CYP2D6 and CYP3A inhibitors were 
not significantly associated with dose-adjusted galantamine concentrations (data not shown). 
Influence of genetic factors 
Allele and genotype frequencies are in agreement with previous reports in Caucasians (Table 1), with 
the exception of CYP2D6*3.14,16 For this null allele, a frequency (95% confidence interval) of 11% (2-
29) was observed, which is higher than the frequency of approximately 2% normally detected in the 
white population.14,16 Consequently, more CYP2D6 PMs than expected were identified in our study 
population. 
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The patients were classified according to their predicted CYP2D6 phenotype.17 Overall, 6 PMs, 9 
heterozygous EMs (hetEMs), 11 homozygous EMs (homEMs) and one UM were identified. The 
CYP2D6 phenotype was significantly related to galantamine dose-adjusted plasma concentrations, 
with PMs displaying 60% higher plasma concentrations compared to hetEMs and homEMs (median 
2.9 vs. 2.0 ng/mlmg, p=0.025, and 1.8 ng/mlmg, p=0.004, respectively) (Table 1, Figure 1). Contrary 
to expectations, the UM had a similar dose-adjusted plasma concentration than EMs. 
No significant relationship was found between CYP3A4 rs4646437, CYP3A5*3, POR*28 ABCB1 
3435C>T and 2677G>T polymorphisms and dose-adjusted galantamine concentrations. However, a 
tendency towards lower concentrations was observed in carriers of the ABCB1 2677TT genotype 
compared to the GG genotype (median TT 1.8 versus GG 2.3 ng/mlmg, p=0.086) (Figure 2). 
Influence of dose and concentration on side effects 
Overall, 11 patients reported no AE while 16 patients experienced at least 1 AE. Of these, 6 patients 
had gastrointestinal problems (nausea, vomiting, diarrhea, abdominal pain, dyspepsia, anorexia, 
weight loss) and 10 patients CNS symptoms (dizziness, confusion, insomnia, headache, depression). 
Neither galantamine doses nor trough concentrations nor genotypes were related to the presence of 
AEs.  
Although the difference is not statistical significant, only one (17%) of the CYP PMs received the 
maximum dose of 24 mg per day compared to 7 (35%) of the EMs. This finding might indicate an 
intolerance of the higher dosage in PMs and should be tested in larger cohorts. 
 
DISCUSSION 
The person-to-person variability in drug response is a major problem in clinical practice leading to 
therapeutic failure or adverse effects in individuals or subpopulation of patients.18 The source of the 
variability is likely to be manifold, but for many drugs evidence exists that genetic variations in drug-
metabolizing enzymes and transporters influence the pharmacokinetics and subsequently the clinical 
outcome.3,4 Up to now, only few clinical trials addressed the issue of inter-individual variability in 
galantamine pharmacokinetics. In this cross-sectional study, we investigated the relationship of 
genetic polymorphisms in CYP2D6, CYP3A4/5, POR and ABCB1 with galantamine concentrations in 
27 dementia patients. 
A significant influence of the predicted CYP2D6 phenotype on dose-adjusted galantamine plasma 
concentrations was observed. CYP2D6 PMs displayed 60% higher concentrations compared to 
CYP2D6 EMs, while homEMs and hetEMs had similar plasma levels. Even though the influence of the 
CYP2D6 PM status was more pronounced in our study population, these results are in agreement with 
a previously published population pharmacokinetic study including 356 patients of two phase III clinical 
trials genotyped for CYP2D6.11 Their model indicated a 25% reduced galantamine clearance in 
CYP2D6 PMs (n=20) and a similar clearance among homEMs and hetEMs.11 In contrast, in a single 
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low dose study with 4 mg galantamine, no apparent difference in plasma concentrations was seen 
between two CYP2D6 EMs and two PMs, but the metabolite profile was substantially different.6 In 
EMs, urinary metabolites resulting from O-demethylation by CYP2D6 represented 33% of the dose 
compared with 5% in PMs, which showed correspondingly higher urinary excretion of unchanged 
galantamine and its N-oxide, formed by CYP3A.6 In none of these studies CYP2D6 UMs were taken 
into account. Since only one UM was detected in our study, it was not possible to draw a conclusion 
either. According to the FDA drug label information, no dose-adjustment is necessary in PMs as the 
dose is individually titrated to tolerability.19 Nevertheless,   the   knowledge   of   a   patient’s   CYP2D6 
genotype might be useful to avoid concentration-related AEs in PMs. 
A tendency towards lower dose-adjusted galantamine concentrations was observed in carriers of the 
ABCB1 2677TT genotype compared to the GG genotype. It might be that the ABCB1 2677G>T 
polymorphism influence galantamine concentrations through altered absorption, distribution and/or 
excretion. On the other hand, it has also been shown that individuals homozygous for the ABCB1 
2677T allele have enhanced constitutive CYP3A4 expression in liver and intestine compared with 
those homozygous for the G allele.20 This difference in CYP3A activity might therefore explain the 
tendency towards lower galantamine concentrations in ABCB1 2677TT carriers. The lack of a 
significant relationship between polymorphisms in CYP3A4/5, POR and ABCB1 might be due to the 
predominant influence of the CYP2D6 phenotype and the small study population and should, 
therefore, be repeated in other cohorts. 
Recently, a therapeutic range of 30-60 ng/ml was proposed for galantamine.21 In the study population, 
the trough plasma concentrations corresponded well to the suggested range for the recommended 
maintenance doses of 16 mg and 24 mg daily. Although a dose related occurrence of AEs has been 
reported,22 no relationship between galantamine dose or plasma concentrations and the presence of 
AEs was found. This result might be a consequence of the cross-sectional study design. Prevalent 
AEs were recorded at inclusion when most patients were already receiving galantamine for several 
months. Therefore, it was complicated to differentiate between galantamine related AEs and effects of 
concomitant diseases or medication. Moreover, transient AEs were no more present and intolerant 
patients would already have reduced the dose or discontinued the treatment and be ineligible.  
In conclusion, the present study shows for the first time in a naturalistic setting the significant influence 
of the CYP2D6 phenotype on galantamine pharmacokinetics, with CYP2D6 PMs displaying 60% 
higher dose-adjusted plasma concentrations than CYP2D6 EMs. Moreover, the results suggest a 
potential influence of the ABCB1 2677G>T polymorphism. Since it is of special importance for elderly 
patients with cognitive impairment to avoid multiple medication changes due to non-response or side 
effects, an individual galantamine dose-adjustment might be useful. Therefore, prospective studies 
including a larger number of patients and investigating the clinical effectiveness and tolerability of 
galantamine with respect to plasma concentrations and genotypes are required. 
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Table 1: Genotype frequencies in the study population (n=27) and dose-adjusted 
plasma concentrations in genotypes. 
 Genotype 
 
Frequency  
 Dose-adjusted plasma levels 
(ng/ml•mg) 
  n (%) 95% CI (%)  Median 
Interquartile 
range p-value 
CYP2D6a         
homEM  11 41 22-61  1.8 1.5-2.3  
hetEM  9 33 17-54  2.0 1.0-2.4 0.676c 
PM  6 22 9-42  2.9 2.5-3.5 0.004c 
UM  1 3 0-19b  2.1   
         
CYP3A4  rs4646438       
CC  22 81 62-94  2.0 1.5-2.5 0.662 
CT  5 19 6-38  2.1 1.3-2.3  
         
CYP3A5 *3         
*1/*3  3 11 2-29  2.3 1.0-2.6 1.000 
*3/*3  24 89 71-98  2.0 1.5-2.5  
         
POR*28         
CC  13 48 29-68  1.6 1.3-2.4 0.356 
CT  12 45 25-65  2.0 1.9-2.4  
TT  2 7 1-24  2.5 1.8-3.2  
         
ABCB1 3435CT      
CC  6 22 9-42  2.3 1.5-3.0 0.600d 
CT  15 56 35-75  2.3 1.5-2.6  
TT  6 22 9-45  1.8 1.0-2.0  
         
ABCB1 2677GT       
GG  10 37 19-58  2.3 1.5-3.2 0.192d 
GT  12 44 25-65  2.1 1.5-2.5  
TT  5 19 6-38  1.8 1.0-2.0  
 
a) CYP2D6: PM, poor metabolizer: *4/*4 (n=1), *4/*5 (n=1), *3/*4 (n=3), medication with 
strong CYP2D6 inhibitor (n=1); hetEM, heterozygous extensive metabolizer: *1/*4 (n=7), 
*1/*5 (n=1); *1/*6 (n=4); homEM, homozygous extensive metabolizer: *1/*1 (n=11), 
*4/*xN (n=1); UM, ultrarapid metabolizer: *1/*XN or *XN/*XN, (n=1). 
b) One-sided, 97.5% confidence interval. 
c) P value refers to homozygous extensive metabolizers (homEM) versus heterozygous 
extensive metabolizers (hetEM) and poor metabolizers (PM), respectively. 
d) P values determined by Wilcoxon test; dominant model grouped by the presence of 
at least one variant allele versus wild type. 
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Figure 1: Influence of the predicted CYP2D6 phenotype on dose-adjusted galantamine trough 
concentrations. 
 
 
 
Figure 2: Influence of the ABCB1 2677G>T genotype on dose-adjusted galantamine trough 
concentrations.
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4.4 Rivastigmine 
 
A total of 44 patients treated with rivastigmine were included in the pharmacogenetic study. Patients 
were administered several different rivastigmine dosages with patch or capsule formulation (Table 1), 
which resulted in a very heterogeneous dataset.  
 
 
  Table 1: Study participants treated with rivastigmine 
 Daily dose Number of 
patients 
Percentage 
(%) 
    
Capsule 3 mg 4 9 
 4.5 mg 2 5 
 6 mg 8 18 
 9 mg 3 7 
 12 mg 1 2 
 Total 18 41 
    
Patch 4.6 mg 11 25 
 9.5 mg 15 34 
 Total 26 59 
 
 
 
Rivastigmine plasma concentrations were determined and the previously reported high inter-individual 
variability was confirmed (Figure 1).66,67 Despite this observation, no genotyping was performed for 
pharmacogenetic analyses given that statistical power was lacking for several reasons. First, a 
comparison of the plasma concentrations by means of normalization by the daily dose was 
circumvented by the non-linear pharmacokinetics of rivastigmine.68,69 Therefore, analyses would only 
be possible in subgroups of patients with the same dosage, which were size limited in our study 
population. Furthermore, rivastigmine has a short half-life of approximately 1.5 h after capsule 
administration leading to high fluctuations between peak and trough concentrations.69 Consequently, 
estimations of trough plasma concentrations using a general pharmacokinetic equation 
(Ctrough=Cmeasured*e-((ln2/t1/2)*dt), t1/2=half-life, dt=time between medication intake and blood sampling) with 
half-life reported in the literature are not accurate enough for the purpose of the study. Finally, a larger 
study sample would be necessary for population pharmacokinetic investigations.  
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Figure 1: Measured rivastigmine plasma concentrations for patients treated with the following dosages: patch 4.6 
mg/24 h (green triangles, n=11), capsules 3 mg b.i.d. (red squares, n=8) and patch 9.5 mg/24 h (blue squares, 
n=15). 
 
In 57% (n=25) of the patients at least one adverse event, including gastrointestinal problems, 
dizziness and fatigue, was reported. No significant relationships were found between the occurrence 
of adverse events and the daily rivastigmine doses. Moreover, analyses were performed in subgroups 
of patients in which peak or trough concentrations were measured. No associations were revealed 
between the frequency of adverse events and peak or trough concentrations. In contrast to previous 
studies, the patch formulation was not related to a lower occurrence of adverse events in our study 
population. This might be due to the cross-sectional study design, as adverse events were recorded at 
inclusion, when most patients were already receiving the treatment for several months. Therefore, 
transient adverse events were no more present and intolerant patients would have already reduced 
the dose or discontinued the treatment and be ineligible. However, an indication of a better tolerability 
of the patch might be that only one patient (5.5%) was treated with the highest therapeutic dose of 
rivastigmine in the capsule group (6 mg b.i.d.) versus 15 patients (58%) in the patch group (9.5 
mg/24h). In previous clinical trials, the 9.5 mg/24h patch has been shown to provide comparable 
rivastigmine exposure to the 6 mg b.i.d capsule administration, with similar efficacy but three times 
fewer adverse events reports due to the favorable pharmacokinetic profile.70 Thus, significantly more 
patients reached the highest dose in the patch group compared to the capsule group, which is in 
agreement with our finding.70 
 
In conclusion, no pharmacogenetic analyses have been performed in the study population receiving 
rivastigmine due to the heterogeneity of the dataset. However, a large interindividual variability in 
plasma concentrations was observed. Thus, pharmacogenetic studies in larger study populations with 
uniform dosage regimens would be of interest. In the present study, preliminary analyses revealed no 
significant relationships between the occurrence of adverse events and rivastigmine dose, plasma 
concentrations or formulation.
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In this last chapter the results of this work are discussed and some perspectives for future research on 
the subjects are given. 
 
5.1 Analytical methods 
 
A prerequisite for any pharmacokinetic study and for TDM is a suitable bioanalytical procedure for the 
measurements of the plasma concentrations of the drugs. 
The HPLC-MS method, that was developed and validated for the determination of antidementia drugs 
in the plasma of the participants of the pharmacogenetic study, is described in Article II. It is the first 
method published that allows the simultaneous determination of all four antidementia drugs, namely 
donepezil, galantamine, rivastigmine (and its metabolite NAP 226-90) and memantine. The sample 
pre-treatment was performed by mixed-mode SPE and the separation of the compounds was 
achieved by reverse phase chromatography. The method was validated according to the 
recommendations of international guidelines with satisfactory results. Moreover, the procedure was 
successfully applied to the 300 study participants, showing to be reliable and robust over the 
concentration range normally measured in patients. 
Since it was planned to introduce the concentration measurements of antidementia drugs in the 
routine TDM-service of our laboratory, the HPLC-MS procedure was transferred to the newly acquired 
UPLC-MS/MS system in order to benefit from the numerous advantages of this new technology. The 
procedure transfer is described in Article III. In the HPLC-MS procedure, the drugs were isolated from 
500  μL  plasma by SPE, which is a powerful procedure to obtain clean extracts. However, the higher 
specificity of the UPLC-MS/MS compared to HPLC-MS allows the analysis of less clean extracts with 
satisfactory results. Therefore, the extraction procedure was simplified and a protein precipitation was 
used with the advantages of a faster sample preparation and lower costs. In addition, the higher 
sensitivity  of  the  MS/MS  allowed  to  reduce  the  amount  of  required  plasma  to  250  μL  and  to  decrease  
the LLOQ of rivastigmine and its metabolite to better correspond to the low concentrations measured 
in patients. Moreover, the run time was shortened from 15 min to 4.5 min. The UPLC-MS/MS method 
was fully validated and a method comparison between HPLC-MS and UPLC-MS/MS was performed, 
showing similar results between the two procedures. During routine use of the method, the reliability 
will be monitored by internal and external quality control samples. Moreover, attention has to be paid 
to analytical interferences with comedication, since the elderly population taking antidementia drugs is 
often polymedicated. However, by the use of the highly specific UPLC-MS/MS technology and of 
isotope-labeled internal standards compensating for potential signal suppression, the risk of analytical 
inferences has been minimized. 
For  a  considerable  number  of  psychopharmacologic  compounds,  the  quantification  of  the  medications’  
plasma concentration has become clinical routine for dose adjustment.32 Clear evidence of the 
benefits of TDM has been given for tricyclic antidepressants, numerous antipsychotic drugs and for 
conventional mood stabilizing drugs.32 Presently, TDM is rarely used for antidementia drugs, though 
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there is some evidence that it can be useful since a relationship between plasma concentrations and 
response to treatment and/or tolerability has been reported.71-73 The following aspects support the use 
of TDM for antidementia drugs. First, a large inter-individual variability in plasma concentrations was 
observed in pervious clinical trials, and could be confirmed by the results of our pharmacogenetic 
study. As substrates of CYP2D6 and CYP3A metabolic enzymes, donepezil and galantamine 
pharmacokinetics is affected by environmental and genetic factors influencing the activity of these 
enzymes. TDM might be beneficial to reveal genetically determined abnormalities in the metabolism, 
but also to monitor the plasma concentrations when administered in combination with comedication 
inhibiting or inducing CYP2D6 or CYP3A. Moreover, age-related changes in physiologic functions and 
comorbidities might affect the pharmacokinetics of antidementia drugs. In particular, a decreased renal 
function could lead to increased plasma concentrations of memantine. Finally, there is some evidence 
supporting the utility of antidementia drugs as a chronic treatment that reduces the progression and 
associated burden of the disease rather than purely to relieve the symptoms.15 Thus, the detection of 
non-adherence to therapy through TDM might be beneficial, especially because non-adherence is a 
particular problem in patients with cognitive deficits.58 
 
In  the  recently  published  “AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: 
Update   2011”,   therapeutic   ranges   for   antidementia   drugs   are   proposed,   which   are   based   on  
pharmacokinetic studies with therapeutically relevant doses.32 Only for donepezil, the therapeutic 
range was based on a concentration-response study.32,71 To recommend a regular monitoring with the 
available data is not possible, but it can be suggested in special cases such as an insufficient clinical 
improvement, adverse events, comedication that are inhibitors or inducers of drug metabolizing 
enzymes or suspected non-adherence. 
The data, which will be collected in future in our TDM service, might contribute to evaluate whether a 
TDM of antidementia drugs could help to minimize the risk of adverse events and to increase the 
probability of clinical effectiveness. However, prospective concentration-response studies to improve 
the quality of data on therapeutic reference ranges are required. 
 
5.2 Pharmacogenetics of Donepezil 
 
A total of 129 patients treated with a constant dose of donepezil were included in the pharmacogenetic 
study on antidementia drugs. The patients were genotyped for polymorphisms in CYP2D6, CYP3A, 
POR, NR1I2 and ABCB1 to investigate their influence on donepezil steady-state concentrations as 
well as on the occurrence of side effects. The results are reported in Article IV. 
The CYP2D6 genotype appeared to be the major genetic factor influencing donepezil plasma 
concentrations. Heterozygous extensive metabolizers and poor metabolizers demonstrated 
significantly higher plasma concentrations than homozygous extensive metabolizers. Moreover, the 
ultrarapid metabolizers had lower donepezil concentrations than homozygous extensive metabolizers 
and might, therefore, be prone to non-response to donepezil treatment. Only one previous study 
examined the relationship between CYP2D6 genotypes and donepezil plasma concentrations.55 In 
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contrast to our results, no significant relationship was revealed, which might be due to the limited 
sample size (n=42) and the lack of poor metabolizers. Nevertheless, their findings showed a tendency 
towards lower plasma concentrations in homozygous extensive metabolizers compared to 
heterozygous extensive metabolizers, and in ultrarapid metabolizers compared to extensive 
metabolizers, which is in line with our results.55 Further accentuating the importance of CYP2D6 in 
donepezil metabolism, we measured significantly higher plasma concentrations in patients receiving 
CYP2D6 inhibitors compared to patients without CYP2D6 inhibiting comedication. In addition, the 
frequency of subjects experiencing at least one side effect related to donepezil treatment was 
significantly higher in CYP2D6 poor metabolizers and patients taking strong CYP2D6 inhibitors. This 
could be due to the higher trough concentrations observed in these subjects, even though the 
difference did not reach statistical significance. Overall, these findings indicate that a dose-adaption 
through monitoring of donepezil plasma concentrations could be beneficial to avoid side effects in 
CYP2D6 poor metabolizers and in patients taking CYP2D6 inhibitors as comedication. However, the 
confirmation of our results in prospective studies is required. 
Interest in the electron transferring enzyme POR and the nuclear receptor PXR resulted from the 
search on variations in genes influencing CYP3A expression and activity. In this study, a significant 
association of the NR1I2 rs1523130 SNP with donepezil concentrations was found. Since in vitro 
studies in liver tissues demonstrated different levels of CYP3A4 expression among NR1I2 rs1523130 
genotypes, this observation could be explained by differences in CYP3A4 activity.45,47 Because PXR is 
implicated in the expression of several phase I and phase II drug-metabolizing enzymes as well as 
transporters including P-pg, the influence of the NR1I2 rs1523130 might also be mediated by other 
factors than CYP3A expression. The most common studied POR polymorphism is the SNP 
rs1057868C>T, defining the allele *28. In a previous study, our group showed an influence of the 
POR*28 polymorphism on CYP3A activity in two independent cohorts, with POR*28 TT carriers 
presenting a 1.6-fold higher CYP3A activity than carriers of the C allele.31 In line with these findings, 
we observed lower donepezil plasma concentrations in patients carrying at least one POR*28 T allele. 
However, the difference reached statistical significance only in CYP2D6 extensive metabolizers, which 
suggests a confounding of the effect by the other CYP2D6 genotypes when considering the whole 
study population.  
The thoughtful assessment of genetic factors that could affect donepezil pharmacokinetics extended 
the current knowledge on donepezil pharmacogenetics. The data used for the present investigations 
were obtained from a larger study population than in previous pharmacogenetic trials. Furthermore, 
this is the first study to examine the relationship of SNPs in POR and NR1I2 with donepezil plasma 
concentrations. The findings on donepezil presented in this work are based on trough plasma 
concentrations calculated by means of a pharmacokinetic equation depending on the average half-life 
observed in patients in previous studies and on the time between medication intake and blood 
sampling. Because of the long half-life of the drug (70 hours),74-77 resulting in small differences 
between peak and trough concentrations, our estimation of the trough concentrations is considered to 
be suitable for the objectives of the study. However, the influence of genetic and clinical factors on 
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donepezil pharmacokinetics is presently investigated with a more sophisticated approach. In 
collaboration with the department of clinical pharmacology at the CHUV (Prof Chantal Csajka, Dr 
Monia Guidi), a population pharmacokinetic model for donepezil has been established, using the 
NONMEM software. A manuscript reporting the results of the population pharmacokinetic analysis will 
be prepared shortly.  
Recently, attention was drawn on the SNP rs35599367 in intron 6 of the CYP3A4 gene, defining the 
allele *22. In vitro this SNP markedly affected the CYP3A4 expression and in vivo it modified dose 
requirements and/or plasma concentrations of CYP3A4-metabolized drugs.78-80 In view of these 
findings, we are presently analyzing this polymorphism in our study population to investigate its effect 
on donepezil pharmacokinetics. Further investigations could include SNPs in other nuclear receptors, 
such as CAR, influencing the expression of drug metabolizing enzymes and transporters. 
 
5.3 Pharmacogenetics of Memantine 
 
In the pharmacogenetic study, 108 patients receiving memantine at steady-state conditions were 
included. The patients were genotyped for SNPs in genes of renal cation transporters and nuclear 
receptors that are involved in transporter expression, and their effect on memantine clearance was 
assessed. The results of these investigations are described in Article V. 
In collaboration with the department of clinical pharmacology at the CHUV, a population 
pharmacokinetic model was developed, integrating clinical and genetic factors. A dominant influence 
of the renal function was observed, which is in agreement with the extensive renal elimination of 
memantine and has previously been shown in a single dose study in elderly volunteers.81 Moreover, 
the model demonstrated slower memantine elimination in female patients. In contrary to expectations, 
no significant relationship was found between genetic variations in renal cation transporters, namely 
OCTs, OCTN, MATE and P-gp, and memantine pharmacokinetics, although the selected variants 
were associated in vitro and/or in vivo with altered transport activity.82-87 Several explanations are 
conceivable for the lack of association, including the naturalistic study design that might have masked 
subtle effects of the genetic variations or the implication of several redundant cation transporters in the 
renal elimination of memantine compensating for a diminished activity of one of the transporters. 
Furthermore, since considerable intersubject differences in OCT expression have been reported, 
mechanisms regulating the expression of renal transporters might be predominant in determining 
memantine elimination.85 Thus, we investigated several polymorphisms in genes of the nuclear 
receptors PXR, CAR,   RXRα   and PPARγ, which are known to be involved in cation transporter 
expression.88-91 The SNP NR1I2 rs1513023 was significantly related to memantine clearance. As 
mentioned above, in vitro this SNP was associated with differential hepatic CYP3A4 expression 
among genotypes.45 A similar effect may be hypothesized for transporter expression in the kidneys, 
influencing memantine elimination.  
The presence of side effects in our study population was analyzed with respect to the proposed 
therapeutic range for memantine of 90-150 ng/ml.32 In good agreement, in patients with average 
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concentrations superior to 150 ng/ml, a significantly increased occurrence of side effects was 
observed. Thus, a dose reduction might be useful if the threshold of 150 ng/ml is exceeded, especially 
in case of AEs that might limit adherence to the treatment. Moreover, simulations were performed to 
predict and compare average plasma concentrations in patients receiving 10 mg, 15mg or 20 mg 
memantine per day with different NR1I2 rs1513023 genotypes and normal or impaired renal function. 
According to the prescription information,35 half of the normal daily dose, i.e. 10 mg, is recommended 
for patients with severe renal impairment (creatinine clearance<30 ml/min). Interestingly, the 
simulations predicted for patients with a creatinine clearance of 30 ml/min and NR1I2 reference alleles 
lower average concentrations than observed in patients with normal renal function. Thus, a dose of 15 
mg per day might be more adequate, as it leads to similar steady-state plasma concentrations as in 
patients without renal impairment taking 20 mg memantine per day. It will be interesting to pay 
attention to this issue in the routine TDM analyses in patients with known renal function. 
To our knowledge, this is the first pharmacogenetic study on memantine. Our findings improved the 
understanding of inter-individual variability in memantine pharmacokinetics and might be useful in the 
context of individual dose-adaption for a better efficacy and safety of the treatment. However, the 
replication of the results in other groups of patients is necessary. The domain of transporter 
pharmacogenetics is presently emerging and, therefore, it is likely that new genetic variants will be 
described that could be examined regarding memantine pharmacokinetics. Moreover, a better 
characterization of the spectrum of transporters for which memantine is a substrate would be 
advantageous for further pharmacogenetic studies. Our analyses on polymorphisms in nuclear 
receptors were exploratory. In vitro studies on renal transporter expression related to genetic 
variations in nuclear receptors, in particular related to NR1I2 rs1513023 genotypes, would be required 
for a profound understanding of the results and for further investigations. 
 
5.4 Pharmacogenetics of Galantamine 
 
In the pharmacogenetic study, 27 patients were included receiving a treatment with galantamine. We 
investigated the relationship of polymorphisms in CYP2D6, CYP3A, POR and ABCB1 genes with 
galantamine concentrations. The results are reported in a short communication (Article VI). 
We demonstrated 60% higher galantamine trough concentrations in CYP2D6 poor metabolizers 
compared to CYP2D6 extensive metabolizers, while homozygous and heterozygous extensive 
metabolizers had similar plasma levels. Interestingly, more CYP2D6 poor metabolizers than expected 
were identified in our study population, which allowed to find a statistical significant influence of the 
CYP2D6 genotypes. Our findings confirmed the results of a population pharmacokinetic study, 
showing a 25% reduced galantamine clearance in CYP2D6 poor metabolizers and a similar clearance 
among homozygous and heterozygous extensive metabolizers.92 Only one ultrarapid metabolizer was 
detected in our study population, thus, it was not possible to draw a conclusion for this genotype. 
According to the FDA drug label information, no dose-adjustment is necessary in poor metabolizers as 
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the dose is individually titrated to tolerability.93 Nevertheless,   the   knowledge   of   a   patient’s  CYP2D6 
genotype might be useful to avoid concentration-related side effects in poor metabolizers. No 
significant relationship was found between polymorphisms in CYP3A, POR and ABCB1 genes and 
galantamine concentrations, which might be due to the predominant influence of the CYP2D6 
genotype and the small study population. Therefore, the genetic analyses on CYP3A, POR and 
ABCB1 should be repeated in larger cohorts for sound conclusions. 
In the present study, we showed for the first time in a naturalistic setting the significant influence of the 
CYP2D6 genotype on galantamine pharmacokinetics. However, the sample size limited the analyses 
of SNPs potentially influencing galantamine concentrations as well as the investigations on side 
effects. For further pharmacogenetic studies, a larger cohort is necessary, for which it will also be 
possible to perform population pharmacokinetic analyses. 
 
5.5 General remarks and perspectives on the pharmacogenetic study on antidementia drugs 
 
The aim of a pharmacological treatment is to administer effective and well tolerated drugs to patients. 
For most drugs, substantial differences in treatment response exist among patients, which is partly 
due to inter-individual variabilities in plasma concentrations of the drugs. Accordingly, a standard dose 
of a drug might not be suitable for every patient. An individual dose adjustment, taking several factors 
into account that influence the pharmacokinetics of a drug, has been shown to improve efficacy and 
safety of treatments. 
Through the pharmacogenetic study presented in this work, we improved the current understanding of 
clinical and genetic factors leading to an inter-individual variability in plasma levels of antidementia 
drugs. Therefore, these findings could contribute, together with the work of other research groups, to a 
more personalized therapy approach in AD patients treated with acetylcholinesterase inhibitors or 
memantine, with individual dose adaption according to drug plasma concentrations and/or genotypes. 
Thanks to the cross-sectional design of the study and large inclusion criteria, the protocol was simple 
and the participation minimally invasive for the patients. However, the heterogeneity of the population 
and the different durations of treatment at inclusion limited the assessment of efficacy and safety. 
Though, our results could be taken into account for the design of prospective studies investigating the 
clinical impact of the genetic variations, and of other clinical factors influencing the pharmacokinetics 
of the drugs, on the efficacy and tolerability of the treatment with antidementia drugs. In addition, 
concentration-response studies are requested to establish evidence based therapeutic ranges of 
antidementia drugs and to evaluate the usefulness of TDM in these drugs.  
Hopefully, increasing the knowledge of pharmacogenetics and of other factors influencing drug 
response, together with more advanced technologies and decreased laboratory costs for genotyping 
and drug concentration measurements, will enable us to establish a more personalized therapy 
approach for AD patients. Through an individual selection of drug regimen and dose, the tolerability of 
the treatment might be improved and higher therapy success rates might be achieved. 
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5.6 General Conclusions 
 
Currently, the three acetylcholinesterase inhibitors donepezil, galantamine and rivastigmine and the 
NMDA-antagonist memantine are licensed for the treatment of AD. Meta-analyses report consistent 
benefits of these drugs regarding cognition and global assessment, but with small treatment effects.94-
96 Furthermore, it has been shown that discontinuation rates are around 40% and 80% after 12 and 24 
months of acetylcholinesterase inhibitor treatment, respectively, with ineffectiveness, intolerance or 
inconvenient dosing schedule as leading reasons for the discontinuation.97 At present, no cure for AD 
is available. Thus, even if an initial improvement is observed in the first months of treatment, the 
cognitive and behavioral decline cannot be prevented. However, an optimization of the current 
treatment to maximize the effectiveness and tolerability should be intended, for example through TDM 
and/or genotyping. The issue of inter-individual variability in pharmacokinetics and pharmacodynamics 
of antidementia drugs has not been extensively addressed up to now. The pharmacogenetic study 
presented in this work might, therefore, contribute to a better tailored pharmacotherapy for AD 
patients, as we demonstrated that genetic factors account for a part of the intersubject variability in 
pharmacokinetics of donepezil, galantamine and memantine in patients recruited from a naturalistic 
therapeutic setting. Due to the cross-sectional study design, prevalent side effects were recorded at 
inclusion when most patients were already receiving the medication for several months. Therefore, it 
was complicated to differentiate between therapy related side effects and effects of concomitant 
diseases or medication. Moreover, transient side effects were no more present and intolerant patients 
would already have reduced the dose or discontinued the treatment and be ineligible. Despite these 
limitations, significant associations between the predicted CYP2D6 phenotype and side effects related 
to donepezil treatment, and between the 150 ng/mL plasma concentration threshold and side effects 
related to memantine treatment were found. 
Taken together, these findings suggest a usefulness of TDM and genotyping in the treatment of AD. 
However, prospective studies investigating the clinical effectiveness and tolerability of antidementia 
drugs with respect to plasma concentrations and genotypes are required. Moreover, 
pharmacoeconomic aspects have to be taken into account. 
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